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ABSTRACT 
The introduction of biologic therapies into clinical practice has greatly improved the 
treatment of chronic disabling inflammatory diseases, such as Rheumatoid Arthritis, 
Spondylarthritis or Inflammatory Bowel Diseases, among others. However, a sizeable 
fraction of patients never achieve therapeutic response or, more often, cannot maintain 
therapeutic response over time. Among the pitfalls of biologicals is their potential 
immunogenicity and the associated anti-drug antibodies (ADAb) produced by the patients, 
which promote faster clearance/neutralization of the drug in circulation and thus interfere 
with drug efficacy. Moreover, ADAb have also been associated with adverse events. 
In this work we aimed at formally document the impact of ADAb in clinical outcomes, and 
use this analysis to construct and test an algorithm for therapeutic decisions based on explicit 
biomarkers of immunogenicity.  
To evaluate the clinical relevance of biological drug’s immunogenicity, we first performed 
a systematic review of the literature coupled with a meta-analysis. We evidenced that in the 
presence of detectable ADAb therapeutic response may be reduced by as much as 80%. Such 
impact is attenuated, although not abrogated, by concomitant immunosuppression, 
particularly with methotrexate that associates with reduced ADAb production. Differences 
in the immunogenic profile of specific biologics were also verified, with monoclonal 
antibodies exhibiting higher immunogenicity than fusion proteins. We next assessed the 
impact of immunogenicity on drug’s safety profile by following a cohort of patients 
receiving intravenous infliximab, a TNF-inhibitor.  Infusion-related adverse events occurred 
exclusively in ADAb-positive patients and nearly half of the ADAb-positive patients 
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developed an acute reaction during or immediately after the infusion, requiring medical 
intervention.  
To evaluate the relevance of drug immunogenicity assessment for therapeutic decisions, we 
first defined a convenient method to assess immunogenicity on a routine basis. We verified 
that a newly developed Bridging ELISA performed as well as antigen-binding radio-immuno 
assay, currently considered by many as the “gold-standard” to assess ADAb. Next, we 
designed an algorithm for the management of patients receiving biologic therapies, which 
combines the usual clinical evaluation with immunogenicity assessment at every three 
months. This algorithm was tested in a cohort of RA patients treated with one of the three 
most commonly used biologics. We evidenced that patients who followed therapeutic 
strategies concordant with the proposed algorithm had close to 10-times higher probability 
of achieving low disease activity, when compared to those who followed other strategies 
commonly adopted in current clinical practice.   
Our work demonstrates that a personalized, evidence-based approach for the management 
of patients receiving biologic therapies will lead to safer and most cost-effective strategies. 
These findings have important clinical, societal and economic consequences. 
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RESUMO 
As terapêuticas biológicas revolucionaram o prognóstico de doenças inflamatórias crónicas 
e incapacitantes como a Artrite Reumatóide, as Espondilartrites, as Doenças Inflamatórias 
do Intestino, entre outras. Ainda assim, um número significativo de doentes não responde a 
esses fármacos ou, mais frequentemente, perde a resposta inicial ao longo do tempo de 
tratamento. Uma das principais limitações destas terapêuticas é o seu potencial imunogénico 
e a consequente formação de anticorpos anti-fármaco (AAF) por parte dos doentes a quem 
são administrados. Os AAF promovem uma rápida eliminação/neutralização do fármaco em 
circulação e podem também interferir com o seu perfil de segurança, associando-se a um 
maior risco de efeitos adversos.  
Este trabalho pretende documentar formalmente o impacto clínico dos AAF, utilizando essa 
informação na construção e validação de um novo algoritmo de apoio à decisão terapêutica 
baseado em biomarcadores de imunogenicidade.  
Para avaliar a relevância clínica da imunogenicidade foi inicialmente realizada uma revisão 
sistemática da literatura e uma meta-análise. Evidenciámos que na presença de AAF 
detetáveis há uma redução de até 80% da resposta à terapêutica. Este impacto é atenuado, 
mas não eliminado, pelo tratamento concomitante com imunossupressores, particularmente 
com metotrexato, que se associa a uma redução da produção de AAF. Foram também 
verificadas diferenças importantes no perfil imunogénico entre os fármacos, com os 
anticorpos monoclonais a exibirem maior imunogenicidade que as proteinas de fusão. 
Seguidamente foi avaliado o impacto da imunogenicidade no perfil de segurança destes 
fármacos, avaliando no tempo uma cohort de doentes tratados com infliximab, um inibidor 
do TNF-alfa. Reações adversas agudas associadas à infusão do fármaco ocorreram 
exclusivamente em doentes com AAF detetáveis, sendo que cerca de metade dos doentes 
x 
com AAF tiveram uma reação aguda durante ou imediatamente após a infusão do biológico, 
requerendo intervenção médica imediata.  
No sentido de avaliar a relevância da avaliação da imunogenicidade para a melhoria das 
decisões terapêuticas, começámos por definir o método laboratorial mais conveniente para 
monitorização da imunogenicidade na prática clínica de rotina. Constatámos uma boa 
concordância entre um novo método de ELISA desenvolvido (“Bridging ELISA”) e o 
método de radioimmunoensaio (“RIA-ABT”), considerado por muitos como “gold 
standard” na deteção dos indivíduos AAF-positivos. Seguidamente, desenhámos um 
algoritmo de apoio à decisão terapêutica para doentes medicados com terapêuticas 
biológicas, que combina a atual avaliação clínica com a monitorização da imunogenicidade 
a cada três meses. Este algoritmo foi testado numa cohort de doentes com Artrite Reumatóide 
inicialmente medicados com um dos três agentes biológicos mais utilizados no tratamento 
desta doença. Evidenciámos que os doentes que tinham seguido estratégias terapêuticas 
concordantes com o algoritmo proposto tiveram cerca de 10 vezes maior probabilidade de 
alcançarem uma baixa atividade de doença, quando comparados com os doentes que 
seguiram outras estratégias, frequentemente adotadas na atual prática clínica. 
O nosso trabalho demonstra que uma abordagem personalizada e cientificamente orientada 
aos doentes medicados com terapêuticas biológicas permite desenhar estratégias mais 
seguras e custo-efetivas. Os nossos resultados têm não só uma elevada relevância clínica, 
como também económica e social.   
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1 GENERAL INTRODUCTION 
Chronic inflammatory immune-mediated diseases are a heterogeneous group of poorly 
understood disorders, which aetiology remains largely unknown. They have been conceived 
as a result of a combination of genetic variants, acquired environmental triggers and 
stochastic events.  
Rheumatoid Arthritis (RA), Spondylarthritis (SpA), Psoriasis (Ps) and Inflammatory Bowel 
Diseases (IBD) are among the most prevalent chronic inflammatory immune-mediated 
diseases that affect predominantly young people at productive age of life, inducing 
significant morbidity and mortality. Therefore, their social and economic impact on society 
is extremely high. 
Despite the poorly understood aetiology of those diseases, their physiopathology ends in a 
chronic inflammatory response against self-tissues with the release of inflammatory 
mediators, production of autoantibodies and activation of leukocytes that will perpetuate 
immune response, leading to an extensive tissue damage and malfunction of the 
corresponding target organs.  
Cytokines are potent-rate limiting extracellular molecules that specifically regulate the 
inflammatory response, the tissue damage and the repair mechanisms. An increasing body 
of evidence has revealed the critical role that cytokines play in the initiation and perpetuation 
of autoimmunity [1, 2]. The important role of cytokines in immune-mediated inflammatory 
mechanisms had lead to the idea that cytokine-based manipulation could offer a possibility 
to interfere with autoimmune process. 
Such idea has revolutionized the treatment approach of the above-mentioned diseases, which 
the most well known example has been RA. 
RA is a chronic disabling disease that affects primarily the joints, inducing an irreversible 
joint damage with significant loss of functionality. In the beginning of 90’s a paradigm shift 
occurred in the treatment approach of RA. In addition to small chemical molecules, such as 
methotrexate (MTX) or corticosteroids, large therapeutic proteins, also known as biologics, 
were introduced in the arsenal of therapeutic options for RA treatment. Biologics represent 
a distinct therapeutic class, which are produced through living organisms using 
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biotechnology and genetic engineering instead of being simply chemically synthesized. 
There are today a wide variety of biotechnologic-derived therapeutic proteins. In the context 
of chronic inflammatory immune-mediated diseases, biologics are mainly represented by 
monoclonal antibodies, and to a less extend by fusion proteins, which target several 
cytokines or cells that play critical role on immune-mediated inflammation. The first 
biologics used in the treatment of RA targeted the Tumor Necrosis Factor (TNF). Given the 
successful results other targets emerged, such as CD-20, co-stimulatory molecules 
B7.1/B7.2 and interleukin (IL)-6. These therapies provide better control of inflammation, 
increasing patient’s quality of life and, most importantly, their functionality.  
The clinical benefit that biologics have brought to RA patients has been extensively 
demonstrated in randomized clinical trials (RCTs). However, biologics have now been used 
in clinical practice for more than a decade and a general pattern seemed to emerge, best 
analysed for Tumor Necrosis Factor inhibitors (TNFi) in RA: there is evidence that i) about 
one third of the patients would not respond to the biological therapy (primary non-
responders); ii) one third would show clinical response, but the beneficial effect would fade 
away within the first 6-12 months of continuous therapy (secondary non-responders); and 
iii) the remaining third would maintain a clinical response beyond a year.  
Over the last years increasing evidence has revealed the production of anti-drug antibodies 
(ADAb), naturally produced by the patients upon administration of biologics, as one of the 
main factors interfering with drug efficacy and safety profile. Although there were good 
indications that immunogenicity of TNFi is one of the main mechanisms behind treatment 
failure, this notion did not permeate the clinical practice.  
The lack of suitable assays to assess immunogenicity in clinical practice has also prevented 
the expansion of the field. Immunogenicity assessment is technically challenging and only 
recently optimized assays, specifically tailored to detect ADAb, have emerged though little 
experience still exists.  
Despite the great improvement in overall clinical responses afforded by biologicals, 
therapeutic failures to these drugs are frequent. Therapeutic decisions in these cases, such as 
whether to increase the dose or to switch to another biological of similar or different 
mechanism of action, would benefit to be guided by reliable biomarkers. Moreover, in 
responding patients, the same lack of guiding biomarkers prevents an educated and desirable 
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dose reduction program, as these therapies are supposed to be maintained for life. 
Monitoring drug levels and potential immunogenicity should help optimize the use of 
biological therapies. However, the way such information might be integrated in clinical 
practice towards more cost-effective strategies remains to be defined.  
The high costs of biologic therapies represent a big concern for societies. Monitoring drug 
levels and ADAb might represent a very promising tool for an optimized and personalized 
use of biological therapies, as it allows revision of the costs engaged in these therapies while 
keeping as a priority the welfare of patients.  
1.1 BIOLOGIC THERAPIES 
The critical role of cytokines in all stages of the immune-mediated inflammatory process, 
lead to the idea that the manipulations of cytokine network could modulate immune 
responses and autoimmune diseases [1, 2]. The easiest and more efficient way to block 
cytokines is through monoclonal antibodies (mAbs), although other type of molecules such 
as decoy receptors can also bind cytokines with specificity and high affinity. The therapeutic 
potential of mAbs has revolutionized the pharmaceutical industry over the last years, which 
has lead to important refinements in the antibody manufacturing techniques.  
Biotechnology-derived therapeutic proteins represent a group of medicines that are produced 
through live organisms and not simply chemically synthetized.  Hence, they are often 
mentioned as biologics. There are a wide variety of biotechnology-derived therapeutic 
proteins available today for the treatment of several diseases. Beyond mAb and soluble 
receptors, enzymes, clotting factors, hormones, or cellular growth factors also exist, namely 
for the treatment of some genetic diseases where there is an absence or pathologic 
modification of the endogenous protein. Nonetheless, mAbs represent the great bulk of 
biologics today produced with therapeutic purposes.  
1.2 IMUNOGLOBULINS STRUCTURE AND FUNCTION 
Antibodies (Abs) are a family of structurally related glycoproteins, also known as 
Immunoglobulins (Igs). Antibodies represent the secreted form of Igs that can also be 
produced in a membrane form (B cell receptor, BCR). All Abs have a common symmetric 
core structure of two identical covalently linked heavy chains and two identical light chains, 
each linked to one of the heavy chains – Figure 1.  
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Abs are classified into different isotypes and subtypes on the basis of amino-acid differences 
in the heavy chain constant (C) regions, which consist of three or four C domains [3]. The 
antibody classes or isotypes are called IgM, IgD, IgE, IgA and IgG. IgG isotype consist of 
four subtypes, numbered according to their frequency in peripheral blood: IgG1, IgG2, IgG3 
and IgG4. Each Ig molecule contains 2 light chains of the same isotype, kappa (κ) or lambda 
(λ), which differ in their single C domain. Even within the same isotype, slight differences 
in the amino-acid sequences of the constant heavy or light chain also exist among different 
individuals, designated as allotypes [4].  
 
Figure 1 – Immunoglobulins Structure 
Allotypes expressed on the constant region of IgG heavy chain are referred as Gm (genetic 
markers) together with the isotype. With the exception of IgG4, different allotypes have been 
described for IgG1 (G1m), IgG2 (G2m) and IgG3 (G3m). Allotypes expressed on the 
constant region of κ light chain are referred as Km. No allotypes have been described for λ 
light chains. Specific Gm haplotypes exist in different populations. In a Caucasian 
population the G1m1,17 allotype is much less frequent than G1m3 [5]. Even within the same 
population group, inter-individual variations may also occur [4]. 
The N-terminal domains of heavy and light chains form the variable (V) regions of Ab 
molecules, which differ among antibodies of different specificities. The V regions of heavy 
and light chains each contain three separate hypervariable regions of about 10 a.a that are 
spatially assembled to form the antigen-combining site of the antibody molecule, known as 
complementary-determining regions (CDR) – Figure 2.  
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Figure 2 – Complementary-Determining Regions (CDR1, CDR2 and CDR3) 
Antibody binding to antigen can be highly specific, but cross-reactions may also occur and 
the same antibody may bind different antigens. Antibodies can bind to two, or in the case of 
IgM, up to ten identical epitopes simultaneously, leading to enhanced avidity of the 
antibody-antigen interaction. The relative concentrations of antigens and antibodies may 
favour the formation of immune complexes.  
The antibodies’ role does not extinguish in the antigen recognition. Antibodies also have 
effector functions, which are mainly mediated by the C regions of the heavy chains [6-8]. 
IgG1, IgG3 and to a lesser extend IgG2 are able to activate the complement system, by 
binding to the C1 complex via their Fc terminals [9]. Activation of the complement system 
may lead to target cell lysis, phagocytosis of pathogens, release of anaphylatoxins, among 
other pro-inflammatory effects [10]. Antibodies may also interact with Fc receptors, 
displayed at surface of immune cells such as macrophages, monocytes, dendritic cells or 
platelets, leading to their activation. This interaction may result in antibody-dependent 
cellular phagocytosis (ADCP), antibody-dependent cell-mediated cytotoxicity (ADCC) and 
cytokine release [11]. The interaction of Fc regions with neonatal Fc receptor protects IgG 
from degradation, increasing their half-live and mediates IgG transfer from mother-to-fetus 
[12]. In contrast, IgG4 has limited effector functions due to its low affinity for complement 
and Fc receptors [13, 14]. IgG4 represents a small fraction of total IgG content and it has 
been described in cases of prolonged or repeated antigenic stimulation [15]. It has been 
thought that IgG4 production may have regulatory or protective effect against chronic 
inflammatory reactions [16, 17]. Human IgG4 has the particular ability to exchange half of 
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the molecule with another IgG4 molecule of different specificity, resulting in a bispecific 
immunoglobulin molecule unable to cross-link identical antigens [17-21]. This dynamic Fab 
arm exchange introduces unpredictability on the binding ability of IgG4, which may be 
unwanted in case of human immunotherapy.  
1.3 ANTIBODY PRODUCTION: FROM HYBRIDOMA TECHNIQUE TO 
ADVANCED BIOTHECHNOLOGY  
The production of antibodies at a large scale, in a reliable manner, started in 1975, with the 
development of mouse hybridoma technology by Cesar Milstein and Georges Köhler [22]. 
The contribution of such invention for science and medicine conceived to its inventors the 
Nobel Prize of 1984 for Medicine and Physiology, shared with Niels Jerne, who also made 
critical contributions to immunology. 
The hybridoma technique consists in the fusion of a mouse myeloma and mouse spleen cells 
from an immunized donor, able to secrete antibodies of a single specificity against a 
predetermined antigen.     Such hybrid cells can be grown in vitro in massive cultures to 
provide specific antibodies. Mouse hybridomas were developed for a number of research 
and therapeutic applications. However, clinical studies with murine mAbs had been 
disappointed due to their weak effector functions, short half-life and ability to evoke immune 
reactions in the human organism [23-25]. An intensive work was subsequently conducted in 
order to refine the production and the clinical use of therapeutic antibodies. To that, much 
had certainly contributed the easy access to hybridoma technology, which was never 
patented by its inventors, deliberatively.  
In 1986, the US Food and Drug Administration (FDA) approved OKT3 (muromonab), the 
first therapeutic monoclonal antibody for human use. OKT3 is a murine monoclonal 
antibody of the IgG2a isotype, which targets CD3, a molecule that is part of a multimolecular 
complex found in association of T-cell receptor (TCR) for antigen. OKT3 acts by blocking 
T-cell function and it was shown to effectively treat acute allograft rejection [26, 27]. 
Subsequently, many other monoclonal antibodies emerged, providing great advantages for 
the treatment of several disabling diseases. However, the use of mouse monoclonal 
antibodies in humans was also accompanied by important immune reactions, limiting its 
clinical use [28-30]. This fact has propelled the pharmaceutical companies to refine the 
production techniques of biologics, creating products which are increasingly identical to 
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human constituents. Even though, immune reactions to biologics have been difficult to 
overcome [31, 32].  
One of the major challenges in applying biopharmaceuticals for medical purposes has been 
to ensure that they circumvent recognition by the immune system, being accepted as self-
molecules and do not elicit a specific or non-specific immune response against themselves.  
Improved techniques have been developed to reduce non-human sequences in biologics. One 
of the first techniques developed with that aim was the antibody chimerization, a process in 
which mouse variable domain regions are fused to human constant regions [33]. This process 
generates chimeric antibodies, which have reduced immunogenicity when compared to fully 
mouse antibodies [34-37].  
Later on, humanized antibodies were developed by grafting mouse CDRs into human 
antibody backbone, restricting even more the non-human sequences [38, 39]. The exclusive 
replacement of the CDRs without framework regions may affect the antibody affinity to the 
antigen, which led to the replacement of human amino acids in the framework region by 
their corresponding mouse sequences. This replacement is then followed by “resurfacing” 
approach, where the exposed mouse residues at surface are replaced by human amino acids 
[40, 41]. 
The clinical success obtained with chimeric and humanized antibodies have motivated 
continuous innovation at the production level, and currently an increasing number of fully 
human antibodies exist [42]. These human antibodies are typically derived from large phage 
display libraries expressing human antibodies fragments or from transgenic mice engineered 
with human immunoglobulin genes [43]. 
Phage display platforms started in 1985 with the discovery that foreign deoxyribonucleic 
acid (DNA) sequences could be cloned into filamentous bacteriophages, being displayed at 
the surface of phage particles as fusion proteins [44]. This discovery was combined with 
polymerase chain reaction (PCR) amplification methods developed in the late 1980s for 
cloning expressed immunoglobulin variable region complementary DNA (cDNA) 
repertoires derived from B cells, to create diverse libraries of antibody variable regions that 
reflect the natural B cell repertoire [45]. The library is then used to select against the target 
protein to capture the phage that binds specifically to the protein. These libraries allow a 
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rapid screen of large number of antibodies against the target protein, in contrast to the 
laborious generation of hybridomas. Libraries started to be built from immune fragments 
isolated from immunized animals or infected humans, resulting in biased libraries toward 
certain specificities [46, 47]. Then naïve libraries emerged, built from a pool of healthy 
donors, followed by a synthetic repertoire rearranged in vitro, which is not biased and 
therefore can be used for selecting specificities against a wide range of targets [48, 49]. Large 
and diverse semi-synthetic libraries represent a valuable source of antibodies against a large 
number of target proteins.  
In 1994, by genetic engineering, it was possible to generate mice expressing fully human 
antibody repertoires [50, 51]. These engineered animals comprised target disruptions of the 
endogenous mouse heavy and κ light chain genes together with introduced transgenes of 
unrearranged human heavy and κ light chain gene segments. The observation that a limited 
germline repertoire can be used by the mouse immune system to construct high specificity 
and high affinity antibodies to a wide variety of antigens reflects the relevance of somatic 
recombination and affinity maturation processes in generating diversity [52]. Subsequent 
progress has included the expression of more V segments by the transgenic mice, thereby 
expanding the potential repertoire of recovered antibodies [53]. 
There are no major advantages for the use of one technique over another. Transgenic mice-
derived antibodies undergo affinity maturation in vivo, which obviates the requirement for 
subsequent in vitro affinity maturation, thereby reducing timelines. However, the reported 
affinities for antibodies derived from the two types of platforms fall into the same range, 
with no overall significant difference between affinity-optimized phage displays derived 
mAbs and un-optimized transgenic derived mAbs [43]. It is often desirable to obtain species-
crossreactive antibodies, which allow the evaluation of their biologic function in animal 
models, which are often mice. Typically self-reactive mice-derived antibodies are not 
selected, due to processes of immune tolerance induction. This constitutes a particular 
strength of phage display libraries, which in contrast to transgenic mice platforms and also 
hybridoma technology, allows direct selection for exquisitely specific binding properties, 
such as species cross-reactivity [54]. 
Despite all the above mentioned advances in mAbs manufacturing, drug immunogenicity 
still represents one of the major drawbacks in the usage of these biologics in clinical practice. 
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1.4 DRUG IMMUNOGENICITY 
Immunogenicity is the ability that virtually all therapeutic proteins have to elicit and 
unwanted immune response against themselves, with the production of anti-drug antibodies 
(ADAb).  
The theoretical basis for biologic’s immunogenicity relies on two main principles: on the 
foreign nature of biopharmaceutical (neo-antigens or non-self antigens) or on their similarity 
to self-molecules in cases of protein replacement, where little or no endogenous protein is 
expressed. In the later case, immune tolerance was never developed for the defective or 
absent protein and the biologic will be recognized as a foreign molecule by the recipient's 
immune system.  
To elicit an antibody response, therapeutic protein must interact with three major types of 
cells: professional antigen presenting cells (APCs), T helper (Th) cells and B cells.  
The first step involves the uptake of therapeutic protein by APCs, through pinocytosis, 
receptor-mediated endocytosis or phagocytosis. The efficiency of this process varies 
according several factors, such as the aggregation state of the therapeutic protein, its 
receptor-binding affinity, the route of administration, the capacity of binding membrane 
receptors that will lead to internalization and effective protein processing [55-58]. Receptor-
mediated endocytosis provides a more efficient antigen uptake than non-specific 
endocytosis, enabling presentation of antigens that are present at very small concentrations 
[59]. Inside the APCs, therapeutic protein is cleaved in a mixture of small peptides. Each 
peptide will bind human leukocyte antigen class II (HLAII) molecules, and those who bind 
with “strongly enough” affinity will be displayed at the cell surface. As such, the 
concentration of a particular epitope that is being presented is a function of the amount 
loaded and, crucially, of its affinity for HLAII receptors. HLA polymorphism and its impact 
on the binding of specific peptides (HLA restriction) are primary mechanisms by which 
patients genetics contributes to immune responses to particular protein therapeutics [60-63]. 
Antigen-specific T cells, through its T cell receptor (TCR), will recognize a specific complex 
peptide-HLAII. This interaction, together with co-stimulatory signals provided by the APC 
through CD80 and CD86 molecules, fully activates the specific Th cell. In the absence of 
this co-stimulation, T cells become inactive. Once fully activated, T cells divide and produce 
an array of pro-inflammatory cytokines. Naive B cells that will recognize, through IgM and 
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IgD surface receptors, a cognate antigen bound via a specific T cell epitope-HLA/TCR will 
be activated, proliferate and mature toward a plasma cell. This interaction results in the 
engagement of CD40 and CD40L between T and B cell, which will provide a further signal 
to B cells that will lead to B cell clonal expansion and differentiation into antibody-secreting 
plasma cells and memory B cells. In the absence of activated Th cells, naïve B cells do not 
fully mature, and are rendered anergic or undergo apoptosis.  
T-cell independent activation of B cells may also occur, usually induced by highly repetitive 
structures, where the co-stimulatory signal can be mediated via alternative signalling 
pathways, such as Toll-like receptors (TLR) engagement [64]. Antibodies produced by 
direct B cell activation are mostly IgM or low affinity IgG isotypes. However, the great bulk 
of ADAb are high affinity IgG antibodies, denoting T cell help to antigen-specific B cells 
[65].  
The great dynamic diversity of TCRs and BCRs ensures the recognition of a wide variety of 
sequences and structures, which is important for the defence role of the immune system. On 
the other hand, such diversity implies the generation of new hypervariable sequences to 
which immune system is not tolerant. This explains, in part, why even fully human 
therapeutic mAbs can be immunogenic.  
Tolerance is ensured by complex mechanisms with origin at the thymus. Promiscuous gene 
expression by thymic epithelial cells (TEC) of tissue-specific antigens (TSA) is highly 
relevant to ensure tolerance, as demonstrated in autoimmune regulator protein (AIRE)-
deficient mice [66-68]. It has been argued that T cells carrying TCRs with “too much high” 
affinity for self HLA-peptide complex will be subjected to negative selection mediated by 
medullary TECs (mTECs) [69, 70]. However, clonal deletion at the polyclonal level is 
incomplete, and autoreactive T cells often escapes into periphery [71-76]. Those 
autoreactive T cells are controlled at the periphery by a particular subset of lymphocytes, 
which although less frequent than effector cells, are able to regulate auto-reactive T cells, as 
elegantly demonstrated by Coutinho et al in the beginning of 90’s [77]. Those cells are 
known today as T regulatory cells (Tregs), which are phenotypically characterized as CD4 
cells that express the high affinity receptor for IL-2 (CD25) and also Foxp3, a transcriptional 
factor codified by X chromosome that is essential for these cells’ development and function 
[78-81].  It has been suggested that Foxp3+ Tregs are selected on high-affinity self-reactive 
TCRs, having higher resistance to negative selection than conventional T cells [82-87]. 
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Therefore, Tregs cells will be selected in an antigen-specific manner, according to the 
antigens presented in the thymus during T cell development. It is thus conceivable to 
postulate that newly variable sequences as those continuously generated through V(D)J 
recombination might represent foreign sequences, not represented in the thymus, thereby 
able to elicit an immune response. Recent evidence has, however, demonstrated that the 
antigens may also reach the thymus via the blood stream or immigrating antigen-loaded 
dendritic cells [88-90]. This, together with the possibility of antigen co-presentation by 
thymic APCs and the existence of inducible Tregs at periphery, may explain tolerance for 
antigens not expressed by TEC [91-96]. 
Taken together, this highlights the complexity of immune response to biologics, which 
represents a highly complex phenomenon resulting from the interaction of drug- and patient-
related factors not fully elucidated.  
1.4.1 Drug-related Factors Influencing Immunogenicity 
Perhaps the most understandable factor responsible for an immune response to 
biopharmaceuticals is the proportion of non-self sequences in the biopharmaceutical. Non-
human sequences represent a primary target of human immune system. However, even fully 
human sequences may elicit the production of ADAb. T cell epitope content represents one 
of the major aspects influencing immunogenicity. Fab regions represent the highly 
immunogenic part of mAbs [60]. As mentioned before, the hypervariable CDR regions may 
represent new determinants unlikely to be present in the thymus during T cell development. 
That notion has propelled the development of immunoinformatic tools, able to easily identify 
T-cell epitopes present in a biologic [97-100]. Despite the good correlation that has been 
found between the in silico prediction and in vivo immunogenicity, often in silico assays 
leads to an overestimation of the potential immunogenic T cell epitopes, as not all peptides 
that fit into the HLAII groove are generated by protein processing in vivo. Therefore, a wide 
array of in vitro and in vivo methodologies exist to further validate the ability of those 
peptides to elicit immune responses. Those methodologies include HLA binding assays, 
antigen and presentation assays, T cell proliferation or cytokine assays, T cell phenotyping 
(effector versus regulatory T cells), naïve blood assays, or humanized mouse models [101].  
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In the course of searching for T effector epitopes, regulatory T-cell epitopes (Tregitopes) 
were also identified in the structure of biologic proteins [102]. Tregitopes are specific, highly 
conserved and promiscuous epitopes from conserved regions of human immunoglobulins, 
able to activate Tregs, with the phenotypic properties of “natural” Tregs that supress immune 
responses in vitro and in vivo [102, 103]. In contrast to T effector epitopes, which mainly 
resides in the CDR regions of immunoglobulins, Tregitopes have been found mainly at the 
Fc portion of the human immunoglobulins [102]. There is a close correlation between the 
presence of highly promiscuous HLAII Tregitopes and the absence of HLA-binding T 
effector epitopes, with lack of immunogenicity in published clinical studies [104]. Therefore, 
validated Tregitopes have been integrated in the immunogenicity prediction, greatly 
improving the accuracy of the in silico analysis [104]. Hence, tolerization represents today 
an emerging approach to reduce unwanted immune responses to therapeutic mAb and 
biologic proteins. With the introduction of tolerogenic sequences in the biologic, which are 
thought to induce T regulatory cell expansion, a tolerogenic immune response to biologic is 
expected [103, 105-108]. Preliminary studies have demonstrated that co-administration of 
antigens with Tregitopes in vivo and in vitro leads to the induction of antigen-specific 
tolerance and suppression of both humoral and cellular immune responses to co-
administered antigens [102, 105, 106, 109, 110]. Other strategy that has been adopted to 
induce tolerance has been the design of  ‘stealth’ antibodies. These ‘stealth’ antibodies are 
composed of a peptide “mimotope” linked to the antibody via a flexible linker and can enable 
the host to develop tolerance to a non-binding conformation of the therapeutic protein. This 
approach has been achieved for alemtuzumab in which tolerance was induced to a soluble 
non-binding (single mutation) alemtuzumab variant [58].  
One of the highest risk factor for drug immunogenicity is still protein aggregation despite 
all the advances in drug formulation over the last years. Aggregates are one of the major 
concerns of regulatory agencies, as their presence may results in quantitative and qualitative 
changes in T cell epitope presentation and cellular activation [64, 111, 112]. Certain 
aggregates, such as fibrils, which are large and highly ordered proteins aggregates can be 
presented in an “array” format, such is the case of viral capsids and bacterial cell walls. Such 
arrays may act as potent immunostimulators of innate defence system, which in turn leads 
to an adaptive, more specific immune response [64, 113, 114].  Multiple sources of protein 
aggregation, particles and leachates exist, namely at the stages of product manufacture, 
storage, shipping and drug infusion [115-119]. Patients’ serum characteristics (e.g. 
13 
hyperlipidemia) may also influence protein aggregation, an issue that needs to be further 
explored. Product mishandling by patients or health care professionals can also contribute 
to protein aggregation, although the extent of this problem remains unknown [120]. Methods 
for predicting aggregation are not currently available. 
Glycosylation pattern is also a key aspect in the biologic’s structure. Non-human 
carbohydrate residues might be highly immunogenic [121-123]. The challenge of 
engineering and analysing glycosylation is a cornerstone of biopharmaceutical drug-design 
in nowadays [124]. Therapeutic proteins are produced in cell lines that arederived from a 
variety of sources, including mamals (human and non-human), bacteria, plants, yeast and 
viruses. Small differences in the protein sequence and/or post-translational modifications, 
such as glycosylation, oxidation, damination, acylation and alkylation, may influence the 
immunogenicity profile of the therapeutic protein. 
Other important sources of immunogenicity in a biopharmaceutical are the so-called 
product-related factors. These factors represent the additional compounds other than the 
active ingredient found in the final product, such as degradation products, process- or 
product-related impurities and additives. These impurities, even in small quantities, have the 
potential to stimulate an unwanted immune response [125].  
Even though, despite all the advances in protein engineering technologies, chemistry and 
manufacturing techniques, which have lead to the production of highly pure fully human or 
humanized mAbs, immunogenicity is still a limitation of biologic therapies. However, the 
fact that the same biological may be highly immunogenic in some patients, but not in all, 
strongly suggests that also patient-related factors are determinant to immunogenicity. 
1.4.2 Patient-related Factors 
Genetic differences among individuals might certainly influence the ability to produce and 
maintain a significant immune response against a biopharmaceutical.  
Allelic differences in HLAII molecules are known to account to the inter-individual 
susceptibility to autoimmune diseases, specific infectious diseases and efficacy of some 
vaccines [126-129]. Similarly, those individual allelic differences may also affect drug 
immunogenicity, as demonstrated for factor VIII or Interferon-alpha (IFNα) [130, 131]. 
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Detailed in silico studies have also confirmed the link between HLA and immunogenicity 
[132]. 
Interindividual variation of T cell repertoire may also contribute to differences in 
immunogenicity between individuals. T-cell repertoire is though to be the result of previous 
exposures to related epitopes, vaccination and gut microbiome [133, 134]. Such individual 
specificity, in addition to antigen processing may explain why some HLA binding peptide 
sequences do not induce T cell activation in some individuals [135].  
Recently, a correlation between Il-10 gene polymorphisms and antibody production against 
adalimumab (fully human TNFi) has been described, but a causal relation has not been 
investigated [136]. 
It has been recently proposed that drug immunogenicity may possibly be affected by pre-
existing antibodies, namely by the natural antibody repertoire. Pre-existing antibody 
responses can regulate immune responses following subsequent antigen challenge [137]. It 
was demonstrated that the presence of antibodies specific for Galα1-3Galβ1-4GlcNAc-R 
(αGal), encoded in the natural antibody repertoire, increases T and B cell responses to poorly 
immunogenic antigens that have been modified to express αGal epitopes [121]. Although 
the exact mechanism is not fully elucidated, it has been shown that the presence of αGal-
specific antibodies may allow immune complex formation or efficient antigen presentation 
by B cells, which increases the efficiency of priming immune response to the antigen [121, 
138, 139]. Anti-hapten responses have shown to be either increased or suppressed depending 
on the titre of pre-existing antibodies [140, 141]. Similarly, in IBD patients, pre-treatment 
infliximab-Fab reactive IgGs were significantly higher in patients developing infusion-
reaction to infliximab than in remaining patients, while were significantly lower among 
those who were in remission one year after infliximab treatment [142]. The role of antibodies 
as immune regulators has first described more than one century ago [143], and may explain 
the effectiveness of intravenous immunoglobulin (IVIG) therapy in many autoimmune 
conditions.  IVIG exerts its effect through a wide array of mechanisms, including immune 
complexes formation and immuno-modulation via anti-idiotypic interactions [144, 145]. 
The evidence that our immune system contains a large variety of antigenic structures in the 
form of the V-regions of immunoglobulins and TCR, able to interact even in the absence of 
nominal antigens, lead Niels Jerne, in early 70’s, to postulate that idiotypic interactions 
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would be on the basis of the selection of “pre-immune repertoires” and in the establishment 
of natural tolerance [146]. Natural antibodies are critical in providing early protection 
against pathogens, although they may also participate in T-cell dependent immune responses 
[147-150]. A huge fraction of natural antibodies are conserved among different individuals 
[151]. Computer simulations of the immune network show that the greater the degree of 
connectivity of a clone, the greater is its degree of tolerance to chronic antigenic stimulation 
[152]. The study of those specificities might integrate further models of drug design, aiming 
to select V-regions of therapeutic antibodies that show the wider connectivity profile with 
pre-existing clones.  
The type of the disease and the immune status of the patient might also influence 
immunogenicity. We might expect to verify higher immune responses in patients with 
autoimmune diseases that are more prone to antibody production. High disease activity and 
baseline inflammatory markers (C-reactive protein) have been detected among RA patients 
who become ADAb-positives, maybe reflecting a highly active immune system [153]. 
Neutralizing ADAb to a Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) 
product was described in 95% of immune-competent cancer patients but only in 10% of 
immune-compromised cancer patients [154]. Similarly, rituximab, a chimeric anti-CD20 
mAb, elicited no immune response from B cell chronic lymphocytic leukemia patients, but 
was immunogenic in 27% of Sjögren syndrome and in 65% of Systemic Lupus 
Erythematous [155-158].  
Drug immunogenicity may also be age related, as protein turnover is different in children 
compared to adults. However, there is a lack of studies specifically comparing the 
immunogenicity of biologics in these two populations.   
The use of concomitant immunosuppressive therapies has also been associated with 
decreased immunogenicity. Co-treatment with methotrexate, azathioprine, 6-
mercaptopurine and hydrocortisone has been associated with lower antibody responses to 
TNFi in RA or Crohn’s Disease patients [159, 160]. Similarly, pre-treatment with 
methotrexate plus rituximab ± IVIG in children receiving alglucosidase for Pompe disease 
or pre-treatment with IVIG in hemophilic patients receiving recombinant human FVIII, was 
associated with reduced immunogenicity and better clinical outcomes [161, 162]. 
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Factors such as administration route, drug regimen and dosage may also affect drug 
immunogenicity.  Administration of a biologic into sites with a high prevalence of dendritic 
cells (DCs), such as subcutaneous tissue, seems to increase the risk of immunogenicity due 
to prolonged exposure to and uptake by DCs, as compared with intravenous administration 
[163-165]. In a recent study, intravenous abatacept (a fusion protein consisting of CTLA4-
Fcγ1) was revealed to be less immunogenic than subcutaneous abatacept [166]. Moreover, 
the immune complexes formation may lead to local inflammation at injection site, and may 
also reduce the absorption of the biopharmaceutical, preventing them to reach the target 
sites.  
Intuitively, we would say that frequent drug administration increase the potential drug 
immunogenicity. However, regular, scheduled administrations have been associated with 
lower incidence of ADAb, in comparison with episodic or on-demand regimens [160, 167, 
168]. Similarly, it is conceivable to assume that higher doses of biologic would increase 
immunogenicity, as higher amounts of drug (antigen) and product-related factors would be 
administered. However, it has been shown that in contrast to initial lower-doses of antigen, 
initial higher doses lead to small numbers of memory T cells and less efficient immune 
responses upon re-challenge with the same antigen [169, 170]. This point is of major 
relevance, since induction dosages are preconized only for some biologics in the treatment 
of specific diseases [171, 172]. 
In comparison to the extensive knowledge that has emerged about the drug-related factors, 
very few are still known about the patient-related factors implicated in drug immunogenicity. 
Further research is warranted to better understand the inter-individual variability on immune 
responses, aiming to predict the patients at risk to develop significant immune responses to 
a given biologic and to modulate immunogenicity below to its clinical significance.  
1.4.3 Immunogenicity Assessment 
As drug immunogenicity may have dramatic impact on product safety and efficacy, the 
assessment of immunogenicity starts at the very early phases of drug development. This 
notion have led the regulatory agencies to develop risk-based guidelines for immunogenicity 
screening, which is mandatory for the approval of biopharmaceuticals [173, 174].  
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Currently, combined in silico, in vitro and in vivo strategies are adopted by drug developers 
in order to rapidly screen therapeutic proteins for potential immunogenicity. Different 
bioinformatics tools are today available to screen T cell epitopes that bind HLAII with high 
affinity [97-101]. However, those in silico methods cannot be used alone to evaluate 
immunogenicity, as they cannot evaluate aspects such as processing and peptide 
presentation, affinity or peptide-HLA stability, TCR affinity or post-translational 
modifications that may influence the immune response against therapeutic proteins. 
Therefore, further in vitro and in vivo validation is warranted to confirm the potential of 
predicted epitopes to induce an immune response. 
A wide array of in vitro assays can be used: 1) HLA binding assays to evaluate the ability of 
peptides to bind HLA class II proteins; 2) Dendritic Cell (DC) assays to detect potential 
endogenous and exogenous DC stimuli, either related to the drug (aggregates, misfolding, 
denaturation) or related to the formulation (impurities and excipients); 3) T cell assays to 
evaluate cellular proliferation, phenotype and cytokine release, which also provides the 
information about the nature of the T cell response. However, in vitro testing may not reflect 
differences in how the protein is processed and presented in vivo or the inter-individual 
variability in DC responses or T cell repertoire, which may lead to some discrepancies in the 
results.  
 In vivo methods represent another mean of evaluating the potential immunogenicity of a 
protein or peptide. Most commonly, NOD scid gamma (NSG) mice transplanted with human 
immune systems and/or transgenic ‘immune tolerant’ mice that express the protein 
therapeutic have been used to predict immunogenicity in humans [175]. They also allow us 
to modulate factors such as dosing, drug concentration and route of administration. 
Transgenic animal models can be used to study the immune response as a consequence of a 
break in tolerance [176-178]. One example of such an approach is the use of a transgenic 
mouse model expressing human IFNβ which was used to model the development of ADAs 
against various recombinant IFNβ products. These transgenic mice were more sensitive than 
previous ‘hybrid’ transgenic mice models, in that they were not only suitable for studying 
factors that break immunological tolerance but could also be used to dissect the effects of 
protein structure, formulation and aggregation on the induction of ADAs [175, 179, 180].  
However, important limitations exist in each model because the mechanisms underlying 
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immunogenicity are still unknown and there may be important differences between the 
human and animal responses. 
Such combined approach for immunogenicity prediction at very early phases of drug 
development allows the rapid identification of potentially high immunogenic drugs before 
entering in clinical phase, saving time, costs and efforts.  Aditionally, the identification of T 
effector epitopes in therapeutic proteins also allow the identification of the best candidates 
for de-immunization with the aim to eliminate or camouflage those epitopes. Such strategy 
reduces the interaction of therapeutic proteins with immune effector cells, thereby reducing 
their immunogenicity [29, 181-186]. Point mutations, pegylation or glycosylation are 
examples of techniques that have been used to mask the immunogenic epitopes [187-189]. 
However, de-imunization techniques have also some limitations, as those changes may alter 
the structural and functional properties of therapeutic proteins, which may render them non-
functional or even more immunogenic. 
Still, it should be also stressed that despite the good correlation that has been verified 
between the T cell epitope content predicted by in silico tools and the development of 
significant immunogenicity in further clinical trials, immunogenicity at population level can 
be quite different from immunogenicity at individual level [61, 132, 190]. Inter-individual 
variability, such as HLA haplotype, TCR repertoire, immune status or concomitant therapies 
may influence immunogenicity at individual level. Therefore, there is a need to monitor 
immunogenicity beyond the approval phase, as recently recommended by the European 
Medicines Agency (EMA) [191]. 
Because ADAb production is the end-result of immune response to therapeutic proteins, 
circulating ADAb has been the chief criterion for defining an immune response to biologics. 
However, the detection of ADAb is technically challenging. 
Different types of ADAb may be defined according to the target epitope region in the 
therapeutic antibodies:  anti- idiotypic, anti-isotypic and anti-allotypic ADAb.  
Anti-idiotypic antibodies, represent the bulk of antibody response against therapeutic mAbs 
[60, 192-194]. Those ADAb will compete with the endogenous ligand for the binding to the 
drug and are designated as neutralizing antibodies because they can immediately inhibit the 
working mechanism of the drug [153, 195]. Antibodies targeting different regions of the 
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drug have also been described, although they represent a minor part of ADAb [196]. It would 
be expected that allotypic mismatch would induce ADAb formation [4]. However, the 
association between the patients’ allotypes and the presence or concentration of ADAb have 
not been verified so far [196-198]. Nonetheless, ADAb that target different regions of 
biologic molecule than idiotypic regions are designated as non-neutralizing antibodies as 
they did not prevent the binding between the drug and the endogenous ligand. 
Several methods are available to detect antibodies, including binding assays based on 
immunochemical procedures such as solid or liquid phase immunoassays, 
radioimmunoprecipitation assays and biophysical methods such as surface plasmon 
resonance [199, 200].  
Immunoassays have been the most commonly used methods to measure ADAb. 
Immunoassays use the specific interaction of antibody with antigen to provide quantitative 
information about antibody (or antigen) concentration. They can be conducted using a 
variety of formats and/or detection systems, including direct, indirect, bridging and 
competitive platforms using radioligand, enzymatic, fluorescent, chemi-luminescent or 
electrochemical luminescence detection systems [201]. However, the detection of antibodies 
against antibodies offers particular concerns and all the methods currently available have 
their own limitations that should be taken into account for a proper interpretation. 
The most common methods employed to assess ADAb are enzyme-linked immunosorbent 
assays (ELISAs) and radioimmunoassays (RIAs). Different assays exist of each method, 
with different sensitivity and specificity [202]. The initial assays used to assess ADAb were 
mainly ELISA methods. However, several limitations were found in those initial methods, 
which may had contributed to an underestimation of true immunogenicity induced by the 
long-term use of biologics in humans.  Often, in those initial ELISAs, an anti-
immunoglobulin antibody was used as secondary reagent, which is not appropriate to detect 
ADAb, as it can also bind to the therapeutic antibody used in the coating. To circumvent this 
problem several strategies were developed, such as coating the microtiter plates with drug-
F(ab’)2 or drug-Fab fragments. However, it has been verified that serum of healthy 
individuals contains high titers of IgG antibodies against coated F(ab’)2 or Fab fragments, 
which lead to very high cut-off levels in normal serum and, thus, high false-negative rates 
in positive samples [203-205]. Furthermore, the immobilization of Fab/F(ab’)2 fragments 
on a plastic surface may alter the antigen conformation, masking some epitopes or revealing 
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new ones, such that antibodies specific to the original epitope of interest may not be 
recognized [206]. In such instances, it may be necessary to preform an “indirect assay” by 
immobilizing a capturing agent (e.g. monoclonal antibody specific to the antigen or 
streptavidin to capture antigen conjugated to biotin), which can then be used to anchor the 
therapeutic protein [206].  
The majority of therapeutic antibodies are of κ light chain in contrast to the majority of 
antibodies produced by human immune system, which are mainly of λ light chain. Anti-λ 
antibodies have been used in an attempt to more specifically assess ADAb. However, it has 
been verified that anti-λ light chain antibodies may also target other antibodies present in the 
sera, which are able to bind to the coated therapeutic antibody through Fc-Fc interactions. 
These antibodies have been detected even in healthy individuals or untreated patients [207]. 
Once more, the high cut-off levels in normal sera lead to a significant underestimation of the 
presence of ADAb. On the other hand, although being a minority, ADAb of λ light chain-
type cannot be revealed by this strategy.  
Several optimizations of ELISA method have been conducted, improving its performance in 
the detection of ADAb. Adoption of a “bridging antibody” format in which ADAb is 
captured by immobilized antigen and detected using the labelled antigen can provide 
ELISAs with high specificity because ADAb must be recognized twice for detection. The 
bridging capacity that is required for ADAb detection, might prevent the detection of he 
majority of IgG4, as human IgG4 tend to exchange half of the molecule with other IgG4 
molecule that can be of different specificity, creating a monovalent Ig that loose bridging 
ability [17, 208] – Figure 3. 
Nonetheless, compared with the previous formats, Bridging ELISA has high sensitivity and 
relatively low background. Cross-linking by C1q and rheumatoid factors (RF) may still 
occur, although both can be eliminated by pre-treatment of serum with RF-neutralization 
reagent, which consists of IgG coated latex particles. This type of assay has been 
increasingly used to detect antibodies against therapeutic antibodies [209-212].  
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Figure 3 – Bridging ELISA 
Radioimmunoassays have been also designed specifically to quantify ADAb, and are 
considered by many as the current “gold-standard” to assess ADAb [195, 202, 213]. RIA-
ABA offers some advantages over ELISAs: it provides a fluid-phase platform, where 
therapeutic antibodies are in solution, which prevents the denaturation effect of coating; in 
contrast to bridging ELISAs, RIAs can detect monovalent IgG4 ADAb and discriminate 
them from other isotypes by the use of isotype-specific sepharose-coupled antibodies – 
Figure 4.  
 
Figure 4 – Radioimmunoassay (RIA) – Antigen Binding Test (ABT) 
RIAs are also less sensitive to drug interference, when compared with ELISAs [209]. On the 
other hand, RIAs are more difficult to automate than ELISAs and samples throughput is 
normally slower. RIAs can also be prone to artefacts, as the radiolabelling processes can 
mask/denaturate epitopes recognized by antibodies. However, the major disadvantage of 
RIAs is the requirement of high amounts of radioactivity and special laboratory conditions 
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for its implementation, which limits its use at a large-scale basis on the routine clinical 
practice.  
The newly developed RIAs and Bridging ELISAs have been developed toward the detection 
of anti-idiotypic antibodies, as they use as secondary reagents the drug or the drug-Fab2. 
However, in rigor the neutralizing capacity of ADAb can only be confirmed through 
bioassays, which are vitro assays based on a functional aspect of the protein or mechanism 
of action. Different type of bioassays can be used. Both cell based and ligand-binding assays 
can be pursued for the detection of neutralizing antibodies (NAb) [199, 214-218]. While 
cell-based assays are believed to be the preferred NAb assay format, they do have 
disadvantages including high variability, low throughput and low sensitivity [214] . 
However, new generation reporter gene assays using growth-arrested cells are able to 
provide the desired sensitivity and limited variability. It is important to remember that 
irrespective of the NAb assay format it will only determine the potential of in vitro 
neutralization, whereas for in vivo translatability additional factors need to be taken into 
account, including clearance of ADA-drug immune complexes, pharmacokinetics in relation 
to ADA levels and efficacy or the equilibrium/affinity in vivo and in vitro between the 
drug/antibody/target. Due to the constraints associated with NAb assays, it could be 
considered whether it is helpful to monitor the pharmacokinetic/pharmacodynamic (PK/PD) 
profile of the biologic as indirect indicator for the presence of neutralizing factors.  
Furthermore, recent data including that of different TNFi have demonstrated that virtually 
all ADA detected in patients through antigen-binding radioimmunoassay are neutralizing 
antibodies since they are directed against the CDR of the therapeutic mAb [219]. This 
evidence calls into question the usefulness of evaluating a second method for the 
measurement of the neutralizing capacity of the ADA against mAb in routine clinical 
practice.  
EMA has recently recommended the routine immunogenicity assessment beyond the 
approval phase of biologics [191]. However, the proper way to do this assessment is not yet 
formally established and some controversies have emerged regarding the type of assays and 
strategies that should be implemented. Irrespectively of the strategy that will be adopted, 
most important than to simply assess ADAb will be to correlate their presence with 
parameters such as PK and/or PD, together with clinical consequences, for an appropriate 
evaluation of their clinical significance.  
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1.5 RHEUMATOID ARTHRITIS 
The paradigmatic example of the clinical success of anti-cytokine biologic approach is 
Rheumatoid Arthritis, starting by TNFi therapies that soon had extended to other cytokines, 
as the complexity of cytokine network in the disease became increasingly known. 
Today, RA represents one of the diseases with more different biologics approved for its 
treatment, which makes it a good disease model to evaluate the impact of drug 
immunogenicity and how its routine assessment might improve the use of these therapies 
towards a higher benefit for the patients and for the society. 
RA is chronic disabling inflammatory disease that primarily affects the synovium, cartilage 
and bone. It affects 1% of the population and is associated with significant increase in 
morbidity and mortality [220].  
Despite RA has been generally accepted as an autoimmune disease, it remains somehow 
controversial as the identification of a dominant arthritogenic autoantigen is still missing and 
the reproducibility of rheumatoid arthritis in animal models has been difficult to 
demonstrate, despite some similarities with human disease [221, 222].   
The idea that autoimmune mechanisms might underlie RA pathogenesis arises with the 
discovery of rheumatoid factors (RFs) in the blood of affected patients [223, 224]. RFs are 
autoantibodies targeting the Fc-part of human IgG. They are mainly of IgM isotype, although 
other isotypes, such as IgG, have also been described in some subgroups of RA patients 
[225]. RFs are thought to form immune complexes with IgGs activating complement in the 
joint, which in turn leads to increased vascular permeability and the release of chemotactic 
factors recruiting immune-competent effector cells to the joint [226]. Even though, RF are 
not sufficient neither necessary for arthritis development, as RF are present in up to 15% of 
healthy individuals and many other medical conditions, whilst around 20% of RA patients 
test negative for the presence of RF [227-229]. Therefore, the role of RFs in disease aetiology 
has not been established.  
More recently, citrulline-specific reactivities against a number of citrullinated proteins, such 
as fibrinogen or vimentin, have been identified in RA patients [230]. Citrullination is a 
process by which arginine residues in a given protein are post-translationally modified 
(“deaminated”) in the presence of high calcium concentrations by an enzyme called PAD 
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(peptidyl arginine deaminase). Citrullination is a physiological process, which is believed to 
be important for degradation of intracellular proteins during apoptosis. Anti-citrullinated 
protein antibodies (ACPA) are found in 60-70% of RA-patients, but have been rarely 
detected in other diseases or healthy subjects [231]. Despite their unique (>95%) specificity 
for RA, the extent to which ACPA are directly involved in RA pathogenesis continues to be 
the subject of intense debate and investigation.  
Genetic factors are known to be critical in the disease pathogenesis. The estimated 
heritability of RA, i.e., to which extent a condition in a population can be explained by 
genetic variation, has been calculated as up to 60% [232-234]. Due to technical advances in 
genotyping, over the last few years, an increasing number of genetic variations that show an 
association with RA have been identified. 
The strongest and most relevant genetic risk factor for the development of RA, contributing 
around 30% to the total genetic effect, is found in the HLAII-encoding locus (chromosomal 
position 6p21.3). Similarities in HLA-DRB1 have been found among RA patients, exhibiting 
a common amino acid sequence at position 70-74 in the third hypervariable region of the 
DRβ1-chain. This sequence, consisting of glutamine/arginine-leucine/arginine-arginine-
alanine-alanine (Q(R)K(R)RAA), is associated with RA and has been termed the “shared 
epitope” [235-237]. This conserved amino acid sequence was thought initially to be situated 
in the antigen binding cleft of HLA-DRB1 and, thus implicated in binding of a putative 
arthritogenic peptide (“shared epitope hypothesis”)[235]. More recently, by crystallography 
techniques, it was verified that the shared amino acids actually face away from the antigen-
binding cleft. Interestingly, this shared epitope despite being a primary risk factor for RA 
per se, it also represents a risk factor for ACPA positivity [236], with these autoantibodies 
developing preferentially (but not exclusively) in patients that harbour one or two shared-
epitope alleles. Residues at the position 70-71 of the shared epitope have found to be critical 
for the affinitiy between HLA II molecules and the citrullinated peptides, and may influence 
risk of ACPA-positivity by modulating T-cells responses. In contrast to the sequence 
Q(R)K(R)RAA at position 70-74 in the third hypervariable region of the DRβ1-chain, the 
amino acid sequence DERAA at the same position have demonstrated an independent 
protective role in its carriers from the development of RA, even in the presence of coexisting 
shared epitope alleles.  The mechanism behind this protection conferred by DERAA 
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sequence remains to be elucidated. DERAA-encoding alleles are found in approximately 
30% of healthy caucasian individuals, but only in 16% of RA-patients [238, 239]. 
Non-HLA genetic association with RA has also been described. With the increasing number 
of genome-wide association studies, several polymorphisms at several genes, namely 
PTPN22, STAT4, CTLA-4, IL2RA, among many others, have been identified as risk factors 
for RA susceptibility [240-249]. However, the functionality of these polymorphisms remains 
to be formally established. Moreover, these non-HLA genetic variants invariably confer only 
very modest independent disease risk, often displaying individual odds ratios of little more 
than 1. The additive effects of such minor genetic determinants are unlikely to ever describe 
all of the unaccounted heritability of RA, and it seems likely that distinct genetic risk factors 
may provide multiplicative, rather than merely additive, combined risk, with gene 
environment interactions further completing the picture. 
Environmental factors are also key players in the induction, magnitude and rate of the disease 
progression, in individuals who are genetically susceptible. Among environmental factors, 
cigarette smoking has been described as the most important risk factor for RA. A correlation 
between cigarette smoking and an increased risk of severe disease, has been described, in 
proportion to the number of pack-years [249]. Moreover, smoking is seen to represent a risk 
factor for ACPA-positivity, particularly in the presence of shared epitope alleles (up to an 
estimated 21-fold as compared to shared-epitope negative non-smokers), illustrating the 
multiplicative effect of combined risk factors [248, 250]. Citrullinated proteins have been 
detected in bronchoalveolar lavage fluid from smokers but not from non-smokers, 
suggesting an induction of protein-citrullination by smoking, through a mechanism not fully 
elucidated [250].  
Other environmental factors, such as infectious microorganisms or sex hormones have also 
been proposed as risk factors for the disease. According to the available evidence, no 
compelling evidence has yet implicated a single microorganism as the cause for RA. The 
higher prevalence of RA in women and a tendency for disease to improve in pregnancy, 
suggests some influence of sex hormones in disease pathogenesis, although the precise 
relationship is not known [251].  
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The main affected tissue in RA is the synovium, which can be easily obtained by tissue 
biopsy. Largely driven by this factor, the histologic and cytokine pattern in the inflamed 
tissue has been extensively scrutinized.  
Rheumatoid synovium is classically hyperplastic, exhibiting a marked cellular infiltrate, 
which includes CD4+ T cells, CD8+ cells, B cells, plasma cells, neutrophils, natural killer 
(NK) cells and also NKT cells. The interaction of these cells with other residential synovial 
cells, including macrophages, fibroblasts, mast cells and dendritic cells, allows the release 
of a multitude of cytokines, chemokynes and other molecules that play an essential role in 
the continuation of the inflammatory process [252-254]. The inflamed synovium invades 
adjacent cartilage and promotes articular destruction, which is mediated by the activation of 
osteoclasts, chondrocytes and synovial fibroblasts [255]. 
The first analysis of the cytokine pattern of the rheumatoid synovium started in the 1980s, 
when cytokine cDNAs were cloned and tools to measure cytokine expression became 
available. It was observed that the rheumatoid synovium is enriched with almost every 
cytokine known, particularly key pro-inflammatory cytokines such as Tumor Necrosis 
Factor Alpha (TNFa), IL1 and IL6 [256-258]. By using short-term cultures of rheumatoid 
synovial cells and neutralizing antibodies against specific cytokines, it was possible to 
demonstrate the dominance of TNFa within the complex cytokine network existed in 
rheumatoid synovium [258]. A linear model was proposed at the time, in which TNFa would 
drive downstream cytokines, such as IL1 and IL6 sequentially [259]. These studies 
represented the first evidence revealing TNFa as a good target in RA.  
1.6 TUMOR NECROSIS FACTOR ALPHA  
TNFa, named for its ability to cause rapid necrotic tumor regression, was the first described 
member of the TNF ligand superfamily, which is known to have pleiotropic functions 
including cell proliferation, differentiation, activation and apoptosis [260]. TNFa is 
primarily produced by monocytes and macrophages, although T- and B-lymphocytes also 
produces significant amounts of TNFa [261, 262]. Other cells, such as neutrophils, 
endothelial cells, keratinocytes and fibroblasts may also be sources of TNFa during acute 
inflammatory responses [263]. Its synthesis is initiated by the transcriptional activation of 
the TNFa gene, which is largely driven by several nuclear factor-κB (NF-κB) responsive 
elements in the 5’ promoter region [264]. TNF gene lies in the class III region of the Major 
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Histocompability Complex (MHC), approximately 250 kilobases centromeric of the HLA-
B locus and 850 kilobases telomeric of HLA-DR [265]. TNFa expression is kept under tight 
control and the bulk of TNFa expression is regulated post-transcriptionally [266-269].  
TNFa exists in two bioactive forms, a transmembrane and a soluble form. It is initially 
expressed as a transmembrane protein of 26 KDa, which is proteolytically cleaved off the 
membrane by TNFa converting enzyme (TACE) to form a secreted protein of 17 KDa [270, 
271]. The 17KDa form of TNFa then aggregates into trimolecular complexes, which bind 
and activates its receptors.  
TNFa exert their functions via two different cell surface receptors: p55-TNFR (TNFR-I, 
CD120α) and p75-TNFR (TNFR-II, CD120b). p55-TNFR is virtually expressed in all cell 
types, whereas p75-TNFR exhibits more restrictive expression, confined to certain 
lymphocytes subpopulations, including CD4+ and CD8+ cells [272], B cells [273], 
thymocytes [274, 275], oligodendrocyte progenitors [276] and few other cell types [277, 
278]. Each of the cell types bearing p75-TNFR also expresses p55-TNFR. The ratio of their 
expression fluctuates according the cell type, its function and its activation state [279, 280].  
TNF receptors are initially synthesized as membrane-anchored proteins, but they can be 
released form the cell surface by proteolysis and are constitutively released in the circulation 
[281]. TNF soluble receptor levels increases in response to several stimuli, such as TNF, 
lipopolysaccharide (LPS), T cell and neutrophil activation [282-285]. The release of TNFR 
into the circulation in response to all of those stimuli leads to an acute decrease in the number 
of TNFR on the cell surface, which probably serves to transiently desensitize cells to the 
TNF action, while the soluble receptors might act as a physiological attenuators of the TNF 
activity, by competing for the ligand with the cell surface receptors.  
Both receptors display structurally similar extracellular domains but signal through distinct 
intracellular regions, with p55-TNFR containing a death domain that is not present in the 
p75-TNFR [286]. In general, TNFa largely relies on p55-TNFR for apoptosis and on p75-
TNFR for any function related to T-cell survival [279, 287-289]. Overall, TNFa binding to 
p55-TNFR activates apoptosis through a pathway involving the adaptor proteins p55-TNFR-
associated death domain (TRADD) and Fas-associated death domain (FADD), to coordinate 
downstream signalling by the caspase cascade [290]. By contrast, p75-TNFR signalling 
begins with the recruitment of the adaptor proteins TNF receptor-associated factor 1 (TRAF 
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1) and TRAF 2, ending with the mobilization and nuclear entry of the pro-survival 
transcription factor NF-κB to promote transcription of pro-survival genes [291, 292]. 
However, some degree of crosstalk and overlap in functions between the two receptors has 
been described, by mechanisms that are not fully known [293, 294]. 
The contribution of TNFa to joint inflammation and bone erosions is quite extensive. TNF 
is able to induce fibroblast-like synoviocytes and collagenases, inhibiting proteoglycan 
synthesis by articular chondrocytes, leading to cartilage destruction [295-299]. Additionally, 
TNFa also stimulate osteoclastogenesis and bone resorption, responsible for the erosive bone 
disease [300, 301]. 
However, the role of TNFa in immune pathophysiology is highly complex. Despite all the 
well-known pro-inflammatory properties of TNFa, an increasing body of evidence has 
emerged over the last years highlighting the immunoregulatory properties of TNFa [302, 
303].  
While TNFa overexpression in newborn NOD mice accelerates disease progression, in adult 
mice it is able to prevent autoimmune diabetes [304-308]. Despite the participation of TNFa 
in inflammatory demyelination of the central nervous system (CNS), demonstrated in several 
animal models, the blockade of TNFa in Multiple Sclerosis (MS) patients had completely 
unsuccessful results [309-318].   The same was verified by using TNFi in SLE patients and 
animal models of the disease, leading to the exacerbation of autoimmune phenotype. 
Similarly, prolonged TNF blockade in patients with RA or IBD have been associated with 
autoimmune phenomena [319-322].  
The level, timing and duration of TNFa exposure, as the differential distribution of TNF 
receptors in different cell types and the genetic background of the organism may account for 
such pleiotrophism [303, 323]. 
1.7 TNF INHIBITORS IN RA 
The critical role of TNFa in rheumatoid arthritis pathogenesis was successfully tested in 
animal models, such as collagen-induced arthritis. These studies provided the rationale for 
clinical trials of anti-TNFα therapy in patients with long-standing RA.  
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The first TNFi tested in RA occurred in 1992, using Infliximab: a chimeric mouse Fv-human 
IgG1 monoclonal antibody that binds soluble and membrane-bound TNFa with high 
neutralizing capacity [324]. The results were highly encouraging, as infliximab treatment in 
comparison to placebo, lead to a 60–70% reduction in the measures of disease activity, such 
as swollen or tender joint counts and inflammatory markers such as C-reactive protein (CRP) 
[325]. However, the duration of this study was very short in order to be able to have patients 
in placebo not dropping out. Longer follow up studies were only possible by enrolling 
patients with active disease despite therapy with methotrexate (MTX), one of the most potent 
therapies in RA. Consequently, infliximab trials have always been conducted in combination 
therapy with MTX, with treatment with infliximab plus MTX revealing significant better 
clinical and radiographic outcomes than MTX alone [326]. Long-term efficacy and safety 
had also been demonstrated. At 52-weeks of follow-up, infliximab treatment demonstrated 
improvement in patient’s quality of life and functionality [327]. The efficacy of infliximab 
has been demonstrated either in established as in early RA, ie, ≤ 3 years’ disease duration 
[327, 328]. Infliximab was approved for RA treatment in combination with MTX, with a 
recommended regimen of an i.v. infusion of 3mg/Kg body weight at 0, 2, 6 and every 8 
weeks thereafter, although higher doses (6 and 10 mg/Kg) had revealed slightly better 
outcomes, with no significant increase in adverse events [327, 328]. Dose escalation is 
recommended in case of partial or non-response, in an attempt to (re)gain efficacy. 
With the successful results obtained with infliximab, other clinical trials started to be 
conducted with other TNFi that were being developed at the time.   
The second TNFi to be tested in RA was Etanercept, a dimeric fusion protein comprised of 
two extracellular portions of p75-TNFR (75-kDa TNF receptors) linked to the Fc portion of 
a human IgG1. Only the junction between these two domains, the hinge region, is composed 
by few non-human a.a. residues. Etanercept inhibits TNFa activity by binding soluble and 
cell bound TNFa with high affinity and by competing with natural TNFa receptors. 
However, the affinity of etanercept to membrane TNFa is lower when compared with 
infliximab or adalimumab, two monoclonal antibodies targeting TNFa [329]. Etanercept can 
also neutralize lymphotoxin alpha (LTa). The efficacy and safety of etanercept have been 
demonstrated either in patients with persistently active RA despite MTX treatment, as well 
in MTX-naïve patients, with or without concomitant MTX [330-335]. However, 
combination therapy has been always associated with better clinical outcomes. Short and 
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long-term efficacy and safety of etanercept has been demonstrated, both in established and 
in early RA [332, 336, 337]. The recommended regimen is 25 mg s.c. twice a week or 50 
mg s.c. weekly, with equivalent efficacy and, with or without concomitant MTX [338]. 
Few years later, adalimumab emerged as the first fully human monoclonal antibody against 
TNFa. Adalimumab is an IgG1κ monoclonal antibody, made by phage display technique. 
Adalimumab has also proven efficacy and safety in both longstanding and early RA, MTX 
resistant or not [339-343]. Again, a synergistic effect was verified with the concomitant 
MTX in comparison with MTX alone or adalimumab alone [340, 342]. Therefore, although 
approved in monotherapy for the treatment of RA, adalimumab is recommended in 
association with MTX, in a dose of 40 mg subcutaneously every other week. 
Recently, two other TNFi were introduced in the market: golimumab and certolizumab, for 
RA treatment.  
Golimumab is an IgG1κ monoclonal antibody produced through genetically engineered 
transgenic mice immunized with human TNF, resulting in an antibody with human-derived 
antibody variable and constant regions. It has high specificity and affinity for soluble and 
transmembrane TNFa [344]. Similar to the previous TNFi, short and long-term efficacy and 
safety have been demonstrated in patients with either early or longstanding RA, MTX-
resistant or MTX-naïves patients, in monotherapy or in combination with MTX [345-348]. 
Because golimumab was the fourth TNFi entering in the market, it was important to assess 
its safety and efficacy in patients who had been previously submitted to one or more TNFi 
(switcher patients). This study, conducted up to 14 weeks, revealed better therapeutic 
outcomes in golimumab-group than in placebo-group. The type of previous TNFi was not 
considered and, although it was described that 58% of patients had switched due to lack of 
effectiveness and 53% due to other reasons (intolerance and accessibility issues), the 
outcomes were not compared between these two groups [349]. Nevertheless, golimumab 
was considered efficient and safe for both biologic naïve and switcher patients, at a 
recommended dosage of 50 mg s.c. once a month [344]. 
Certolizumab is a PEGylated recombinant, humanized antibody Fab’ fragment 
specific for human TNFa. Several clinical trials have demonstrated superior efficacy 
of certolizumab plus MTX versus MTX alone at 24 weeks of treatment. The 
combined therapy significantly improved disease activity scores, inflammatory 
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parameters, radiographic progression, patients’ functionality and quality of life [350, 
351]. When compared with placebo, certolizumab-treated patients also exhibited 
better clinical outcomes at week 24 [352]. Certolizumab has also shown efficacy in 
RA patients with secondary inadequate response or intolerance to previous TNFi 
(switchers) [353, 354]. Certolizumab is approved for RA treatment at a recommended 
initial dosage of 400 mg at weeks 0, 2 and 4, followed by maintenance dose of 200 
mg every other week. A more convenient dosing regimen of 400 mg every four weeks 
can be, however, considered. 
The therapeutic success of TNFi has motivated the emergence of other anti-cytokine drugs 
for RA treatment. However, TNF blockade still represent the most widely used strategy 
adopted in RA patients.  
1.8 NON-TNFI BIOLOGIC THERAPIES IN RA 
Although TNFa has been shown to play a central role in RA physiopathology, it has also 
been demonstrated that TNFa is not absolutely required for osteoclastogenesis, osteolysis 
and erosive arthritis, since all of those events may occur in the absence of TNFa [355-357]. 
Additionally, there is still a subgroup of RA patients that never achieve response to TNFi 
agents, being described in the literature as the “TNF-independent” RA. Taken together, this 
evidence propelled the introduction of biologic therapies with different targets than TNFa 
for the treatment of RA, with successful results.  
Anakinra is a recombinant, non-glycosylated version of the human interleukin-1 receptor 
antagonist (IL-1Ra) that competitively inibiths the binding of IL1 to IL1 receptor. IL1 is a 
pivotal pro-inflammatory cytokine mediating many cellular responses including those 
important in synovial inflammation and subsequently joint destruction in RA [358]. A 
correlation has been reported between IL1concentration in the plasma and the activity of the 
disease [359]. Clinical trials of anakinra have shown that it reduces the signs and symptoms 
of active disease and slows the rate of radiographic destruction in adults with RA [360, 361]. 
Anakinra was approved by EMA in 2002 for the treatment of moderately to severely active 
RA patients who have failed one or more synthetic disease-modifying antirheumatic drugs 
(DMARDs) [362]. Anakinra can be used alone or in combination with DMARDs other than 
TNFi, in a daily subcutaneous injection of 100 mg. Although no direct head-to-head studies 
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have been performed between anakinra and other biologics, such as TNFi, indirect 
comparisons with adalimumab, etanercept and infliximab, showed a trend towards greater 
efficacy for the TNFi [363]. Anakinra also seems to be associated with comparably high 
rates of injection reactions [363]. Such evidence has lead to an underuse of anakinra in RA 
and in nowadays its use is merely occasional [364].   
Rituximab is a chimeric human-murine anti-human antigen CD20 monoclonal antibody 
[365]. Initially developed for the treatment of certain lymphomas, the efficacy and safety of 
rituximab for the treatment of RA have been extensively demonstrated in both clinical trials 
and observational studies [366-372]. Although their efficacy was verified in methotrexate-
naive patients and as first line biologic therapy for RA treatment, a favourable risk-to-benefit 
ratio has not been established in these populations.  Therefore, in RA, rituximab is only 
approved in combination with methotrexate for treatment of moderately to severely active 
RA, in adults with disease that has shown inadequate response to ≥1 TNFi [365]. The 
recommended regimen is 1 g administered i.v. 2 weeks apart, on days 1 and 15 (for a total 
of 2 doses). A similar course of rituximab might be repeated every 24 weeks or based on 
clinical response, although no sooner than every 16 weeks between courses [365]. 
Abatacept is a recombinant fusion protein with an extracellular domain of human cytotoxic 
T-lymphocyte-associated antigen (CTLA-4) and modified Fc domain of human 
immunoglobulin G1.  CTLA4Ig binds to CD80 and CD86 on antigen-presenting cells, 
blocking the engagement of CD28 on T cells, thus preventing T-cell activation [373]. The 
efficacy and safety of abatacept were demonstrated for early or longstanding active RA, in 
MTX-resistant or MTX-naïve population, in combination or not with MTX [374-376]. 
Moreover, treatment with abatacept has been also efficacious in patients who had had an 
inadequate response to TNFi therapy, with clinical improvements observed at 6 months and 
maintained throughout the next 2 years [377]. Therefore, abatacept can be used alone or with 
other DMARDs for the treatment of active RA despite synthetic DMARD therapy. 
Abatacept was recently approved in Europe as first-line biologic therapy in RA. The 
recommended dosage varies according to the patient’s weight [373], as following: <60 kg 
weight: 500 mg i.v. at 0, 2, and 4 weeks, then every 4 weeks; 60–100 kg weight: 750 mg i.v. 
at 0, 2, and 4 weeks, then every 4 weeks; >100 kg weight: 1 g i.v. at 0, 2, and 4 weeks, then 
every 4 weeks.  
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Tocilizumab is a recombinant humanized IgG1monoclonal antibody specific for IL6 
receptor [378]. The efficacy and safety of tocilizumab have been demonstrated by several 
RCTs, in different RA subpopulations: in patients with early or longstanding resistant RA, 
despite conventional synthetic DMARDS (MTX, chloroquine or hydroxychloroquine, 
sulfasalazine, leflunomide, azathioprine, or parenteral gold); in MTX-naïve patients; either 
in combination with MTX or as monotherapy [379-385]. Tocilizumab has also been tested 
in patients with moderate to severe RA who had a previously inadequate response to TNFi 
related to safety or inadequate efficacy [381]. Notably, high remission rates have been 
observed with tocilizumab treatment. Studies enrolling MTX- or other synthetic DMARDs-
inadequate responders have revealed remission rates at 6 months that rage from 27%-30.2% 
in patients receiving tocilizumb, in comparison to 0.8%-3.4% in the placebo-DMARDs 
group [379, 380]. Even greater results have been described in observational studies, where 
50 to 60% of tocilizumab-treated patients achieved remission after 6-12 months of therapy 
[386-389]. Additionally, tocilizumab has been, so far, the only agent showing no inferiority 
(or even slight superiority) in monotherapy when compared with combination therapy with 
MTX. A significant higher remission rate was verified among patients treated with 
tocilizumab monotherapy (34%) when compared to MTX (12%) [382, 383]. Tocilizumab is 
also approved in Europe as first-line therapy for RA treatment, either in monotherapy or in 
combination with synthetic DMARDS. The recommended dosage is 4 mg/kg i.v. once every 
4 weeks, which may be increased to 8 mg/kg once every 4 weeks based on clinical response. 
Doses higher than 800 mg are not recommended [378]. 
Many other cytokines are currently under investigation for its role in RA. Recent research 
has revealed that the complexity of cytokine network is far more complex than the linear 
model initially proposed with TNFa at the apex controlling all downstream mechanisms.  
1.9 THE CURRENT MANAGEMENT OF RA AND THE TREAT-TO-TARGET 
STRATEGY 
The general approach to RA treatment has changed remarkably in recent years. The key 
message from many recent studies is the requirement for early recognition of disease and 
early “aggressive” intervention with traditional synthetic DMARDs and if necessary with 
biologic DMARDs, to that remission or at least low disease activity can be achieved [364, 
390]. Examples of traditional synthetic DMARDs are Methotrexate (MTX), Salazopirine 
(SLZ), hydroxicloroquine (HCQ) or Leflunomide (LFN). 
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Disease activity is commonly assessed in RA by a composite index, named DAS28 
(Modifyied Disease Activity Score). This index evaluates:  the number of tender and swollen 
joints in 28 predefined joints (including small joints of the hands and feet, elbows, shoulders 
and knees); the erythrocyte sedimentation rate (ESR, mm/1st h) or C-reactive protein (CRP, 
mg/dL); and patient global assessment, through a visual analogue (0-10) scale. The DAS28 
can be calculated using the following formula: DAS28 = 0.56 * sqrt(tender28) + 0.28 * 
sqrt(swollen28) + 0.70 * ln(ESR) + 0.014 * GH [391]. 
Clinical remission has been until very recently defined as DAS28<2.6 [392]. However, such 
definition has not been regarded as sufficiently stringent today to define remission, since 
multiple joints can remain swollen or tender at that score [393-396]. This led the Ammerican 
College of Rheumatology (ACR) and the European League Against Rheumatism  (EULAR), 
together with the Outocome Measures in Rheumatology Initiative (OMERACT) to form a 
committee to redefine remission in RA. It was agreed that remission should be defined as: 
1) when scores on tender joint count, swollen joint count, CRP (mg/dL) and patient global 
assessment (0-10 scale) are all ≤ 1 or 2) when the score on the Simplified disease Activity 
Index (SDAI) is ≤ 3.3 [390]. SDAI is an index similar to DAS28 (CRP, mg/dL) that 
additionally includes the physician global assessment of disease activity through a visual 
analogue (0–10) scale [397].  
Despite remission is today the treatment target in RA, low disease activity defined by 
composite measures, such as DAS28<3.2, might be an alternative goal for many patients 
who cannot attain remission, such as those with long-standing disease [398, 399]. 
The importance of an early diagnosis in RA has recently lead the EULAR Task Force to 
reformulate the RA classification criteria, such that it would be possible to identify more 
patients at very early stages of the disease. The early institution of DMARDs lead to better 
structural and functional outcomes [400-403]. 
The therapeutic target should ideally be achieved within the first 3 months of diagnosis and 
definitively attained by a maximum of 6 months [404], as there is evidence that disease 
activity states at 3–6 months after treatment initiation predict outcome at later time points 
[405]. If there is no improvement by at most 3 months after treatment start or the target have 
not been reached by at 6 months, therapy need to be adjusted. Such strategy requires fast and 
assertive therapeutic decisions, with a tight control of disease activity [406-408]. However, 
35 
the abundant therapeutic options available and insufficient information on differential 
efficacy and safety, make treatment decisions in clinical practice remains highly challenging.  
The EULAR Task Force is continuously updating recommendations for the management of 
RA with synthetic and biologic DMARDs, based on systematic literature reviews and expert 
opinion committee. Several countries, including Portugal, have based their own national 
recommendations on such EULAR guidelines.  
According to the last published recommendations, MTX remains the anchor drug on RA 
treatment and should be part of the first treatment strategy in patients with active RA [364]. 
Despite MTX has revealed to be effective as monotherapy in some RA patients, in the 
majority of the cases a combination therapy with glucocorticoids and other synthetic or 
biologic DMARDs are required [328, 409, 410]. Low dose glucocorticoids should also be 
part of the initial treatment strategy (in combination with MTX or other synthetic DMARDs) 
for up to period of 6 months, after which its risk- benefit profile is not clear yet [411, 412].  
If the treatment target is not achieved within 3-6 months of the first DMARD strategy, and 
in the absence of poor prognostic factors, switch to, or the addition of, other synthetic 
DMARDs might be an option. If poor prognostic factors are present, such as high disease 
activity, autoantibody positivity (rheumatoid factor and/or antibodies to citrullinated 
proteins) and the early presence of joint damage, addition of a biologic DMARD should be 
considered [413, 414]. 
Currently, there are several biologics approved for RA treatment: five TNFi (one chimeric 
mAb, Infliximab; two fully-human mAbs, Adalimumab and Golimumab; one construct p75-
TNFR-Fcγ soluble receptor, Etanercept; and one F(ab)2’ fragment, Certolizumab, which has 
very recently approved in Portugal); one IL6-R antagonist, Tocilizumab; one CTLA4-Fcγ 
construct, Abatacept and one anti-CD20 agent, Rituximab.  
Overall, similar efficacy and safety profile have been found in the different Randomized 
Clinical Trials (RCTs) but there are very few comparative head-to-head RCTs involving the 
different biologics approved for RA treatment [415, 416]. Indirect inferences have been 
drawn from systematic reviews of the literature and meta-analysis of RCTs. Those pooled 
analysis have revealed no significant differences in efficacy between the different TNFi 
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[417-422]. However, the majority of those results were associated with very large confidence 
intervals and significant heterogeneity between studies, which may have clinical relevance.  
Both TNFi, Il6-R antagonist and abatacept can be now used as first-line biologic therapies 
in patients responding insufficiently to MTX and/or other synthetic DMARD strategies, with 
or without glucocorticoids [415, 416, 423-425]. 
Rituximab, despite effective in MTX-naïve patients and as a first-line biologic agent, did not 
show a favorable risk-to-benefit ration in these populations. Therefore, it may be used as 
first-line therapy in cases where contra-indications exist for other agents, such as recent 
history of lymphoma, latent tuberculosis with contraindications to the use of 
chemoprophylaxis, living in a tuberculosis-endemic region, previous history of 
demyelinating disease or recent history of malignancies [426, 427].  
Significant disparities between data obtained from randomized versus observational studies 
in RA patients treated with biological have been observed by several investigators [420, 428, 
429]. Emerging evidence from observational registries suggests differences in the 
effectiveness of different biologics, although with some inconsistencies. From the analysis 
of Dutch Rheumatoid Arthritis Monitoring (DREAM) registry, by monitoring RA patients 
who start on TNFi agents for the first time, it was verified that over one-year of follow-up, 
patients treated with etanercept or adalimumab had a significant decrease in DAS28 than 
patients receiving infliximab. No significant differences in the one-year effectiveness were 
verified between etanercept and adalimumab [430]. In contrast, the results from the Danish 
DANUBIO registry revealed clinical superiority from adalimumab over etanercept [431, 
432]. Consistent results across several observational studies have revealed higher drug 
survival for etanercept in comparison with infliximab or adalimumab [422, 432-435]. 
Given such heterogeneity among the published studies, the EULAR Task Force decided that 
no preference of one over another biological agent should be expressed in the EULAR 
recommendations for the management of biologic-naïves RA patients. Thus, the choice 
between different biologics remains an empirical rather than a scientific-based decision. 
Despite the great overall clinical benefit that biologics have brought to the RA patients, some 
are never able to achieve therapeutic response to those therapies or, more often, they loose 
an initial good response over time, usually within the first year of therapy. In case of non-
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response to the current biologic therapy, assessed at every 3 months, patients should switch 
to another biologic agent, of similar or different mechanism of action. Similarly of what was 
described for biologic-naïve patients, the Task Force has considered that current evidence 
does not suggest superiority of any one agent over others in biologic-experienced patients. 
Therefore, the choice of the next therapy also represents an empirical clinical decision.  
Several observational studies, including meta-analysis results, have shown the effectiveness 
and safety of switching between different TNFi [436-440]. However, the heterogeneity that 
is often observed in those pooled analysis, also suggests that therapeutic response to 
subsequent TNFi may vary according to different subgroups of switchers. Better outcomes 
have been achieved in switchers that had discontinued the previous TNFi by loss of efficacy 
(secondary non-response) or adverse events, when compared with patients that had never 
achieved response to the first TNFi [440-444]. Other analyses have suggested that patients 
who had already experienced failure to etanercept are unlikely to achieve response to another 
TNFi agent [443, 445, 446], although not consistently [447-449]. Some studies have reported 
that the likelihood of response to subsequent TNFi declines with the increasing number of 
previous TNFi, with some revealing an inefficiency of the third TNFi after the failure of two 
previous TNFi [446, 450]. Two independent prospective cohort studies, from the British 
Society for Rheumatology Biologics Register and from the Swiss Clinical Quality 
Management RA cohort, revealed that switching to Rituximab (B-cell depleting agent) is 
more effective than switching to another TNFi [372, 451]. Contradictory results exist, 
revealing no differences in efficacy and safety by switching from one TNFi to another TNFi 
versus to an agent with different mechanism of action [452-454].   
In all the above mentioned studies, the reason for therapeutic failure is never taking into 
account and switchers have been always considered as a homogeneous group. However, 
such heterogeneity in the results is likely due to some confounder(s) factors that were not 
properly addressed. Over the last years, an increasing number of papers have revealed a clear 
association between the presence of ADAb and poor therapeutic responses [153, 160, 195, 
210, 211, 213, 455, 456]. Differences in immunogenicity among individuals and among 
different therapies might well underlie such heterogeneity. Despite the biologic plausibility 
for the interference of ADAb on the therapeutic outcomes of patients receiving biologic 
therapies, this notion did not permeate the clinical practice and immunogenicity assessment 
is still not part of the current approach to biologic-treated patients.  
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2 OBJECTIVES/SCOPE OF THE THESIS 
Accumulating evidence has suggested that drug immunogenicity might be one of the major 
factors underlying therapeutic inefficacy. Thus, its routine assessment might represent a 
powerful tool to optimize the use of biologic therapies. However, the clinical significance of 
drug immunogenicity is not formally established. Additionally, the way drug levels and anti-
drug antibodies (ADAb) should be assessed and integrated in routine clinical practice 
remains to be defined.  
The main objectives of this thesis work are: 
1. To formally document the impact of ADAb in therapeutic responses  
Given the clinical, scientific and societal/economic relevance of the topic, the clinical 
consequences of drug immunogenicity need to be clearly defined.   
Systematic reviews of the literature with meta-analysis represent today the top of the 
evidence for clinical decision-making. Meta-analysis is a statistical technique for combining 
data from independent studies, having higher statistical power to detect an effect than 
individual studies. Moreover, it is less influenced by local biases than single studies will be, 
as it combines several studies. Therefore, we aim to determine the clinical impact of drug 
immunogenicity on therapeutic efficacy/effectiveness, by conducting a systematic review of 
the literature with a meta-analysis.  
2. To evaluate the impact of drug immunogenicity on drug safety profile  
Some studies have revealed an association between the presence of ADAb and acute adverse 
reactions to infusions of biologics, though other reasons may mediate such type of adverse 
reactions. We aim to evaluate the association between the presence of ADAb and infusion-
related adverse events, in a cohort of patients receiving infliximab treatment (an intravenous 
TNFi). 
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3. To define a convenient assay to assess immunogenicity on routine clinical 
practice 
After establishing the clinical relevance of drug immunogenicity, the way drug 
immunogenicity can be assessed in routine clinical practice might be defined. 
Radioimmunoassay-Antigen Binding Test (RIA-ABT) has been considered by many as the 
“gold standard” to quantify ADAb. However, RIA requires high radioactivity dose and 
special conditions to its implementation. We aim to compare the assay performance in the 
detection of ADAb between a newly developed Bridging ELISA with RIA-ABT, while a 
simple ELISA will be tested to assess serum drug levels.  
4. To construct and test an algorithm for therapeutic decisions based on explicit 
biomarkers of immunogenicity 
We aim to integrate immunogenicity information in the current clinical approach of patients 
receiving biopharmaceuticals. We intend to design a new treatment algorithm introducing 
immunogenicity data. The concordance between rheumatologist´s current clinical practice 
and our proposed algorithm will be assessed. Therapeutic response rates, over one year, 
between patients who followed the proposed algorithm and patients who followed other 
therapeutic strategies will be compared. Secondarily, we aim to evaluate the role of ADAb 
as a mediator of therapeutic response. 
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3 RESULTS 
3.1 THE IMMUNOGENICITY OF TNFI THERAPIES IN IMMUNE-
MEDIATED INFLAMMATORY DISEASES – A SYSTEMATIC REVIEW 
OF THE LITERATURE WITH A META-ANALYSIS 
3.1.1 Introduction 
Tumor Necrosis Factors Inhibitor (TNFi) therapies, such as infliximab, adalimumab 
and etanercept, are effective in treating Rheumatoid Arthritis (RA), Spondyloarthritis 
(SpA), Psoriasis (Ps) and Inflammatory Bowel Diseases (IBD), such as Crohn’s 
Disease (CD) and Ulcerative Colitis (UC).  Some patients maintain active disease and 
others show loss of efficacy after continued treatment [457]. Recent studies have 
highlighted drug immunogenicity as a mechanism behind treatment failure [153, 160, 
458]. 
Immunogenicity is the ability that biotechnology-derived therapeutic proteins have in 
generating antibodies against themselves, since they contain unique sequences that can 
elicit an immune response [60]. 
The European Medicines Agency (EMA) and Food & Drug Administration (FDA) 
define the assessment of immunogenicity as mandatory for the approval of 
biopharmaceuticals; however, clinical trials may not reflect true immunogenicity 
induced by long-term treatment.  
Quantification of such antibodies is challenging and undertaken by different assays 
[202, 205, 209, 459, 460]; assays have been optimized with improved sensitivity and 
specificity [196, 213, 461-463]. New evidence reveals a significant impact of 
immunogenicity on treatment response to biologics [153]. 
A systematic review (SR) and meta-analysis (MA) were undertaken to evaluate the 
impact of anti-drug antibodies (ADAb) on therapeutic response and the effect of 
immunosuppression (IS) on ADA detection. 
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3.1.2 Methods 
We followed the PRISMA guidelines for reporting SRs and MAs and MOOSE 
recommendations for observational studies [464, 465]. 
3.1.2.1 Eligibility Criteria  
To be included in this review, studies had to meet the following pre-defined eligibility 
criteria, defined according to the “PICOS” strategy [465]. The rationale for these 
criteria is also provided [466-469] – Table 1. 
3.1.2.2 Data Sources 
A comprehensive search strategy was designed to retrieve relevant clinical data from 
published literature. The following databases were examined up to August 19 2012: 
PubMed, EMBASE and Cochrane Library. Article reference lists were also scanned. 
The following search terms were used: ((“Arthritis, Rheumatoid”) OR (“Spondylitis, 
Ankylosing”[470]) OR (“Arthritis, Psoriatic”[Mesh]) OR (“Psoriasis”[Mesh]) OR 
(“Colitis, Ulcerative”[Mesh]) OR (“Crohn Disease”[Mesh])) AND “Treatment 
Outcome”[Mesh] AND ((“TNFR-Fc fusion protein “[Substance Name]) OR 
(“infliximab “[Substance Name]) OR (“Adalimumab “[Substance Name])). 
3.1.2.3 Study Selection 
Two independent authors selected studies and extracted data. Disagreements were 
resolved by discussion between the two reviewers. To ascertain the validity of eligible 
studies and to minimize the risk of bias, two blinded reviewers determined the adequacy 
of study characteristics. We decided to use more broad inclusion criteria and then to 
perform metaregressions, subgroup analyses, and sensitivity analysis, rather than using 
highly restrictive study quality assessment scores [464]. 
3.1.2.4 Data Extraction 
The following information was extracted from each study: 1) Population demographic 
characteristics: age, gender; 2) clinical data: diagnostic criteria and disease activity; 3) 
treatment: TNFi, duration, dose, schedule, route of administration, immunosuppressors; 
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4) exposure and outcome: therapeutic response, serum trough ADAb, time of 
assessment, assay; 5) publication: study design, follow-up period, author, year.  
3.1.2.5 Statistical Analysis 
Data were analyzed by calculating risk ratios (RR) for each study and performing forest 
plots; uncertainty was expressed by 95% confidence intervals (CI). Assuming clinical 
and methodological heterogeneity in the available body of evidence, random-effects 
models (REM), according to the Laird method, were used to cluster the results. 
Heterogeneity of study results was examined by calculating the χ2 test for heterogeneity 
(when the χ2 test had a P< 0.1) and the I2 measure of inconsistency [471]. Potential 
sources of heterogeneity were explored through analysis of the following predefined 
subgroups and confirmed through meta-regression: a) primary diagnosis b) proportion 
of patients co-treated with IS: methotrexate (MTX) or azathioprine/6-mercaptopurine 
(AZA/MCP); c) proportion of patients who underwent TNFi dose escalation; d) 
proportion of patients who started with higher initial doses of TNFi; d) scheduled 
treatment regimens; e) assay for ADAb detection; f) population characteristics and g) 
study characteristics. Publication bias was analyzed through the Egger’s plot and test. 
STATA version SE 12 was used. 
3.1.3 Results 
Figure 5 shows the flow of studies through the SR process. Search of literature 
databases yielded 2082 references. Seventeen eligible studies were evaluated 
quantitatively, through MA. Five additional studies were exclusively qualitatively 
assessed because of significant missing data, but considered important evidence. 
To address the impact of ADA on drug response, 865 patients (540 RA, 132 SpA, 58 
Ps, 130 IBD) from 12 observational prospective cohort studies were analyzed [153, 
211, 213, 455, 458, 463, 472-477]; and 5 additional studies were described qualitatively 
[212, 478-481] – Table 2. 
Two publications used the same cohort of patients.[153, 455] We selected “Bartelds 
2007” for the MA based on it being the original study and showing less heterogeneity 
in the pooled analysis – Figure 6 and Figure 7.  
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Two studies had multiple time points of assessment [211, 463].  The 12-month time 
point was selected for the MA, because of consistency with the included studies and 
less heterogeneity in the pooled analysis – Figure 8 to Figure 10.  
Overall, detectable ADAb reduced the drug response rate by 68% (RR=0.32, 95%CI= 
0.22-0.48) – Figure 11. Significant between-study heterogeneity was observed 
(I2=45.5%, p=0.037). Seeking for potential sources of heterogeneity, we observed a 
trend to an increased effect size in studies where the proportion of patients co-treated 
with IS (%IS) was <67% - Figure 12. However, univariate meta-regression did not 
detect %IS as a significant effect modifier of the effect of ADA on response rates - 
Table 3.  A closer look at these subgroups showed that among studies where %IS <67%, 
detectable ADAb was associated with a reduction in therapeutic response by 78% 
(RR=0.22, 95%CI=0.12-0.39) and in studies where %IS ≥67%, the effect size reduction 
of drug response was attenuated to 59% (RR=0.41, 95%CI=0.27-0.62) – Figure 12.  
Univariate meta-regression detects the proportion of patients co-treated with MTX 
(%MTX) as a significant effect modifier of ADAb on drug response – Table 3. In the 
subgroup analysis, we observed that in studies where %MTX<74%, the presence of 
ADAb reduced therapeutic response by 77% (RR=0.23, 95%CI=0.15-0.36), while in 
studies where that proportion was ≥74%, the effect size reduction was attenuated to 
51% (RR=0.49, 95%CI=0.35-0.69) – Figure 13. 
Univariate meta-regression also showed primary diagnosis (AR vs others) and initial 
higher doses of biologics to be significant effect modifiers of the effect of ADAb on 
drug response - Table 3. We verified a decreased effect size in studies evaluating RA 
patients and in studies where patients received initial lower doses of biologics – Figure 
14 to Figure 16. These studies are also those with lower proportion of patients receiving 
IS and MTX. Significant heterogeneity in the pooled analysis was abrogated by 
dividing the studies according to the proportion of patients receiving IS, and particularly 
MTX, independently of the disease or the doses of biologics that were used. 
The impact of ADAb on drug response was not significantly affected by the proportion 
of patients who underwent TNFi dose escalation – Table 3.  
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We could not test the effect size modification by scheduled treatment regimens or by 
the assay used for ADAb detection since most studies used schedule regimens and RIAs 
to assess ADAb.  
The Egger’s test provided evidence for no significant publication bias – Figure 17. 
Studies with etanercept were not analyzed quantitatively because they did not fit the 
eligibility criteria and/or because no anti-etanercept antibodies were detected. Three 
studies are described qualitatively. Both described absence of anti-etanercept 
antibodies, by using Bridging ELISA and fluid-phase RIA, in a total of 332 RA patients 
[212, 480], and 53 AS patients [478], treated with 25 mg twice weekly or 50 mg weekly 
– Table 2. The absence of anti-etanercept antibodies persisted 3 months after therapy 
withdrawal [478]. 
We found two additional studies among Ps patients, which could not be included in the 
MA due to missing data. In a study enrolling 15 Ps patients receiving infliximab, those 
with detectable ADAb had higher PASI values than patients without such antibodies 
(PASI (mean, sd)= 10(4.9) vs. 5.3(2.4); p=0.02) [481]. Similarly, another study, among 
22 PsA patients, revealed that ADAb-positive patients had a significantly worse DAS28 
at 12 months of adalimumab therapy, when compared with patients without such 
antibodies (DAS28 (SEM)= 5.05 (0.84) vs. 2.58 (0.32); p=0.01) [479].  
To address the influence of IS on the detection of ADAb 936 patients (376 RA, 94 SpA, 
29 Ps, 437 IBD) from 12 studies were analyzed quantitatively [153, 159, 160, 211, 455, 
473-476, 482-484] – Table 2. 
MTX (dose range: 7.5-25 mg/wk) was the main immunosuppressor used in RA patients; 
AZA (2-2.5 mg/Kg/d) or MCP (1-1.25 mg/Kg/d) were the main immunosuppressors 
used in IBD patients. 
ADAb were assessed through slightly different fluid-phase RIAs,[455, 474, 476, 484] 
and 3 different ELISA methods [159, 160, 211, 473, 474, 482, 483]. 
Two of the included studies used the same cohort of patients [153, 455, 484]. We 
selected “Bartelds 2007” for the MA based on the fact that it was the original study and 
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also the one that offered lower heterogeneity in the pooled analysis – Figure 18 to 
Figure 20.  
Immunosuppressors reduced the proportion of patients with detectable ADAb by about 
41% (RR=0.59, 95%CI=0.50-0.70) – Figure 21. Meta-regression confirmed the assay 
as a significant source of heterogeneity – Table 3. Concomitant IS reduced detectable 
ADA by 64% (RR=0.36; 95%CI=0.23-0.55) when RIA was used to detect ADAb, 
while when ELISA methods were used the effect size reduction of detectable ADA was 
attenuated to 37% (RR=0.63, 95%CI=0.42-0.67) – Figure 22. 
It was not possible to evaluate potential differences in detectable ADAb between MTX 
and AZA/MCP, due to limited data. 
The Egger’s test provided evidence of significant publication bias for the studies 
evaluating the effect of immunosuppression on ADA production – Figure 23. Positive 
results may be more likely to be published. However, the presence of small and 
heterogeneous studies may also underlie that result. 
3.1.4 Discussion 
Immunogenicity reduces therapeutic response to TNFi, an effect that is attenuated by 
immunosuppressors. Detectable ADAb decreases TNFi response by as much as 80%. 
This contrasts with descriptions in most RCTs, considering immunogenicity as a minor 
problem [326, 340, 485, 486]. ADAb might reduce drug efficacy by competing with 
the endogenous ligand (neutralizing antibodies) and/or by forming immune complexes, 
which accelerates the clearance of the drug from the circulation, decreasing its 
bioavailability. Anti-idiotypic antibodies, which include neutralizing antibodies, 
represent the most significant part of the antibody response against infliximab and 
adalimumab [192, 197, 198]. The detection of ADAb is technically challenging and the 
assay may influence the results. The majority of studies in this paper used two 
independent but similar RIAs, with higher specificity than ELISAs [196, 202, 209, 
461]. They are both fluid-phase RIAs, which avoids the artifacts induced by solid-phase 
adsorption of proteins and they both detect ADA against drug-F(ab’)2, not favoring the 
detection of low-avidity antibodies. RIA is less susceptible than ELISAS to drug 
interference and is able to detect monovalent IgG4 ADA, which may represent a 
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significant proportion of ADAb [17, 209].  ELISAs have been the main method used in 
RCTs, perhaps explaining the contrasting descriptions in RCTs. We believe that the 
association remains underestimated: four of the included studies used ELISAs; the 
assays employed cannot detect ADAb that are in complex with the drug, not even RIA 
and we included EULAR moderate response within the responder group. 
Despite few published studies reporting anti-etanercept antibodies [331, 333, 487, 488], 
all showed transient low titers, with no impact on drug response; this suggests the 
presence of “binding antibodies” or false positive results, since ELISAs of low 
specificity were used. Etanercept is administered more often than other biologics, 
possibly creating more drug interference in ADA detection. However, the absence of 
anti-etanercept antibodies has been confirmed months after therapy withdrawal [478]. 
Etanercept also blocks lymphotoxin-alpha (LTa), which among other functions is 
important for germinal center formation [489]. The involvement of LTa on drug 
immunogenicity remains unknown. The absence of clinically significant 
immunogenicity attributable to etanercept is consistent with the higher drug survival 
that has been reported for etanercept in comparison with infliximab or adalimumab 
[432, 490, 491]. 
Factors able to modulate the clinical impact of immunogenicity need to be identified.  
We verified that concomitant IS attenuated the impact of ADA on drug response, 
particularly MTX. The exact mechanism remains unknown. Concomitant MTX has 
been shown to be efficient in reducing immunogenicity in a dose-dependent manner, 
either by reducing the frequency of detectable ADA or by delaying its detection [195, 
211, 492]. The time point of ADA assessment is also important. In our MA the majority 
of included studies assessed ADA at 12 months, showing a lower ADA frequency in 
patients receiving concomitant IS. That reduction was more apparent when RIA was 
used compared with ELISA methods (64% reduction vs. 34%), which may be explained 
by the increased specificity and less drug interference of RIAs over ELISAs.  
These results are of high clinical interest, since they reveal a putative beneficial role of 
concomitant IS in diseases such as SpA, by modulating immunogenicity, increasing 
drug survival and treatment effectiveness. A recent study, in Ankylosing Spondylitis 
(AS) patients, failed to demonstrate the influence of MTX on infliximab 
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pharmacokinetics [493]. Infliximab is administered more frequently and at higher doses 
in AS, compared to RA, which may create drug interference and false-negative results 
if highly drug-sensitive assays are used to detect ADAb.  That study was conducted up 
to 18 weeks of infliximab treatment, which for some patients may be too early for full 
development of immunogenicity. RCTs, with larger follow-up times should be 
conducted to show the beneficial effect of IS/MTX in these patients. 
We could not assess differences between MTX and AZA/MCP regarding their impact 
on ADAb detection, due to the low number of studies using AZA/MCP and the fact that 
some studies in IBD also enrolled patients receiving MTX, who cannot be separated 
from the group receiving IS. However, univariate meta-regression detected  %MTX as 
a significant source of heterogeneity, but not %IS (MTX + AZA/MCP).  Subgroups 
based on  %MTX resulted in homogeneous groups, whereas, the same did not happen 
for %IS subgroups. Further studies are warranted to verify whether this effect modifier 
is extended to other immunosuppressive agents and whether dose and scheduled 
regimens influence response by detectable ADA. 
In some trials, initial higher doses of infliximab or adalimumab have revealed to be less 
immunogenic [159, 494]. It is not clear if that is a true effect or just an assay limitation 
of detecting ADAb in the presence of high drug concentration. We could not draw any 
conclusions in our MA because the studies that used higher biologic doses enrolled only 
patients with SpA, Ps and IBD, who also had lower proportion of patients co-treated 
with IS, confounding the results. Moreover, the limited number of studies and the 
clinical heterogeneity among them also prevent robust conclusions. Despite the high 
costs of biologic therapies, it would be of great clinical interest to know if higher 
induction doses of biologics would reduce immunogenicity, which could result in an 
improvement of its cost-effectiveness over the long-term.  
Some reports show that dose escalation decreased ADAb detection, improving drug 
response [213, 455], but others [458], show that the procedure can indeed boost the 
immune response with serious consequences, such as infusion-related adverse events 
[463] or severe thromboembolic phenomena [495]. The absence of ADAb might be 
explained by drug interference, but it is striking why some ADAb-positive patients do 
not boost the ADA production. In our analysis, the proportion of patients who 
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underwent dose escalation did not interfere with the impact of ADAb on drug response.  
Very limited data are available and more studies are warranted to specifically address 
this question, since dose escalation is often adopted in clinical practice in case of 
inadequate response. We believe that increasing the dose may be risky since, so far, 
there is no way to identify which patients are at risk of boosting an anti-biologic 
response after dose escalation. 
Scheduled regimens have revealed to be less immunogenic, by poorly defined 
mechanisms [160, 167, 168]. The limited number of studies prevented us to draw such 
conclusions in our analysis 
A limitation to our study is that patient population, assessment of antibodies and 
therapeutic response definitions are not standardized across studies, although we 
addressed those sources of heterogeneity in the pooled analysis. The power of meta-
regression analysis has limitations by the relatively small number of studies and the 
imprecision of the measurement techniques. The results obtained driven largely by 
findings in patients with RA. Although we excluded significant effect size modification 
by the disease itself, generalizations should be done cautiously.  
This is the first SR and MA on TNFi immunogenicity. Our study strongly supports the 
notion that drug immunogenicity should be considered in clinical practice, during long-
term use of therapeutic proteins. It is also an exploratory study, trying to identify factors 
able to influence the clinical impact of drug immunogenicity. It adds some evidence 
that unwanted immunogenicity may be modulated. Increasing evidence shows that 
monitoring immunogenicity will help us to better understand the clinical heterogeneity 
among patients, representing a very promising tool for an optimized and more 
personalized usage of biologic therapies.  
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Table 1 – Eligibility criteria for studies included in the systematic review 
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Table 2– Study and baseline patient characteristics // 1. Quantitative Evidence 
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Table 2 (Cont.) – Study and baseline patient characteristics // 1. Quantitative Evidence (Cont.) 
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Table 2 (Cont.) – Study and baseline patient characteristics // 2. Qualitative Evidence 
 
Legend: ADL= Adalimumab s.c.; AS= Ankylosing Spondylitis; AZA= Azathioprine; biw= twice a week; qw= every week; qXw= every X weeks; CD= Crohn’s Disease; CST= Corticosteroids; 
ETA= Etanercept s.c; INF= Infliximab i.v.; IS= Immunosuppression; MCP= 6-Mercaptopurine; MTX= Methotrexate; na= not available; OD= on demand; Ps= Psoriasis; PsA= Psoriatic 
Arthritis; RA= Rheumatoid Arthritis; SD= single dose; sd= standard deviation; SpA= Spondyloarthritis; UC= Ulcerative Colitis; wk= weeks. 
a= DAS28 for RA and PsA patients, ASAS 20 or ASDAS for SpA and AS patients, PASI for Ps patients; b= Induction dose of 3mg/Kg at 0, 2 and 6 weeks; c= Induction dose of 5mg/Kg at 0, 
2 and 6 weeks; d= Induction dose of 160mg at wk 0 and 80mg at wk 2; e = Induction dose of 80mg at wk 0 and 40mg at wk 2;  f= mean (SD); g= median (range/IQR);  h= mean (range/IQR); 
i= mean (Standard Error Mean); j= range 
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Table 3 – Meta-Regression stratified by clinical characteristics to address the effect of ADAb on 
drug response and the effect of IS on ADAb detection 
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Figure 5 – Flow of studies through the systematic review (SR) process 
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Figure 6 – Effect of ADAb positivity on TNFi response (excluding the study “Bartelds 2011”) 
Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked immunosorbent assay; 
ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; CD, Crohn’s Disease; INF, Infliximab; 
Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; TNFi, Tumor Necrosis Factor Inhibitor, UC, Ulcerative 
Colitis. 
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Figure 7 – Effect of ADAb positivity on TNF responsei (excluding the study “Bartelds 2007”) 
Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked immunosorbent assay; 
ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; CD, Crohn’s Disease; INF, Infliximab; 
Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; TNFi, Tumor Necrosis Factor Inhibitor; UC, Ulcerative 
Colitis. 
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Figure 8 – Effect of ADAb positivity on TNFi response (including “Pascual-Salcedo 2011” and 
“Plasencia 2012” at 6 months of follow-up time) 
Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked immunosorbent assay; 
ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; CD, Crohn’s Disease; INF, Infliximab; 
Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; TNFi, Tumor Necrosis Factor Inhibitor; UC, Ulcerative 
Colitis. 
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Figure 9 – Effect of ADAb positivity on TNFi response (including “Pascual-Salcedo 2011” and 
“Plasencia 2012” at 12 months of follow-up time) 
Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked immunosorbent assay; 
ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; CD, Crohn’s Disease; INF, Infliximab; 
Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondylarthritis; TNFi, Tumor Necrosis Factor Inhibitor; UC, Ulcerative Colitis. 
NOTE: Weights are from random effects analysis
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Radstake 2009
de Vries 2007
Radstake 2009
West 2008
Wolbink 2006
Steenholdt 2010
Lecluse 2010
Plasencia 2012
Pascual-Salcedo 2011
Hoffman 2011
Bartelds 2007
Bender 2007
Steenholdt 2010
Study
fp-RIA
fp-RIA
fp-RIA
fp-RIA
fp-RIA
fp-RIA
fp-RIA
Br ELISA
Br ELISA
ELISA
fp-RIA
ELISA
fp-RIA
Assay
RA
AS
RA
CD
RA
CD
Ps
SpA
RA
Ps
RA
RA
UC
Disease
ADA
INF
INF
ADA
INF
INF
ADA
INF
INF
INF
ADA
ADA
INF
aTNF
6
12
6
12
12
6
12
12
12
6
3
(months)
Exposure Time
0.32 (0.22, 0.48)
0.05 (0.00, 0.70)
0.12 (0.02, 0.81)
0.24 (0.11, 0.55)
0.23 (0.04, 1.32)
0.53 (0.29, 0.96)
0.14 (0.05, 0.42)
0.28 (0.10, 0.79)
0.11 (0.02, 0.71)
0.60 (0.31, 1.14)
0.38 (0.12, 1.20)
0.56 (0.34, 0.94)
0.39 (0.15, 0.96)
0.08 (0.01, 1.24)
RR (95% CI)
40/166
0/10
1/11
4/18
1/5
8/22
3/23
3/13
1/10
4/7
2/6
9/21
4/13
0/7
ADA-pos
Events,
340/403
24/24
20/27
17/17
22/25
20/29
56/62
13/16
37/41
23/24
20/23
76/100
2/2
10/13
ADA-neg
Events,
100.00
1.86
3.51
10.69
3.92
13.49
8.05
8.41
3.57
12.87
7.32
14.95
9.49
1.87
Weight
%
Lower Response by ADA-positive  Higher response by ADA-negative 
1.01 .5
RR and 95% CI Based on a Random-Effects Model
Effect of ADA-Positivity on aTNF ResponseEffect of ADAb-Positivity  TNFi Respon e 
61 
 
Figure 10 – Effect of ADA positivity on TNFi response (including “Pascual-Salcedo 2011” and 
“Plasencia 2012” at  > 48 M follow-up time) 
Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked immunosorbent assay; 
ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; CD, Crohn’s Disease; INF, Infliximab; 
Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondylarthritis; TNFi, Tumor Necrosis Factor Inhibitor; UC, Ulcerative Colitis. 
Note: The time point of 12 months offered less heterogeneity in the pooled analysis, when compared with the time point of 6 or 
>48 months (I2=45.5%, p=0.037 vs I2=51.8%, p=0.015 vs I2=49.4%, p=0.022).  
NOTE: Weights are from random effects analysis
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Figure 11 – Effect of ADAb positivity on TNFi response 
Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked immunosorbent assay; 
ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; CD, Crohn’s Disease; INF, Infliximab; 
Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; TNFi, Tumor Necrosis Factor Inhibitor; UC, Ulcerative 
Colitis. 
  
Effect of ADAb-Positivity on TNFi Response 
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Figure 12 – Effect of ADAb positivity on TNFi response (IS<67% and IS≥67%) 
Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked immunosorbent assay; 
ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; CD, Crohn’s Disease; INF, Infliximab; 
IS, Immunosuppression; Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; TNFi, Tumor Necrosis Factor 
Inhibitor; UC, Ulcerative Colitis. 
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Figure 13 – Effect of ADAb positivity on TNFi response (MTX<74% and MTX≥74%) 
Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked immunosorbent assay; 
ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; CD, Crohn’s Disease; INF, Infliximab; 
MTX, Methotrexate; Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; TNFi, Tumor Necrosis Factor Inhibitor; 
UC, Ulcerative Colitis. 
  
Effect of ADAb-Positivity on TNFi Response (MTX<74% & MTX≥74%) 
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Figure 14 – Effect of ADAb positivity on TNFi response (by diagnosis) 
Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked immunosorbent assay; 
ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; CD, Crohn’s Disease; INF, Infliximab; 
Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; TNFi, Tumor Necrosis Factor Inhibitor; UC, Ulcerative 
Colitis. 
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Figure 15 – Effect of ADAb positivity on TNFi response (by diagnosis) 
Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked immunosorbent assay; 
ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; CD, Crohn’s Disease; INF, Infliximab; 
Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; TNFi, Tumor Necrosis Factor Inhibitor; UC, Ulcerative 
Colitis. 
Note: The stratification by each diagnosis individually offers higher heterogeneity than the stratification by RA vs other 
diagnosis.  
NOTE: Weights are from random effects analysis
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Figure 16 – Effect of ADAb positivity on TNFi response according to initial biologic dose 
Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked immunosorbent assay; 
ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; CD, Crohn’s Disease; INF, Infliximab; 
Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; TNFi, Tumor Necrosis Factor Inhibitor; UC, Ulcerative 
Colitis. 
NOTE: Weights are from random effects analysis
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Figure 17 – Egger’s publication bias plot for the effect of ADAb positivity on TNFi response 
Legend: ADAb, anti-drug antibodies; TNFi, Tumor Necrosis Factor Inhibitor. 
 
Figure 18 – Effect of immunosuppression on ADAb production (by excluding “Bartelds 2010” 
and “Bartelds 2011”) 
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Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked 
immunosorbent assay; ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; 
CD, Crohn’s Disease; INF, Infliximab; Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; UC, 
Ulcerative Colitis. 
 
Figure 19 – Effect of immunosuppression on ADAb production (by excluding “Bartelds 2007” 
and “Bartelds 2011”) 
Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked immunosorbent assay; 
ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; CD, Crohn’s Disease; INF, Infliximab; 
Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; UC, Ulcerative Colitis. 
Note: By leaving the study “Bartelds 2010” we introduced more heterogeneity in the pooled analysis, in comparison with Figure 
18. 
NOTE: Weights are from random effects analysis
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Figure 20 – Effect of immunosuppression on ADAb production (by excluding “Bartelds 2007” 
and “Bartelds 2010”) 
Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked immunosorbent assay; 
ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; CD, Crohn’s Disease; INF, Infliximab; 
Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; UC, Ulcerative Colitis. 
Note: By leaving the study “Bartelds 2011” we introduced more heterogeneity in the pooled analysis, as compared with Figure 
18. 
NOTE: Weights are from random effects analysis
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Figure 21 – Effect of immunosuppression on ADAb production 
Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked immunosorbent assay; 
ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; CD, Crohn’s Disease; INF, Infliximab; 
Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; UC, Ulcerative Colitis. 
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Figure 22 – Effect of immunosuppression on ADAb production (by assay) 
Legend: ADAb, anti-drug antibodies; AS, Ankylosing Spondylitis; Br ELISA, Bridging enzyme-linked immunosorbent assay; 
ELISA, Enzyme-linked immunosorbent assay; fp-RIA, Fluid-phase radioimmuno assay; CD, Crohn’s Disease; INF, Infliximab; 
Ps, Psoriasis; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; UC, Ulcerative Colitis. 
Effect of Immunosuppression on ADAb Production (by Assay) 
IS-Pos  IS-Neg 
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Figure 23 – Egger’s publication bias plot for the effect of IS on ADAb production 
Legend: ADAb, anti-drug antibodies; IS, immunosuppressors. 
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3.2 THE IMPACT OF IMMUNOGENICITY ON DRUG SAFETY PROFILE 
3.2.1 Introduction 
Biologics, and particularly monoclonal antibodies, are structurally immunogenic, as virtually 
all of them exhibit epitopes that can elicit an immune response.  
Over the last years, an increasing body of evidence has highlighted the clinical significance of 
drug immunogenicity. Previously, we formally established the impact of anti-drug antibodies 
(ADAb) on therapeutic responses [496]. However, ADAb have also been associated with 
increased incidence of drug-related adverse events (AE) [160, 210, 211, 213, 458, 495, 497-
501]. Acute infusion reactions occur during or within 1 h after infusion, while delayed reactions 
may occur from 1h to 14 days post-infusion [502, 503]. AE to biological are clinically very 
heterogeneous. The majority of those adverse reactions are mild (headache, flushing, nausea) 
but moderate or even severe reactions, with dyspnoea, angioedema, wheezing and stridor may 
also occur [502, 504-509]. Different mechanisms may underlie AE to biologics, and a specific 
classification based on those mechanisms have been proposed, aiming to guide clinicians in the 
management of such adverse reactions [503]. However, that classification is not easily 
applicable in clinical practice and the management of AE, as the decision to rechallange or 
discontinue treatment, has been based on the severity of the symptoms [505]. Severe reactions 
usually impose treatment discontinuation, while mild-to-moderate reactions are usually 
managed by temporary infusion interruption, reduction of the infusion rate and symptoms 
management, with re-treatment schemes. Those re-treatment schemes do not minimize adverse 
reactions in all patients and it medium-long term effectiveness has not been established [510]. 
Beyond the management of AE, the identification of markers able to predict the higher risk 
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patients to develop AE to biologics is warranted.  The presence of ADAb might well represent 
a biomarker able to identify patients at higher risk to develop AE and those where re-treatment 
schemes might not be advisable, as rechallenge may boost the immune response to biologic. 
Therefore, immunogenicity assessment might represent a tool to help us preventing important 
adverse events, improving the biologics’ management and their safety profile. 
3.2.2 Objectives 
We aim to evaluate the association between acute infusion-related adverse events (IrAE) and 
the presence of ADAb in patients with chronic immune-mediated inflammatory diseases 
receiving Infliximab.  Secondarily, we assessed therapeutic response maintenance in patients 
who had IrAE. 
3.2.3 Methods 
During a period of 2 years (January 2010 - December 2011) we followed all adult patients (≥18 
years) with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA) 
and Inflammatory Bowel Disease (IBD), receiving infliximab 3-5mg/Kg i.v. at 0, 2, 6 and every 
6 or 8 weeks thereafter, in monotherapy or with concomitant immunosuppressors, at the 
Department of Rheumatology and Department of Gastroenterology of Hospital Garcia de Orta, 
Portugal. All patients fulfilled the American College of Rheumatology 1987 revised criteria for 
RA, the Assessment of SpondyloArthritis international Society (ASAS) 2009 classification 
criteria for spondyloarthritis or clinical, endoscopic, histological and/or radiological criteria 
(ECCO criteria) for CD or UC [511-514].  All patients followed the Portuguese 
recommendations for the management of RA, SpA or IBD patients receiving biologic 
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therapies[515-518]. The study was approved by the hospital ethics committee. All patients gave 
written informed consent.  
Drug immunogenicity was assessed every 3-6 months.  Through serum samples were collected 
just before the next administration of a biologic. Serum drug trough levels were measured by 
ELISA, using a setup as described before [462, 519]. Limit of detection was determined by 
testing 100 sera of RA patients before treatment. The mean +/- 6 times standard deviation (SD) 
was chosen as a cut off. Limit of detection was about 2 ng/ml for all TNFi. ADAb were tested 
by Bridging ELISA as described before [209]. The sensitivity of these assays depends on the 
affinity of the ADAb. We used a series of patient-derived monoclonal antibodies to establish 
the sensitivity of the assay. A monoclonal antibody to adalimumab with the median affinity 
showed reached half-maximal extinction at 10 ng/ml and a detection limit <1 ng/ml. However 
non-specific binding of serum components such as rheumatoid factor or C1q sets the limit of 
detection for sera at about 20 ng/ml. 
Acute infusion-related adverse event was defined as any abnormal sign or symptom occurring 
during or within two hours after the infliximab infusion.  
Therapeutic response was defined according to the European League Against Rheumatism 
(EULAR) criteria for RA and RA-like PsA [466]; ASAS group guidelines for AS and AS-like 
PsA [513, 514]; and by an expert clinician for IBD patients. 
3.2.4  Results 
The study included 94 consecutive patients (22 AR, 33 AS, 9 PsA and 30 IBD), 76% females, 
with mean (SD) age of 48 (10.2) years, disease duration of 8 (6.4) years, and receiving biologic 
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therapy by 2.9 (2.0) years. Patients were receiving infliximab at 3-5 mg/Kg every 6 or 8 wks. 
All RA patients and 89% of PsA were receiving concomitant methotrexate (MTX), at a dose 
range of 10-20mg every week. IBD patients were receiving concomitant azathioprine, at a dose 
range of 2-2.5 mg/Kg/day and additionally 100 mg i.v. hydrocortisone, 2 mL i.v. clemastin and 
500 mg i.v. acetaminophen prior to each Infliximab infusion. 
During the follow-up period, twelve patients (13%) developed an overt IrAE (4 RA patients, 2 
PsA, 2 AS and 4 IBD patients), between the fourth and tenth infusion – Figure 24. All the 
reactions were mild-moderate requiring hydrocortisone and anti-histaminic administration. 
Twenty-five patients (27%) had detectable ADAb (41% of RA, 33% of PsA, 18% of AS and 
23% of IBD patients) – Figure 25. 
Nearly half (48%) of ADAb-positive patients developed an IrAE, while none of ADAb-negative 
patients had acute adverse reactions to infliximab – Figure 26. Notably, in all cases, except two, 
the detection of ADAb occurred prior to the IrAE. In these two exceptional cases, we had no 
access to the patients’ serum before the development of IrAE. All patients who developed acute 
IrAE were unable to maintain therapeutic response over time (one year) and re-treatment 
schemes did not prevent treatment failure. Furthermore, in 4 patients re-treatment increased the 
severity of adverse reaction (chest pain, severe hypotension). 
Although not planned in the initial study protocol, we assessed serum drug levels every week 
between two infliximab administrations in the four IBD patients who had an IrAE. We intended 
to evaluate drug kinetics between two infliximab administrations in patients who had a mild 
IrAE and were kept in the same treatment. Notably, in three patients serum drug levels become 
undetectable already from week 2 after the infusion of 5mg/Kg of infliximab. In one patient the 
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drop in drug levels was slower, but still, no circulating drug was detected from week 5 after 
treatment – Figure 27.  
3.2.5 Discussion 
In the present study, acute IrAE to Infliximab occurred exclusively in patients with detectable 
ADAb and nearly half of ADAb-positive patients developed an adverse reaction. Notably, in all 
cases ADAb could be detected prior to the IrAE and none of those patients were able to maintain 
therapeutic response over time.  
Despite the great benefit that biologic therapy brings to the majority of patients with chronic 
inflammatory diseases, they are not always effective. Moreover, they can cause a great variety 
of adverse side effects. Different type of IrAE may occur with the use of therapeutic proteins, 
requiring different approaches. There are several known mechanisms by which a therapeutic 
protein can induce an acute IrAE [32, 503].  Those adverse events may be related to the drug 
itself and to its molecular structure, or they may be related to the drug’s target and biologic 
activity [520].  
The great bulk of biologic therapies are represented by monoclonal antibodies. Antibodies are 
structurally immunogenic, even the fully human ones. The association between ADAb and acute 
IrAE have been extensively reported in the Literature, over the last years [502, 504-509]. As in 
our study, the vast majority of acute IrAE occurred in ADAb-positive patients [210, 211, 458, 
501, 521]. Exception is a study published by Rutgeerts et al, where a similar incidence of acute 
IrAE to infliximab was found between ADAb-positive and –negatives [167]. In this study, an 
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ELISA with low specificity and sensitivity was used to assess ADAb, and false positive or 
negative results cannot be excluded.  
The development of ADAb does not necessarily lead to drug adverse events, but in our study 
nearly half of ADAb-positive patients developed an acute IrAE, which is highly significant. 
Other groups have also reported extremely high incidence of IrAE among ADAb positives, 
ranging from 32% to 80% [210, 211, 458, 501, 521]. 
The presence of ADAb can be detected from the very beginning of infliximab treatment and 
before a clinically overt adverse reaction, as we also confirmed [210, 211, 458, 501, 521]. This 
fact is of high clinical relevance because it highlights the predictive value of ADAb for the 
development of IrAE. ADAb titres tend to increase with treatment continuation and IrAE have 
been associated mainly, although not exclusively, with the highest ADAb titers [210, 213, 521, 
522]. This may also explains why all patients with IrAE were not able to sustain therapeutic 
response over time.  
The majority of acute IrAE occur after the third infusion, which suggests a sensitization phase 
as occur in IgE-mediated hypersensitivity reactions. We did not assess IgE-ADAb in our study 
but previous studies have demonstrated that the great bulk of ADAb are of IgG isotype and not 
of IgE [461, 523]. Even though, IgE antibodies to infliximab and other biologics have been 
reported, often in association with a positive skin test [500, 501, 524-527]. Both IgE and non-
IgE acute reactions are clinically undistinguishable, despite the former tend to induce more 
severe reactions and to occur at the very beginning of the infusion course [501].   Virtually all 
the acute IrAE are usually accompanied by symptoms suggestive of anaphylatic reaction [506-
509, 521, 527, 528]. However, the mechanism behind might be an alternative pathway IgE-
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independent, mediated by IgG, FcγRIII, macrophages, basophils and platelet activating factor 
(PAF) [529, 530]. Infliximab-specific IgG may also lead to another effector mechanism 
involving complement activation and the production of anaphylatoxins (complement-cleavage 
products), which may or may not activate mast cells unspecifically. A mast cell-independent 
pathway may explain the absence of increased serum tryptase levels reported in many cases of 
biologic-related anaphylaxis [531]. 
Although IgE-mediated IrAE to infliximab seem to represent a minor proportion of the acute 
adverse events, it would be clinically relevant to confirm a true IgE-mediated anaphylaxis, as 
those reactions are potentially more severe and cannot be avoided with pre-medication [524, 
532]. These patients should not be kept in the same therapy. An in vitro assessment of IgE-
ADAb and an in vivo skin test have been proposed to identify the IgE-mediated IrAE [501, 521]. 
However, IgE-ADAb assessment is technically challenging due to low serum concentration of 
IgE antibodies and interference of IgG-ADAb antibodies. Further assays’ optimization need to 
be conducted in order to better assess different ADAb isotypes. Skin testing protocols have been 
proposed, which despite the high specificity (90%) still have low sensitivity (26%). 
Additionally, positive skin tests became negative over time, meaning that they need to be 
performed shortly after an immediate IrAE [501]. 
In our study, as in others in the literature, all patients with IrAE had detectable ADAb [210, 213, 
458]. However, IrAE have also been reported in ADAb-negative patients, suggesting an 
immunogenicity-independent mechanism [160, 211, 500]. Supporting this notion is the fact that 
some patients develop acute IrAE at the first infusion and can be successfully retreated by 
reducing the rate of infusion [531, 533]. Most likely, a cytokine release might be on the basis of 
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such acute reactions, which may be clinically indistinguishable from type I hypersensitivity 
[499]. Although the precise mechanism underlying this syndrome is not fully understood, it has 
been hypothesized as being related to the cross-linking of therapeutic monoclonal antibodies 
bound to target cells with subsequent complement activation and apoptosis of the target cell, 
leading to cytokine and chemokines release. In contrast to type I hypersensitivity reactions, 
cytokine-release syndromes can be managed by short-term cessation of biologic infusion, 
administration of histamine blockers and corticosteroids, restarting the infusion at a slower rate 
[534-536]. A pre-existing sensitization towards some additives may be a further mechanism 
accounting for some acute IrAE during the first infusion of the biologic. This event has been 
described for polysorbate, used for rapid solubilisation of pharmaceuticals in aqueous solution 
[537, 538].  
In our study all the IrAE occurred from the fourth infliximab infusion and were all associated 
with ADAb, which explains the recurrence of acute reactions despite pre-medication and 
infusion-rate reduction.  
This study has also some limitations. It is a small, single-centre observational study, with 
possible bias. However, our studies are in clear agreement with other larger studies published 
in the literature. We did not access ADAb titers neither isotypes, as our primary intention was 
to simply verify the association between the presence of ADAb and acute IrAE.  
Our study demonstrates a clear association between ADAb to infliximab and acute IrAE, 
highlighting the predictive value of ADAb for adverse reactions. Our results stress the high 
clinical value of routine immunogenicity assessment, which represents a powerful tool to 
optimize the management of biologics and their safety profile.   
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Figure 24 – Patients with infusion-related adverse events (IrAE) 
Legend: During the follow-up period 12 patients had an IrAE, 4 (33%) of RA, 2 (17%) of PsA, 2 (17%) of AS and 4 (33%) of 
IBD patients  
AS, Ankylosign Spondylitis; IBD, Inflammatory Bowel Diseases; PsA, Psoriatic Arthritis; RA, Rheumatoid Arthritis 
 
Figure 25 – Patients with detectable ADAb 
Legend: During the follow-up period 25 (27%) patients developed ADAb, 41% of RA, 33% of PsA, 18% of AS and 23% of 
IBD patients 
ADAb, Anti-Drug Antibodies; AS, Ankylosign Spondylitis; IBD, Inflammatory Bowel Diseases; PsA, Psoriatic Arthritis; RA, 
Rheumatoid Arthritis 
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Figure 26 – Proportion of patients with IrAE among ADAb-positives and ADAb-negatives 
All patients with IrAE had detectable ADAb. None IrAE were described among ADAb-negative patients whereas 48% of 
ADAb-positive patients developed an IrAE  
ADAb, Anti-Drug Antibodies; IrAE, Infusion.Related Adverse Events 
 
Figure 27 – Serum drug levels at every week between two infliximab infusions in 4 IBD patients 
who had IrAE 
Legend: Four IBD patients who had an IrAE were selected to measure serum drug levels (ug/mL of infliximab) between two 
infliximab administrations. Three patients had undetectable serum drug levels from week 2 and one from week 5. 
Pre-inf, Pre-infusion; Pos-inf, Pos-infusion; W, Week  
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3.3 IMMUNOGENICITY ASSESSMENT IN ROUTINE CLINICAL PRACTICE 
3.3.1 Introduction 
The immunogenicity of biologics has been associated with therapeutic failures and adverse 
events. ADAb have been detected before overt adverse reactions to biologics, which reveals an 
important predictive value in preventing those reactions. Moreover, immunogenicity assessment 
may help us to identify the reason for therapeutic failure in non-responder patients, which might 
be relevant for future therapeutic decisions [484, 539].   
Despite all the advances in predicting immunogenicity at pre-clinical phases of drug 
development, it has become evident that the long-term use of biologics in clinical practice seems 
to induce a grade of immunogenicity different from that initially predicted.  Such fact has 
attracted the attention of regulatory agencies, which have emitted guidelines on immunogenicity 
assessment beyond the approval phase [191].  
Despite that, immunogenicity assessment is still not part of the routine clinical practice. This 
deficiency may be partially explained by technical issues of the available monitoring assays. 
The assessment of drug immunogenicity is technically challenging. Most commonly, ADAb are 
detected by radioimmunoassays (RIAs), specifically tailored to detect antibodies against 
therapeutic antibodies. Several formats of RIAs exist and they are considered by many as the 
“gold-standard” to assess ADAb. However, RIAs represent a method of high complexity and 
low throughput, which also imposes safety concerns related to the handling of radioactive 
material, limiting its use on a routine basis. To overcome these limitations a particular ELISA 
have been developed, using a bridging format, based on the principle that bivalent ADAb will 
crosslink the biologic (drug) coated on plate and the biotinylated biologic (drug) that will be 
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added as secondary reagent. This “bridging antibody” format implies that ADAb must be 
recognized twice for their detection, which increases the assay’s specificity. On the other hand, 
it may prevent the detection of ADAb of IgG4 isotype. Human IgG4 tend to exchange half of 
the molecule with other IgG4 molecule that can be of different specificity, creating a 
monovalent, bispecific antibody that loose bridging ability [17, 208]. Even though IgG4 
represent a minor proportion of total IgG and ADAb of exclusively IgG4 isotype are unlikely to 
occur. Taken together, this indicates that ELISA format may represent a convenient method to 
use in the routine clinical practice.  Additionally, it represents a simple and relatively cheap 
method that does not require special equipment and laboratory conditions to its implementation. 
3.3.2 Objectives: 
This study aims to compare the proportion of ADAb-positive patients assessed by RIA-ABT 
and by Bridging ELISA, in a cohort of 110 patients with chronic inflammatory diseases 
receiving TNFi. Secondarily we evaluated: a) the proportion of IgG4-ADAb among total IgG-
ADAb; b) the presence of ADAb at least three months after therapy discontinuation; c) IgM-
ADAb to etanercept.  
3.3.3 Methods: 
3.3.3.1 Patients 
Consecutive patients with diagnosis of Rheumatoid Arthritis (RA), Ankylosing Spondylitis 
(AS), Psoriatic Arthritis (PsA) and Inflammatory Bowel Diseases (IBD) were included.  
All patients were followed at the day hospital of Hospital Garcia de Orta, Almada, receiving 
infliximab i.v. at a dose ranging from 3-5mg/Kg every 6-8 weeks, adalimumab 40 mg eow, 
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etanercept 50 mg every week, according to national recommendations for the use of biologic 
therapy to each disease [515-518]. 
The study was approved by the hospital ethics committee. All patients gave written informed 
consent. 
Serum samples were collected in trough, immediately before the next drug administration. 
3.3.3.2 ELISA to assess serum drug levels 
TNFi levels were measured by Elisa developed at Sanquin, Amsterdam, the Netherlands, using 
a setup as described before [212, 462, 519] – Figure 28. Briefly, a mouse monoclonal anti-TNF 
antibody was pre-incubated overnight onto microtitre plates. Thereafter, recombinant TNF 
(10ng/mL) in High Performance ELISA (HPE) buffer was added. After one hour plates were 
washed with phosphate buffered saline 0.02% Tween. Subsequently patient serum sample in 
different dilutions was added and incubated for 1 hour at 37°C. After washing the plates with 
phosphate buffered saline 0.02% Tween plates were incubated with biotinylated polyclonal 
rabbit antibodies against infliximab or adalimumab or etanercept in HPE buffer for 1 hour at 
37°C. After washing the plates with phosphate buffered saline 0.02% Tween, poly-HRP 
streptavidin was added for 30 min at 30°C, followed by incubation with tetramethylbenzidine 
(TMB). Afterwards reaction was stopped and absorption at 450 nm was assessed. Test results 
were reading out of a titration curve infliximab or adalimumab or etanercept, which was present 
in each plate. Limit of detection was determined by testing 100 sera of RA patients before 
treatment. The mean +/- 6x SD was chosen as a cut off. Limit of detection was about 2 ng/ml. 
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Because relevant serum levels of these drugs are > 1 µg/ml, sera can be easily tested at 1:100 
dilution. 
3.3.3.3 Bridging ELISA to assess ADAb 
ADAb against infliximab were measured by Bridging ELISA as described previously [209, 212] 
- Figure 29. In short, maxisorp ELISA plates (NUNC) were coated overnight with infliximab or 
adalimumab or etanercept in PBS at room temperature. After washing 5 times with PBS/0.02% 
Tween, plates were incubated with patient’s serum, serially diluted in High Performance ELISA 
(HPE) buffer, from Sanquin, Amsterdam, the Netherlands) for 1 h. The highest serum 
concentration was 10%. All incubations were performed at room temperature in an assay 
volume of 100 uL.  Subsequently the plates were washed in PBS/0.02% Tween and incubated 
for 1 hour with biotinylated infliximab or adalimumab or etanercept in HPE for one hour. After 
washing, streptavidin-poly-HRP (Sanquin) (1/10 000 in HPE) was added for 20 minutes for 
detection. After washing with PBS Tween, the ELISA was developed with 100ug/mL 
tetramethylbenzidine (TMB) in 0.11 M sodium acetate (pH 5.5) containing 0.003% (v/v) H2O2. 
The reaction was stopped with 2M H2SO4. Absorption at 450 nm was measured with an ELISA 
reader (Multiskan; Titertek, Elfab Oy, Filand). The sensitivity of these assays depends on the 
affinity of the ADAb.  Results were related to a titration curve of infliximab- or adalimumab- 
or etanercept-specific rabbit serum containing anti-infliximab or anti-adalimumab or anti-
etanercept antibodies in each plate. The lowest level of detection was 1ng/mL. However non-
specific binding of serum components such as rheumatoid factor or C1q sets the limit of 
detection for sera at about 20 ng/ml, which when converted to arbitrary units set the limit of 
detection in 2AU/mL. 
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3.3.3.4 RIA-Antigen Binding Test (ABT) to assess total IgG-ADAb  
ADAb of IgG isotype were measured by RIA-ABT as described previously [209, 462] – Figure 
29. One uL of serum diluted in PBS/0.3% bovine serum albumin (BSA) (PA buffer) was 
incubated over night with 1 mg Sepharose-immobilized protein A (GE healthcare, Chalfont St. 
Giles, UK) in a final volume of 800 uL for total IgG detection. Subsequently, the samples were 
washed with PBS 0.005% Tween and specific ADAb binding was detected by over night 
incubation with 20 000 dpm (approximately 1 ng) 125I-labeled F(ab’)2 infliximab or 
adalimumab or etanercept diluted in Freeze buffer (Sanquin). Unbound label was removed by 
washing, and protein A bound radioactivity was measured. When binding was more than 25% 
of the input, sera were further titrated. Antibody levels were compared to a standard rabbit serum 
containing anti-infliximab or anti-adalimumab or anti-etanercept antibodies and expressed in 
arbitrary units (AU). One AU corresponds to approximately 12 ng. In the etanercept assay, 
serum from an etanercept-vaccinated rabbit served as positive control. The lower limit of 
detection for ADAb was determined as 6 SD above the average signal measured for a panel of 
100 RA patients that were not yet treated with TNFi and corresponds to 12AU/mL [455]. 
3.3.3.5 RIA-Antigen Binding Test (ABT) to assess specific IgG4 or IgM-
ADAb  
Antibodies to infliximab or adalimumab or etanercept of IgG4 subclass were measured as 
described before [15] – Figure 29. Briefly, 80 mg anti-human IgG4 monoclonal antibody 
(MH164-1, Sanquin) or anti-human IgM monoclonal antibody was coupled to 8g CNBR-
activated sepharose (GE Healthcare). Per test 1 mg sepharose was incubated with serm in 750 
uL. After washing, IgG4 ADAb was detected by incubation with 125I-labeled F(ab’)2 of 
infliximab or adalimumab or etanercept in Freeze buffer. Antibody levels were compared to a 
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titration curve of infliximab- or adalimumab- or etanercept-specific rabbit serum containing 
anti-infliximab or anti-adalimumab or anti-etanercept antibodies, and expressed as arbitrary 
units (AU). The lower limit of detection was 19 AU/mL, determined as described above.  
3.3.3.6 RIA-Antigen Binding Test (ABT) to assess specific IgM-
antietanercept 
IgM antibodies to etanercept were detected by using a RIA-ABT as above described, although 
instead of using anti-human IgG, an anti-human IgM was used.  
3.3.3.7 Statistical Analysis: 
Descriptive statistic was used and data is presented as values, proportions, mean (standard 
deviation) or median (interquartile range), as appropriate.  
3.3.4 Results: 
We evaluated 110 patients (12 PsA, 43 RA, 22 IBD and 33 AE), 63% female, with mean (SD) 
age of 44 (13). Eighty-two patients were receiving infliximab, 13 patients adalimumab and 15 
patients were treated with etanercept, with a mean (SD) biologic duration of 3.2 (1.4) years.  
A total of 26 patients (24%) tested positive for ADAb in RIA-ABT (IgG total): 21anti-
infliximab and 5 anti-adalimumab. All those patients had also detectable ADAb measured by 
Bridging ELISA. No anti-etanercept antibodies were detected in any of the assays, either of IgG 
or IgM isotype. Among the 26 ADAb-positive patients, 16 (62%) also tested positive for IgG4-
ADAb – Figure 30. Eight patients had similar ADAb titres assessed by both total IgG-RIA and 
specific IgG4-RIA, while the remaining 8 had IgG4-ADAb of significant lower magnitude than 
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total IgG-ADAb, suggesting the presence of other IgG isotype rather than IgG4 – Figure 31. No 
ADAb of exclusively IgG4 isotype were detected. 
All ADAb-positive patients had undetectable serum trough drug levels and only one patient had 
undetectable etanercept levels in the absence of ADAb. Compliance was evaluated in that 
patient and nearly six months after, serum etanercept trough levels had normalized.  
We tested ADAb in 16 patients who had discontinued TNFi (8 adalimumab and 8 etanercept) 
for more than 3 months. In 3 out of 8 adalimumab patients, anti-adalimumab remain detectable 
in both RIA-total IgG and Bridging ELISA. No anti-adalimumab of IgG4 isotype were detected 
in those patients. Among etanercept patients, anti-etanercept antibodies remain undetectable 
even three months after therapy discontinuation. 
3.3.5 Discussion 
In out study Bridging ELISA was able to detect the same ADAb-positive patients as RIA-ABT, 
even in cases where IgG4 isotype represented a significant proportion of total ADAb. ADAb 
exclusively of IgG4 isotype were not detected. Low amounts of circulating drug prevent ADAb 
detection by Bridging ELISA but also by RIA-ABT, denoting significant drug interference in 
both assays. Therefore, all ADAb-positive patients had undetectable drug levels. No anti-
etanercept antibodies (IgG or IgM) could be detected by any of the assays. In some patients 
ADAb remain detectable several months after therapy discontinuation, which was not verified 
for etanercept.  
The increasing evidence of the impact of drug immunogenicity in clinical practice has propelled 
the development of better and simpler assays able to monitor immunogenicity on a routine basis.  
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So far, on of the most optimized assays to specifically assess ADAb to biologic drugs have been 
the RIA-ABT. This method has proven to be a method with reasonable sensitivity and high 
specificity to assess ADAb. However, as stressed before, one of the major drawbacks of RIA is 
the requirement of high doses of radioactivity, special laboratory conditions and relatively low 
throughput. Several companies have done great efforts in the optimization of ELISA-based 
assays to assess immunogenicity, given it simplicity, relatively low price and high throughput. 
For this work we used two ELISA-based assays developed at Sanquin, Netherlands, with whom 
we established a partnership for the use and optimization of these assays, specially tailored to 
monitor drug levels (simple ELISA) and ADAb (Bridging ELISA).  
Previous work has demonstrated that Bridging ELISA is more sensitive than RIA-ABT for 
ADAb detection, although more susceptible to drug interference [209]. Consequently, Bridging 
ELISA can only detect ADAb in the absence of circulating drug. RIA-ABT or IgG4-RIA are 
also highly affected by the presence of the drug, though less than Bridging ELISA. This explains 
why in some studies higher proportion of ADAb positive patients have been detected in RIA-
ABT, when compared to Bridging ELISA [209]. However, in all those cases the ADAb levels 
are low and not able to fully neutralize the drug. The clinical significance of such low ADAb 
titres is not so clear and remains to be established [462]. In our study, we detected the same 
positive patients in both assays, Bridging ELISA and RIA-ABT. This might be due to the fact 
that, in contrast to the above mentioned studies, we used a cohort with relatively long treatment 
duration and relatively high ADAb levels.  
Because the detection of ADAb by Bridging ELISA is only possible in the absence of drug 
levels, some authors have claimed that Bridging ELISA do not offer additional information to 
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the assessment of drug levels by using a simple ELISA. However, other reasons may underlie 
undetectable drug levels, namely patient’s non-adherence to the therapy. Increasingly evidence 
has revealed that patient’s non-adherence represents a major problem in our society, being even 
more dramatic in patients with chronic diseases [540]. Undetectable drug levels in the absence 
of detectable ADAb by Bridging ELISA may easily reveal those patients. In our small study we 
identify one patient in such conditions, to whom an educational reinforcement about the 
importance of compliance to those treatments was applied. Few months after, at the following 
evaluation, drug levels had returned to normal values. 
A significant proportion of ADAb-positive patients also tested positive for IgG4 isotype, which 
is in agreement with previous studies [193, 209]. Repeated antigenic stimulation may lead to 
IgG4 class switch [16]. As mentioned before, IgG4 is able to exchange half of the molecule with 
another IgG4 molecule of different specificity, creating a monovalent antibody that cannot 
bridge [17, 208]. Even though, IgG4 represents a small fraction of total IgG and in presence of 
significant amount of IgG4-ADAb, it is likely that the Fab arm exchange occur with another 
IgG4 of the same specificity. This may explain why in our study all patients who tested positive 
for IgG4-ADAb had also tested positive in Bridging ELISA. Moreover, ADAb of exclusively 
IgG4 isotype is not common and often ADAb of IgG1 isotype co-exist. However, some patients 
have tested positive in IgG4-RIA and not in RIA-ABT, which can be simply explained by 
different drug interference with both assays [209].  
No anti-etanercept antibodies could be detected either by RIA-ABT or Bridging ELISA, which 
is consistent with many other studies that have used more recent and optimized assays [496].  
Etanercept is able to neutralize both TNFa and Lymphotoxin-alpha (LTa). Among other 
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important functions in the immune system, LTa is important for germinal centre formation 
[489]. Though hypogammaglobulinaemia have not been associated with etanercept treatment, 
still, we decided to assess anti-etanercept of IgM isotype, with negative results. As etanercept is 
administered to patients more often than infliximab or adalimumab (every week; e6-8w; eow, 
respectively), we wonder if residual circulating drug was interfering with ADAb detection. 
However, no anti-etanercept antibodies were found even several months after therapeutic 
withdrawal, which has also been reported by others [478]. On the other hand 3 out of 8 patients 
previously exposed to adalimumab, remain ADAb positive years after therapy discontinuation, 
assessed by Bridging ELISA and by RIA-ABT but not by IgG4-RIA. ADAb status in those 
patients, at the time of therapeutic failure, was not known. We cannot exclude that in some 
patients ADAb became undetectable over time after stopping therapy. However, our results 
highlight the notion that these ADAb are hypermutated, high affinity and class switch 
antibodies, resulting from a mature immune response that induces immunologic memory. Such 
fact is of high clinical relevance, as sometimes patients return to previous treatment long after 
its discontinuation. Re-challenging these patients with the same antigenic drug may boost the 
immune response against the drug with important adverse consequences. 
Our study represents a very small-scale study, which was not designed to detailed comparissons 
between the above mentioned assays. However, our main purpose was to validate in our lab the 
performance and the easy implementation of this ELISA-based therapeutic monitoring (ELISA 
and Bridging ELISA), in order to evaluate to which extend these two assays can be proposed to 
monitor immunogenicity in routine clinical practice. We concluded that Bridging ELISA is a 
simple and effective method in detecting clinically significant immunogenicity, though not 
being able to detect ADAb of low levels and in the presence of residual circulating drug levels. 
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However, the clinical significance of those low levels is not entirely clear, as some patients are 
able to maintained such low titres with no apparent clinical consequences. Thus, only those 
patients with undetectable drug levels should be assessed for ADAb, by using Bridging ELISA. 
The assessment of ADAb in such conditions will help us to distinguish immunogenicity from 
non-adherence, which requires different approaches. This type of therapeutic monitoring 
represents a powerful tool to optimize the use of biologic therapies.  
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Figure 28 – ELISA to assess serum drug levels 
Legend: TNF, Tumor Necrosis Factor; TNFi, Tumor Necrosis Factor Inhibitor 
 
 
Figure 29 – Assays used to measure ADAb 
Legend (from the left to the right): Bridging ELISA; RIA-ABT using Protein A sepharose able to detect total serum IgG; IgG4-
RIA-ABT using anti-IgG4 sepharose to specifically assess serum IgG4. 
TNF, Tumor Necrosis Factor; TNFi, Tumor Necrosis Factor Inhibitor  
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Figure 30 – Proportion of ADAb-positive patients detected in each assay.  
Legend: Twenty-six out of 110 patients (24%) tested positive for ADAb in Bridging ELISA and in RIA-ABT (IgG total). 
Sixteen (62%) also tested positive for IgG4-ADAb in IgG4-RIA-ABT. 
ABT- Antigen Binding Test; ADAb, Anti-drug antibodies; Br ELISA, Bridging Enzyme-Linked Immunosorbent Assay; RIA, 
Radioimmuno assay 
 
 
Figure 31 – ADAb titres assessed by IgG-RIA-ABT and specific IgG4-RIA-ABT 
Legend: Eight out of 16 patients had similar ADAb titres (AU/mL) assessed by both total IgG-RIA and specific IgG4-RIA, 
while the remaining 8 had IgG4-ADAb of significant lower magnitude than total IgG-ADAb. 
ABT- Antigen Binding Test; ADAb, Anti-drug antibodies; Br ELISA, Bridging Enzyme-Linked Immunosorbent Assay; RIA, 
Radioimmuno assay  
 
>1280 
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3.4 A PRELIMINARY ALGORITHM INTRODUCING IMMUNOGENICITY 
ASSESSMENT IN THE MANAGEMENT OF RA PATIENTS RECEIVING 
TUMOR NECROSIS FACTOR INHIBITORS THERAPIES 
3.4.1 Introduction 
The “treat to target” strategy, now part of the European League Against Rheumatism (EULAR) 
recommendations, has revealed the importance of an early tight control of disease activity 
among Rheumatoid Arthritis (RA) patients [404, 541-543]. To reach clinical remission or at 
least low disease activity, fast and assertive therapeutic decisions are required. No formal 
recommendations exist to guide the order of the sequence of biologics, particularly after the 
failure of previous Tumor Necrosis Factor Inhibitors (TNFi), which represents a common 
situation in daily practice. The effectiveness of cycling between different TNFi is controversial 
and currently, the decision to switch mechanism of action (MOA) is largely empirical.  
Drug immunogenicity has been proposed as one of the main mechanisms behind biologic 
therapeutic failure [153, 210, 213, 461]. We recently conducted a systematic review and meta-
analysis concluding that anti-drug antibodies (ADAb) are clinically relevant and lead to 
significant decrease of therapeutic response rates. [496] 
The presence of ADAb results in functional neutralization of the drug and formation of immune 
complexes that promotes a faster clearance of the drug from circulation [193, 544]. ADAb-
positive patients exhibit very low or undetectable serum drug trough levels, in contrast to 
ADAb-negative patients, who often have normal or even high serum drug trough levels [210, 
455, 472, 519]. 
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Non-responder patients, who exhibit adequate serum drug levels and no detectable ADAb, have 
lower probability of response to another agent with the same MOA and may benefit in switching 
to a drug with a different MOA [484]. Non-responders, who have no detectable serum trough 
levels and detectable ADAb, may benefit in switching to a less immunogenic drug [539]. These 
patients may have a higher probability of developing ADAb against the new biopharmaceutical 
[484]. Neutralizing ADAb against etanercept or abatacept have not been detected [193, 496, 
545]. 
The added value of assessing immunogenicity in current clinical practice has been questioned. 
Based on available evidence we designed a preliminary algorithm that introduces 
immunogenicity assessment in the current clinical approach to RA patients receiving biologic 
therapies – Figure 32. We propose to evaluate the concordance between the new algorithm and 
current clinical practice, comparing the effectiveness of “immunogenicity-based” versus 
“empirical-based” switches. The combination of clinical and immunogenicity data may provide 
a tool to optimize the use of biologic therapies.  
3.4.2 Objectives 
This study aims to evaluate how concordant rheumatologist´s current clinical practice was with 
our proposed treatment algorithm and to compare therapeutic response rates between patients 
who followed the proposed algorithm and those who followed other therapeutic strategies. 
Therapeutic responses over one year in non-responders, who switched according to the 
following two main branches of our algorithm were compared to other strategies in both 
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occasions: 1) Switching to non-TNFi if serum drug levels were detectable; 2) Switching to a 
less immunogenic drug if serum drug levels were undetectable and ADAb testing positive. 
Secondarily, we evaluated the role of ADAb as a mediator of therapeutic response. 
3.4.3 Methods 
3.4.3.1 Patients 
During a period of 2 years (January 2010 - December 2011) we followed all adult patients (≥18 
years) with established RA, receiving TNFi (infliximab 3mg/Kg i.v. at 0, 2, 6, 14 weeks and 
every 8 weeks thereafter, adalimumab 40 mg s.c. every other week, or etanercept 25 mg s.c. 
twice a week or 50 mg once a week) in monotherapy or with concomitant immunosuppressors, 
at the Department of Rheumatology, Hospital Garcia de Orta, Portugal. All patients fulfilled the 
American College of Rheumatology 1987 revised criteria for RA and followed the Portuguese 
recommendations for the management of RA patients receiving biologic therapies [512, 546]. 
The study was approved by the hospital ethics committee. All patients gave written informed 
consent. 
For the concordance between rheumatologist´s current clinical practice and our proposed 
treatment algorithm, disease activity was evaluated in all patients every 3 months, using the 
Disease Activity Score in 28 joints (DAS28), according to the rheumatologist’s standard of care. 
Therapeutic response was defined as EULAR good and moderate responses (improvement 
DAS28>1.2 and DAS28≤3.2; improvement DAS28>1.2 and DAS28>3.2 or improvement 
0.6>DAS28≤1.2 and DAS28≤5.1) and low disease activity as a DAS28≤3.2, according to 
national and international guidelines [466, 546]. 
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Drug immunogenicity was assessed every 3 months, through serum samples collected just 
before the next administration of a biologic. Serum drug trough levels were measured by ELISA, 
using a setup as described before [462, 519]. Limit of detection was determined by testing 100 
sera of RA patients before treatment. The mean +/- 6 times standard deviation (SD) was chosen 
as a cut off. Limit of detection was about 2 ng/ml for all TNFi. ADAb were tested by Bridging 
ELISA as described before [209]. The sensitivity of these assays depends on the affinity of the 
ADAb. We used a series of patient-derived monoclonal antibodies to establish the sensitivity of 
the assay. A monoclonal antibody to adalimumab with the median affinity showed reached half-
maximal extinction at 10 ng/ml and a detection limit <1 ng/ml. However non-specific binding 
of serum components such as rheumatoid factor or C1q sets the limit of detection for sera at 
about 20 ng/ml. 
Clinicians were blind to immunogenicity test results and therapeutic decisions were undertaken 
according to the Portuguese recommendations for the management of RA patients [546]. 
We classified patients into Group A if, during the entire study follow-up, they followed, 
empirically, any of the branches proposed in our algorithm, and Group B, those who followed 
different therapeutic strategies. Therapeutic responses were evaluated over one year after 
therapeutic decision, which may have included to switch or maintain therapy. 
For comparison of therapeutic responses over one year in non-responder patients who switched 
according to the two main branches of our algorithm, therapeutic response was assessed before 
the switch and at 3, 6, 9 and 12 months thereafter. The proportion of patients with therapeutic 
response and the proportion of patients with low disease activity were compared, over one year 
after the switch, between: a) non-responders with detectable serum trough levels who switched 
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to another TNFi and non-responders with adequate serum trough levels who switched to a non-
TNFi; b) non-responders with undetectable serum drug trough levels, ADAb-positives, who 
switched to therapeutic monoclonal antibodies and non-responders with undetectable serum 
drug trough levels, -positives, who switched to etanercept or abatacept. 
To evaluate the role of ADAb as a mediator of therapeutic response, the proportion of patients 
with therapeutic response was assessed at study beginning, between ADAb-positive and ADAb-
negative patients.  
3.4.3.2 Confounders or effect modifiers: 
To assess the impact of the proposed algorithm on therapeutic response and the influence of 
“immunogenicity-based” switches versus “empirical-based” switches on therapeutic response 
and low disease activity rates, we defined as potential confounders or effect modifiers: age, 
disease duration, disease duration before biologic DMARD introduction, exposure time to 
biologic, concomitant immunosuppressors, Erythrocyte Sedimentation Rate (ESR), C-Reactive 
Protein (CRP), DAS28 and response status (responder vs. non-responder) at the study beginning 
or time of therapeutic decision. 
3.4.3.3 Statistical analysis 
Differences in patient characteristics between groups at study beginning were analyzed by chi-
square test (binary variables), T-test or Mann-Whitney U test (continuous, variables), as 
appropriate. The threshold for significance was set at a P value (p) of less than 0.05, 2-sided. 
To estimate the course of therapeutic response and low disease activity status over time in 
patients that followed specific therapeutic strategies, we used generalized estimation equation 
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(GEE) with binary response. All the variables previously defined as potential confounders or 
effect size modifiers were tested in our model. Statistical software SPSS 17.0 (Chicago, Illinois) 
and R 2.14.2 platform - package “GEE” were used [547]. 
3.4.4 Results 
3.4.4.1 Characteristics of the cohort 
The study included 105 RA patients, 45% switchers, with a median (interquartile range [IQR]) 
disease duration of 10.1 (4.6-12.6) years. At the study beginning, 22.9% patients were receiving 
infliximab, 31.4% adalimumab and 45.7% etanercept. During the follow-up period, 51.4% of 
patients (Group A) had therapeutic concordant decisions with the proposed algorithm, whereas 
48.6% (Group B) had discordant. Therapeutic decisions concordant with the proposed algorithm 
were undertaken with a median delay of 249 days (IQR 116-388). Patient’s baseline 
characteristics of both cohorts are listed in Table 4. 
3.4.4.2 The Impact of the Proposed Algorithm on Clinical Response Over 
One Year after Therapeutic Decision 
GEE demonstrated that patients from Group A had significantly higher probability of achieving 
therapeutic response (OR=7.91, p<0.001, 95% CI=3.27-19.13) and low disease activity over 
one year after the therapeutic decision (OR=9.77, p<0.001, 95%CI=4.69-20.37), in comparison 
with patients from Group B – Table 5. 
By excluding ADAb-positives patients, the probability of achieving therapeutic response 
(OR=5.97, p<0.001, 95% CI=2.38-14.99) and low disease activity (OR=7.88, p<0.001, 
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95%CI=3.57-17.39) remained significantly higher in patients in Group A when compared to 
those in Group B. 
Response status (responder vs. non-responder) at the time of therapeutic decision had a 
significant effect modification on both outcomes: therapeutic response (OR= 9.59, p<0.001, 
95%CI=4.21-21.84) and low disease activity (OR=5.23, p<0.001, 95%CI=2.30-11.89).  In 
Group A, higher DAS28 scores at the time of therapeutic decision were associated with a lower 
probability of achieving low disease activity over the following year (OR=0.40, p<0.001, 
95%CI=0.27-0.61), whereas in group B the DAS 28 scores did not affect the probability of 
achieving low disease activity (OR=0.84, p=0.33, 95%CI=0.58-1.20). In both situations, either 
response status or DAS28 scores at the time of therapeutic decision did not abrogate the 
association between therapeutic decision and the studied outcomes, which remained highly 
significant and nearly unchanged (less than 10%). The same result was verified after controlling 
for all other considered confounders or effect modifiers, assessed at the time of therapeutic 
decision. 
3.4.4.3 Therapeutic responses over one year in non-responder patients who 
followed the two main branches of our algorithm  
Non-responders to a TNFi in the presence of detectable serum drug trough levels and no 
detectable ADAb had higher probability of achieving response by switching to a drug with 
different MOA, rather than another TNFi, even after adjusting for potential confounders, such 
as DAS28 at the time of switch (OR=6.76, p=0.004, 95%CI=1.82-25.04). Despite a trend toward 
higher probability of achieving low disease activity, statistical significance was not reached 
(regression coefficient=0.24, p=0.73). 
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By analysing the 18 non-responder patients with undetectable serum drug trough levels, ADAb-
positives, we verified that: 1) only two patients switched to a less immunogenic drug, both 
achieving response and low disease activity after the switch; 2) 15 patients maintained 
immunogenic drugs (14 remained within the same MOA and one switched to a different MOA), 
none was able to achieve therapeutic response; 3) one patient, despite ADAb-positivity, was 
considered as a responder and maintained the same therapy, achieving low disease activity and 
even clinical remission over the following year. 
3.4.4.4 ADAb as a mediator of therapeutic response 
At the study beginning, ADAb was detected in 37.5% of infliximab-treated patients and in 
27.3% of adalimumab-treated patients. No detectable ADAb were verified among patients 
receiving etanercept. All ADAb-positive patients had undetectable serum drug trough levels, 
which were not verified in patients without detectable ADAb. Patient’s baseline characteristics 
among ADAb-positive and ADAb-negative are listed in Table 7. 
Lower proportion of responders was observed among ADAb-positive patients than ADAb-
negatives (22.2% vs. 62.1%, p=0.003). One patient with detectable ADAb had low disease 
activity, in comparison with 34.5% of patients without detectable ADAb (5.6% vs. 34.5%, 
p=0.02) - Table 5. ADAb-positive patients had significantly higher mean (SD) CRP values, 
compared with ADAb-negatives: 5 (3-10) vs. 2.15 (1-4) mg/L, p=0.001 – Figure 33 – C-
Reactive Protein (CRP) concentration among ADAb-negative and ADAb-positive patients, at 
study beginning. 
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3.4.5 Discussion 
Our results demonstrate that therapeutic decisions according to the proposed algorithm lead to 
better disease control with significantly better clinical outcomes in RA patients, receiving 
biologic therapies. These results were independent of ADAb status and DAS28 scores at the 
time of therapeutic decision. Less than half of patients empirically followed therapeutic 
strategies concordant with the proposed algorithm.  Had our algorithm been followed, about 8 
months would have been gained, with important clinical and economic impact. Serum drug 
trough levels predict therapeutic responses in switchers. Non-responders to etanercept, 
adalimumab or infliximab, in the presence of detectable serum drug trough levels, were most 
likely to respond when switched to a drug with different MOA, in comparison with those who 
switched to another TNFi. In this subset, TNF might not play a central role in disease 
pathogenesis. Our results are in agreement with two previous studies, where switchers who 
failed previous TNFi (infliximab or adalimumab) in the absence of ADAb had poor responses 
to a second TNFi [484, 539]. 
Non-responders to TNFi in the presence of undetectable serum drug trough levels, ADAb-
positives, were poorly represented in our study and no robust conclusions should be drawn 
exclusively from our data. Our data suggest that those patients might benefit in switching to a 
less immunogenic drug, TNFi or non-TNFi. Previous studies have revealed that patients, who 
discontinued a TNFi due to immunogenicity, were able to achieve response to another TNFi, if 
free of significant immunogenicity [539]. In contrast, lower therapeutic responses were verified 
when the second TNFi was a monoclonal antibody [484, 539].   
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Previous studies have revealed that TNFi therapy is more efficient in patients who discontinued 
the first TNFi due to secondary failure or adverse events, rather than by primary failure [438, 
548]. Therapeutic algorithms based on the clinical distinction between primary and secondary 
failures have been proposed by some authors, who have underestimated the added value of 
immunogenicity assessment in clinical practice [549]. Such a clinical distinction is not 
straightforward, as therapeutic response assessment is based on subjective criteria that can be 
strongly affected by certain biases. The placebo effect, “regression to the mean”, or optimization 
of concomitant therapies may be the cause of initial clinical response. 
A decision tree algorithm based on immunogenicity monitoring was recently proposed by others 
[550]. In this work, contrarily to ours, the first branching implicitly concerns clinical response, 
as the study addresses specifically patients with primary and secondary failures to TNFi. We 
propose a first branching according to drug level that offers the possibility to readily identify 
patients that are over or uselessly treated. The previous algorithm also considers dose escalation 
in non-responders presenting low drug level and undetectable ADAb. In some of these cases 
ADAb might be hidden by the presence of drug and dose escalation may boost ADAb 
production with serious adverse events [209, 210, 462, 495]. In the previous algorithm, a switch 
to another TNFi is recommended for non-responder patients that present optimal serum drug 
levels and ADAb positive. Such ADAb titers, which have no significant impact in serum drug 
concentrations, are unlikely to fully neutralize drug’s bioactivity [193, 462]. No clinical 
response, despite TNF neutralization, may warrant switching to an agent with a different MOA. 
We did not include this category of patients in our own algorithm, as in presence of optimal 
drug levels, ADAb are unlikely to be revealed by using Bridging ELISA or RIA assays [195, 
209, 210, 455]. 
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The inclusion of responders in our algorithm should help identify patients for whom drug dose 
reduction or increased interval between drug administrations might increase treatment cost-
effectiveness. Correlation between DAS28 improvement and serum drug trough levels has been 
verified up to a threshold of drug level, above which no significant DAS28 changes occur [551]. 
EULAR recommendations, according to expert opinion, suggest that tapering a biological 
DMARD should only be considered in patients in remission for at least 12 months [404]. 
Biologic withdrawal might be considered earlier among patients in remission despite 
undetectable drug levels and high titres of ADAb. Subclinical synovitis might lead to bone 
damage in patients who clinically seem to have controlled RA [552, 553]. Image techniques, 
including ultrasonography or magnetic resonance imaging (MRI), have revealed higher 
sensitivity and reproducibility than clinical evaluation in assessing active synovitis and may be 
used to confirm remission [554]. 
Our experience suggests that high ADAb titres in the trough are associated with undetectable 
drug levels during most of the interval between two drug administrations. It seems reasonable 
to postulate that in these cases, remission is not maintained by the therapy. Further double-blind, 
randomized controlled trials may better clarify this point.  
At the study beginning, 37.5% of infliximab-treated patients and 27.3% of adalimumab-treated 
patients had detectable ADAb.  These proportions might be underestimated, since many patients 
with obvious non-responses, potentially ADAb-positives, had already switched from initial 
therapy. Interestingly, in some cases, we were still able to detect ADAb against the previous 
biologic, several years after drug discontinuation. We did not find anti-etanercept antibodies, 
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which is in agreement with previous studies that used more specific methods to detect ADAb 
[478, 496, 539]. 
Patients with detectable ADAb had higher mean CRP values, reflecting the poor control of 
inflammation. Previous studies have revealed higher baseline CRP values in ADAb-positive 
patients, but its association with the development of ADAb is not clear [153]. Concomitant 
immunosuppressive therapies, particularly methotrexate, have been associated with decreased 
ADAb frequencies [496, 555]. In our study, almost all patients were receiving concomitant 
methotrexate and low dose corticosteroids, which limited us to confirm this. 
Our study has important limitations, despite reflecting real-world evidence. This is a small-scale 
study, conducted at one single center, and not powered to assess all the branches described in 
our algorithm, as this was not our main purpose. We did not categorize detectable serum drug 
trough levels from low to high, since no robust studies have clearly defined those cut-offs. 
ADAb are unlikely to be detected in the presence of circulating drug by the most common 
assays, namely Bridging ELISA. We assessed immunogenicity of three TNFi approved for RA 
treatment. Extrapolations to other agents in the same class, such as golimumab and certolizumab 
should be done cautiously.  We treated non-TNFi agents as a homogeneous group and did not 
evaluate the potential differences among them, due to limited data. Etanercept and abatacept did 
not reveal clinically significant immunogenicity and were both considered “less immunogenic”. 
Further studies, using the same methodology, should be conducted to better compare the 
immunogenic profile of biopharmaceuticals. 
Many questions regarding immunogenicity remain to be elucidated. We are proposing strategies 
that are already approved for RA patients. This algorithm represents a preliminary tool to aid 
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decision-making among clinicians and how immunogenicity assessment can be integrated in the 
care for these patients, leading to personalized and more cost-effective strategies to RA 
treatment.  
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Table 4 – Patient’s Baseline Characteristics 
 
Legend: Values shown are n (%), means (standard deviation [SD]) or median (interquartile range [IQR]).  
Differences between patients’ baseline characteristics were tested by Mann-Whitney U or chi-square tests; ns = non-singificant 
Switchers = patients who have been previously exposed to biologic therapy and switch to a new agent 
ACPA – Anti-Citrullinated Peptides Antibodies; Biol. – Biologic; CRP – C-Reactive Protein; DAS – Disease Activity Score; 
Dis. – Disease; ESR – Erytrocyte Sedimentation Rate; Initial DAS28 – DAS before biologic therapy; RF – Rheumatoid Factor 
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Table 5 – Response and Low Disease Activity in patients from Group A and Group B, over one 
year after therapeutic decision  
 
Legend: Values shown are n (%), odds ratio (OR) and 95% confidence intervals (95% CI). P-values were obtained from 
generalized estimation equation (GEE) with binary response. 
Group A represents patients that followed the proposed algorithm (any branch) and Group B represents patients that followed 
different strategies. 
Therapeutic response was assessed every 3 months over one year after therapeutic decision. Therapeutic response was defined 
as decreased DAS28>1.2 and DAS28≤3.2, improvement DAS28>1.2 and DAS28>3.2 or improvement 0.6>DAS28≤1.2 and 
DAS28≤5.1 and Low disease activity as DAS28≤3.2. 
 
Table 6 – Therapeutic Response and Low Disease Activity among ADAb-negative and ADAb-
positive patients, at study beginning 
 
Legend: Values shown are n (%). Therapeutic response was assessed every 3 months and defined as an improvement 
DAS28>1.2 and DAS28≤3.2, improvement DAS28>1.2 and DAS28>3.2 or improvement 0.6>DAS28≤1.2 and DAS28≤5.1 
(EULAR good and moderate response). Low disease activity was defined as a present DAS28≤3.2. 
P-values were obtained from chi-square tests. 
ADAb + - anti-drug antibodies positive; ADAb- - anti-drug antibodies negative 
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Table 7 – Patient’s Baseline Characteristics among ADAb+ e ADAb- 
 
Legend: Values shown are n (%), means (standard deviation [SD]) or median (interquartile range [IQR]).  
Differences between patients’ baseline characteristics were tested by Mann-Whitney U or chi-square tests; ns = non-significant 
ACPA – Anti-Citrullinated Peptides Antibodies; ADAb – anti-drug antibodies; ADAb- - Anti-drug antibodies negative; ADAb+ 
- Anti-drug antibodies positive; Biol. – Biologic; CRP – C-Reactive Protein; DAS – Disease Activity Score; Dis. – Disease; 
ESR – Erytrocyte Sedimentation Rate; Initial DAS28 – DAS before biologic therapy; RF – Rheumatoid Factor 
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Figure 32 – Preliminary Algorithm to Approach RA Patients receiving TNF Inhibitor Therapies, 
introducing immunogenicity assessment  
Legend: Serum drug trough levels and therapeutic response (EULAR criteria) assessed every 3 months 
1) Serum drug trough levels detectable (Detect): 
a. EULAR responder - maintain therapy, eventually reducing dosage or increasing the interval 
between drug administrations  
b. EULAR non-response - switch (sw) to a drug with different mechanism of action 
2) Serum drug trough levels undetectable (Und) – assess ADAb: 
a. ADAb positive: 
i. EULAR response: 
1. Re-evaluate patient (concurrent therapies; alternative diagnosis) 
2. Assess active synovitis – if remission, eventually consider withdrawal therapy 
ii. EULAR non-response - switch to a less immunogenic drug 
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b. ADAb negative: 
i. Assess patient’s compliance 
ii. Verify if drug is adjusted to the patient’s weight 
iii. EULAR response: 
1. Re-evaluate patient (concurrent therapies; alternative diagnosis) 
2. Assess active synovitis – if remission, eventually consider withdrawal therapy 
iv. EULAR non-response - switch to a less immunogenic drug 
1. Repeat tests 
2. Assisted drug administration 
 
 
 
 
Figure 33 – C-Reactive Protein (CRP) concentration among ADAb-negative and ADAb-positive 
patients, at study beginning 
Legend: Values shown are median (interquartile range [IQR]) of CRP: 5 (3-10) mg/L in ADAb+ patients and 2.15 (1-4) mg/L 
in ADAb- patients. 
Differences between CRP median values from two groups were tested by Mann-Whitney U test, p=0.001. 
ADAb – anti-drug antibodies; ADAb+ - anti-drug antibodies positive; ADAb- - anti-drug antibodies negative 
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4 GENERAL DISCUSSION  
The introduction of biological therapies into clinical practice has greatly improved the treatment 
of chronic inflammatory diseases. The efficacy, effectiveness and safety of biological therapies 
have been extensively demonstrated in clinical trials and observational studies. There is a net 
positive balance where health care is concerned. However, this new class of drugs has also 
imposed several challenges for clinicians, biologists and economists. Those challenges are 
inherent to the very nature of these agents: large proteins (often antibodies), costly to produce 
and hard to reproduce under generic forms. Moreover, biologicals are replicates of natural 
compounds synthesized by the organism, administrated at doses far above physiological 
concentrations of their natural equivalents. Hence, their usage interfere with fundamental 
principle of life, that of physiological homeostasis. For over a century, immunologists have 
attempted to decipher the rules of immune tolerance, self / non-self discrimination (or assertion) 
and have proposed that variations from steady state (homeostatic conditions) alert the immune 
system and provoke adaptive immune responses. These fundamental notions are quite relevant 
to the challenge imposed by the use of biological therapies.  
Over the last years increasing literature have revealed the ADAb as one of the main reasons 
behind therapeutic failure, also having impact on drug safety profile. Even though, the concept 
of drug immunogenicity has not reached medical community and clinical decision-makers. This 
overall neglect may owe to conflicting results from RCTs, which has higher impact near medical 
community than observational studies. However, immunogenicity induced by the long term of 
biologics in clinical practice has been poorly addressed by large RCTs, and never as a primary 
objective. Moreover, detection of ADAb is technically challenging and optimized assays were 
116 
only recently available. Therefore, we reavaluated all the available evidence, pooling all studies 
togheter in a meta-analysis, to formally established the clinical impact of ADAb. Posteriorly, 
we defined a convenient assay to monitor immunogenicity in clinical practice and we designed 
an algorithm introducing immunogenicity information into the current clinical management of 
patients receiving biologic therapies. We demonstrated the possibility of a personalized and 
scientifically-based approach to patients receiving biologic therapies, providing more safer and 
cost-effective strategies with obvious advantages for the patients and society.  
4.1 THE IMPACT OF ADAB ON THERAPEUTIC RESPONSES  
To formally document the impact of ADAb on therapeutic responses we performed a systematic 
review (2,082 studies) with a meta-analysis (17 included studies) of the literature. We assessed 
the effect of anti-drug antibodies on therapeutic response to infliximab, adalimumab and 
etanercept in patients with Rheumatoid Arthritis, Spondyloarthritis, Psoriasis and Inflammatory 
Bowel Diseases. We also scored the effect of concomitant immunosuppression on the detection 
of ADAb.  
Meta-analysis is a statistical technique for combining data from independent studies, having 
higher statistical power to detect an effect than individual studies. Meta-analysis is also less 
influenced by local biases and it represents today the top of the evidence for clinical decision-
making.  
This approach revealed that i) anti-drug-antibodies significantly reduce drug effectiveness; ii) 
this effect can be attenuated by concomitant immunosuppression, which iii) reduces ADAb. 
Strikingly, detectable ADAb decreased drug response by as much as 80%. This result contrasted 
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with reports from most RCTs, which considered immunogenicity as a minor problem. Our 
analysis support the notion that lack of sensitivity and specificity in most ADAb assays has been 
the major misleading factor in these randomized clinical trials [326, 340, 485, 556]. Moreover, 
the appropriate time for sample collection was also not always respected. It is known today that 
in the majority of patients ADAb become detectable after 12-24 weeks of therapy, when ADAb 
titres exceed the circulating drug’s concentration [153, 210, 213]. Clinical trials of short-term 
duration might underestimate the frequency of ADAb. Additionally, residual circulating drug 
significantly interferes with the detection of ADAb in the most conventional assays (ELISAs or 
RIAs) due to immune complex formation that prevents the binding or the capture of ADAb in 
those assays [209]. Therefore, to avoid drug interference, samples must be collected 
immediately before the next drug administration (trough), where it is expected the lowest drug 
concentration. Going back to those RCTs we may verify that many of these aspects were not 
always taking into account.  
4.2 THE INFLUENCE OF CONCOMITANT IMMUNOSUPPRESSION AND OTHER 
POSSIBLE MODULATOR FACTORS ON ADAB DETECTION 
We demonstrated that concomitant immunosuppression, mainly with MTX, attenuates the 
impact of ADAb on therapeutic response. This explains, in part, why combined therapy with 
biologic plus MTX is more effective than biologics in monotherapy. A sub-group analysis 
confirmed that in studies where higher proportion of patients was receiving concomitant MTX, 
the impact of ADAb on therapeutic response rates was attenuated to 68%. This result also 
suggests that in some cases clinical response is maintained by MTX and not the biologic 
anymore, when high ADAb titers and undetectable drug (biologic) levels are seen. We could 
not analyze the modifier effect induced by AZA or 6-MCP due to lack of data. However, our 
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results suggest that MTX may have higher modulating effect of drug immunogenicity than AZA 
or 6-MCP, which need to be confirmed in further large trials. This is of high clinical relevance 
for IBD patients, where AZA represents the main immunosuppressor. Similarly, in diseases 
where MTX is not approved, such as SpA or Ps, MTX although not having apparently 
significant role in disease pathogenesis, might be important to increase drug survival and 
efficacy. We verified that concomitant immunosuppression reduced detectable ADAb by 64%.  
The exact mechanism by which MTX reduces ADAb detection and why that reduction is more 
evident in some patients, remain unknown. At lower concentrations, such those commonly used 
in RA (7.5-20mg/weekly), MTX has been shown to induce apoptosis of activated but not resting 
T-cells, thereby reducing cytokine production and inflammation [557-559]. As such, we might 
expect that MTX will suppress biologic-specific T cells when they became fully activated, i.e. 
shortly after biologic administration.  Fully advantage of MTX efficacy may occur at this time 
point. Moreover, it is known that plasma bioactive MTX half-life is relatively short and some 
hours after MTX intake, which may also vary between individuals, its inactive metabolite rise 
in plasma [559-562]. In RA, MTX is given weekly and its intake is not usually coordinated with 
biologic administration. Differences in MTX metabolism and in the interval between its intake 
and biologic administration may explain, at least in part, inter-individual differences in the 
modulating effect of MTX on ADAb production.  
We also assessed the influence of other factors that may modulate the clinical impact of drug 
immunogenicity, such as initial higher doses or scheduled regimens. Limited data prevent us to 
drawn robust conclusions. However, previous studies have demonstrated that initial higher 
doses lead to small numbers of memory T cells and less efficient immune responses upon re-
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challenge with the same antigen, when compared with initial lower-doses [169, 170]. Small-
scale studies have suggesting that higher initial infliximab doses (10mg/Kg compared with 
1mg/Kg or 3mg/Kg) or higher initial adalimumab doses (160/80mg compared with 80/40mg at 
week 0 and 2, respectively, followed by 40mg eow) are associated with sustained better clinical 
outcomes, higher circulating drug levels and lower ADAb detection [159, 494]. However, 
induction doses are preconized only for some biologics and just for some diseases. This topic 
has not been specifically addressed, and although this approach may increase the initial therapy 
costs, if it lowers immunogenicity increasing drug survival, it might represent a cost-effective 
strategy over time. Scheduled administrations have also been associated with lower incidence 
of ADAb than episodic or on-demand regimens [160, 167, 168]. All these aspects have 
important clinical implications as they may reduce immunogenicity below its clinical 
significance. Therefore, further studies specifically addressing these topics are warranted.  
4.3 ETANERCEPT (FUSION PROTEIN): BIOLOGIC FREE OF SIGNIFICANT 
IMMUNOGENICITY 
Despite all the advances in biologics manufacturing, immunogenicity still represents one of the 
major drawbacks in the use of these therapies. However, important differences regarding 
immunogenicity exist among biologics. In our previous studies, no anti-etanercept antibodies 
were detected by using the most recent and optimized assays to detect ADAb. Very few studies 
in the Literature report the presence of anti-etanercept antibodies [331, 333, 487, 488]. In all of 
those studies, the detected antibodies were of low titer, transient, non-neutralizing and with no 
clinical impact. Because ELISAs of lower specificity were used in those studies to detect ADAb, 
false-positive results cannot be excluded. Consistent with this low immunogenic profile is the 
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fact that etanercept has consistently exhibited higher drug survival than infliximab or 
adalimumab in clinical studies [422, 432]. 
The reason why etanercept is of low/absent immunogenicity remains largely unknown. Some 
factors can, however, be hypothesized. Etanercept is a dimeric fusion protein comprised of two 
extracellular portions of p75-TNFR (75-kDa TNF receptors) linked to the Fc portion of a human 
IgG1. Only the junction between these two domains, the hinge region, is composed by few non-
human a.a. residues. Etanercept does not contain the highly variable CDR regions present in 
Fab arms of mAbs, where resides the higly immunogenic epitopes [60]. On the other hand, 
etanercept contains a human Fcγ portion, where it is though to reside tolerogenic epitopes 
(Tregitopes) [102]. Possibly, the balance between lower Teffector and higher Tregitopes content 
may contribute to the low immunogenicity of etanercept.  Consistently, abatacept, the CTLA4-
Fcγ construct, has also been associated with low immunogenicity. However, lenercept, a fusion 
protein similar to etanercept, did not receive approval for clinical use due to high 
immunogenicity revealed during its development. In contrast to etanercept (p75-TNFR-Fcγ), 
lenercept consists in the extracellular part of p55-TNFR fused with Fcγ portion. Lenercept (i.v.) 
was also tested in RA, and anti-lenercept antibodies, IgM and IgG, were detected in the serum 
of 60% of RA patients [563, 564]. Subcutaneous formulations were subsequently developed but, 
still, anti-lenercept antibodies were associated with a faster drug clearance [565]. Differences in 
the structure and function of the two TNFR may account for differences in the immunogenicity 
between lenercept (p55-TNFR) and etanercept (p75-TNFR). While p55-TNFR becomes 
primarily internalized after ligation, p75-TNFR is rapidly shed [566-569]. The higher 
internalization of p55-TNFR may increase the possibility of its processing and presentation, 
which may constitute a pressure force for the selection and maintenance of specific T and B cell 
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clones and antibodies to p55-TNFR and not to p75-TNFR. Qualitative or quantitative 
differences in the thymic expression between p55- and p75-TNFR could be also hypothesized, 
although no suggestive evidence of that has been reported in the Literature.  
Some studies have revealed that etanercept has lower affinity to transmembrane TNFa and 
induces significantly less antibody-dependent cell-mediated cytotoxicity (ADCC) than 
infliximab or adalimumab [329, 570]. Overall speaking, drugs that have membrane targets tend 
to be more immunogenic. By converting cell-binding antibodies into monomeric non-cell-
binding mutants, tolerance can be induced to the therapeutic cell-binding forms, as demonstrated 
with the anti-CD52 CAMPATH [58]. Moreover, the complex etanercept-soluble TNFa cannot 
interact with transmembrane TNFR, at least with p75-TNFR, as both etanercept and 
transmembrane p75-TNFR is suppose to bind to the same TNF epitope. However, it is likely 
that infliximab and adalimumab recognize epitopes in the TNF molecule other than those 
recognized by the TNFR, not preventing the binding between the complex infliximab- or 
adalimumab-TNFa with transmembrane TNFR and its consequent internalization and 
processing. This aspect may also contribute for the lower immunogenicity of etanercept by 
comparison with infliximab and adalimumab. Finally, in addition to TNFa blockage, etanercept 
also blocks lymphotoxin-alfa (LTa), which among other functions is also important for germinal 
centre formation [489]. The role of LTa in drug immunogenicity is not known.  
4.4 THE IMPACT OF ADAB ON DRUG’S SAFETY PROFILE 
Beyond the impact of ADAb on therapeutic effectiveness, drug immunogenicity may also 
interfere with drug safety profile, increasing the risk of adverse events [160, 210, 211, 213, 458, 
495, 497-501]. 
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The most common adverse events that have been associated with ADAb are the ”anaphylactoid-
like” acute reactions after intravenous infusions of biologics such as infliximab. ADAb may also 
mediate subacute symptoms such as arthralgia, myalgia or thromboembolic phenomena [495]. 
However, in this case the temporal relationship is not so obvious between the symptoms and the 
drug’s administration, which may have prevented a more clear association. 
Although IgE-ADAb have been reported, the great bulk of ADAb are of IgG isotype. This 
suggests an alternative pathway (IgE-independent) mediated by IgG, FcγRIII, macrophages, 
basophils, platelet activating factor (PAF) and complement activation with the consequent 
production of anaphylatoxins. Both IgE and non-IgE mediated acute IrAE might be clinically 
indistinguishable and tend to occur only from the second biologic’s infusion. Adverse reactions 
immediately during the first exposure to the drug have also been described, however they 
represent a minority. These reactions occurring at the first infusion are not related with ADAb, 
although the precise mechanism is not fully understood. A pre-existing sensitization towards 
some additives or cytokine release during cell apoptosis induced by the cross-linking of 
therapeutic monoclonal antibodies bound to target cells, may underlie these immediate 
reactions. These cytokine-release syndromes can be managed by short-term cessation of 
biologic’s infusion, restarting the infusion at a slower rate, or by the administration of histamine 
blockers and corticosteroids [534-536]. However, this approach has been employed indistinctly 
to all types of IrAE, irrespectively of the mechanism behind. This explains why in the majority 
of the cases pre-medication or slower infusion-rates do not prevent the recurrence of IrAE, as 
in the vast majority of the cases they are mediated by ADAb. Moreover, the persistence on the 
same therapy in the presence of ADAb may boost the immune response to biologic in some 
patients, which may increase the severity of adverse reactions without further clinical benefit. 
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The majority of the patients with ADAb-related IrAE end up loosing therapeutic response 
rapidly. Acute IrAE tend to be associated with high ADAb titres, which tend to increase with 
treatment continuation. ADAb can be detected at lower levels before the clinically overt IrAE, 
highlighting the predictive value of ADAb for such adverse events. Thus, immunogenicity 
monitoring may help us to better understand the mechanism underlying the adverse reactions, 
which have serious implications in their management. This type of approach can help us to 
prevent serious adverse events, namely through a timely therapy withdrawal.   
4.5 SUITABLE ASSAYS TO MONITOR IMMUNOGENICITY IN ROUTINE 
CLINICAL PRACTICE 
The detection of ADAb could be technically demanding and the quality of the assay may 
significantly affect the results. Newly developed assays have emerged to assess ADAb with 
better sensitivity and specificity. There are several optimized methods to detect ADAb. The 
most commonly used have been RIA-based methods. However, RIA requires high doses of 
radioactivity and special technical conditions, which prevent its use in the routine practice. In 
close collaboration with Sanquin Research Institute, Amsterdam, we developed a modified 
ELISA, known as Bridging ELISA, to specifically assess ADAb. Microtiter plates are incubated 
with the drug. After the incubation of the serum samples in the plates, the biotinylated drug are 
added and revealed through poly-HRP. This double recognition of ADAb leads to an ELISA of 
higher specificity.  
We tested the performance of this Bridging ELISA in our cohort of patients by comparison with 
RIA-ABT, which have been considered by many as the “gold-standard” to assess ADAb. The 
same positive samples were detected by both assays. Bridging ELISA offers the advantage of 
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being a simple and cheap method, easy to automate and to implement in the routine practice. 
Some limitations also exist, namely drug interference and inability to detect ADAb of IgG4, 
which may represent a significant proportion of ADAb. Drug interference is one of the major 
drawbacks of both ELISA and RIA [209]. By using these methods, ADAb can only be detected 
when their concentration exceeds the concentration of the drug. In the presence of the drug, 
ADAb might be hidden due to immune complex formation.  New methods are now available, 
which by promoting an acidic IC dissociation, allow the assessment of very low ADAb titres 
[462]. However, the clinical significance of such low titres remains unknown, as free drug 
remains available and no significant impact in therapeutic response has been seen. Both RIA 
and Bridging ELISA are, thus, able to detect clinically significant immunogenicity. The majority 
of ADAb are of IgG1 and IgG4 isotypes. Human IgG4 is able to exchange half of the Ig molecule 
with another IgG4 of different specificity, losing their bivalency and the ability to bridge. In 
these cases Bridging ELISA is not able to detect ADAb. However, we have not seen ADAb 
exclusively of IgG4 isotype. Strangely, some reports have shown patients IgG4-RIA-ABT 
positives, who tested negative in total IgG-RIA-ABT [209]. However, this might be owed to 
different drug interference between these two assays. Moreover, IgG4 represent a minority of 
total amount of IgGs and when a great proportion of ADAb is of IgG4 isotype is likely that they 
exchange half of the molecule with IgG4 of the same specificity, maintaining the bivalency. 
Therefore, the inability of detecting IgG4 by Bridging ELISA is a more theoretical than practical 
issue.  
We concluded that drug levels monitoring through an ELISA format and the detection of ADAb 
through Bridging ELISA, in case of undetectable serum drug trough levels, represent a suitable 
strategy to monitor immunogenicity in routine clinical practice. This strategy will provide very 
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important information, namely: a) the reason for therapeutic failure (mechanism of drug action 
versus drug immunogenicity); b) the identification of non-adherent patients and c) possibly 
patients that are overtreated, in which dose drug reduction programs might be implemented.  
4.6 INTEGRATING IMMUNOGENICITY INFORMATION IN THE MANAGEMENT 
OF PATIENTS RECEIVING BIOLOGIC THERAPIES 
RA has been seen as a paradigmatic example of a chronic disabling disease, where cytokine 
manipulation through biologic therapies has revolutionized the prognosis of the disease. Given 
the successful results of biologics, an increased number of patients are receiving these therapies, 
which represents an enormous burden to our societies. Moreover, therapeutic failures to these 
drugs are frequent and therapeutic decisions in these cases, such as whether to increase the dose 
or to switch to another biological of similar or different target, are more an empirical rather than 
a scientific-based decision.  
Until recently only TNFi were approved as first-line therapy in naïve RA-patients. In the 2013 
updated EULAR recommendations, tocilizumab and abatacept was also included in the 
approved first-line agents for RA treatment. However, TNFi still represent the most commonly 
used mechanism of action. In case of therapeutic failure to the initial agent, a switch to any of 
the approved biologics is recommended, irrespectively of the reason behind the failure. Given 
the lack of direct comparative RCT, all biologics have been considered equally effective and 
safe. However, according to our work and an increasing body of evidence, non-responders 
definitively do not represent a homogeneous group, and according to the reason of failure 
patients might benefit switching to specific agents. Similarly, in responding patients, the same 
lack of objective guidance prevents an educated and desirable dose reduction program, as there 
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are recent reasons to believe that over-treatment is common in patients receiving biological 
therapies [571-575]. 
Through the routine immunogenicity monitoring of our patient’s cohort, together with an 
exhaustive analysis of the literature, we designed an algorithm that integrates immunogenicity 
data in the current approach of patients receiving biologics - Figure 32. 
This algorithm is a binary decision maker, where the first node is defined by the serum drug 
trough levels (at every three months) and, the second, by the detection of ADAb (in case of 
undetectable drug levels). The three months interval represents the usual and recommended 
schedule for clinical visits and therapeutic decisions in clinical practice.  
We propose start divinding the patients according to detectable or undetectable serum drug 
levels, assessed by ELISA using a setup as described before. We did not categorize positive 
levels in an arbitrary low, normal or high level, as a paucity of studies exists to rigorously define 
the therapeutic range for each biologic and a high inter-individual variability has been reported. 
We purposefully choose this rough classification, as there is, today, no rigorous argument to 
define those cut-off values. Further analyses are needed to better discriminate those ranges and 
it is expected that routine assessment of serum drug levels will constructively contribute to this 
aim. 
In the presence of no clinical response, despite TNF neutralization, we might assume that the 
drug mechanism of action might not be the most appropriate for those patients and a switch to 
a drug with different mechanism of action is advisable. Some patients are never able to achieve 
therapeutic response to TNFi and are, thus, designated as primary non-reponders or as patients 
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having a “TNF-independent” RA. The identification of these patients has not only practical 
interest, as it is also of high scientific relevance. A better characterization of these “TNF-
independent” RA patients would be certainly important to better understand pathophysiologic 
mechanisms underlying RA and patient’s heterogeneity. Cytokines are redundant and 
pleiotropic. The predominance of a given cytokine may change over time during the disease 
course, and also may be affected by the presence or absence of other cytokines. This may in part 
explain why some RA patients do not achieve clinical improvement with TNFi. Early 
rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine pattern, 
which is not found in patients with established disease [576]. The effect of some cytokines are 
often linked to the presence and effects of other cytokines. For example, TGFβ together with 
IL6 promotes the differentiation into Th17 cells, but in the relative absence of IL6 it can favours 
the induction of T regulatory cells [577]. It might be possible that in the near future different 
cytokines profiles will be identified in different patients and at different stages of the disease, 
where different therapies will have different efficacy. 
Primary non-responders are currently defined as patients who cannot achieve DAS28 response 
as early as three months of therapy, in contrast to secondary non-responders, who loose initial 
DAS28 response at month six or later.  This means that currently the distinction between these 
two groups of patients may rely only in DAS28 assessment at one single time point (3 months 
after the beginning of therapy). Considering that DAS28 is based on some subjective parameters 
and that therapeutic responses at month three may be affected by several bias, such as the 
placebo effect, it is conceivable to consider this classification of low reliability. However, some 
authors have proposed algorithms for therapeutic decision merely based on this classification, 
arguing that primary non-responses are associated with refractoriness to the drug’s mechanism 
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of action, while secondary non-responses are likely mediated by ADAb development [549].  Not 
only this clinical classification is extremely fragile, as explained before, as non-responses at 
month three does not mean necessarily refractoriness to the drug’s mechanism of action because 
they can have already developed significant immunogenicity by this time. Therefore, we 
propose to assess drug levels (and ADAb in case of undetectable drug trough levels) for a more 
reliable and objective distinction between primary and secondary non-responders. Primary non-
responders will be those who, despite detectable and adequate drug levels, cannot achieve 
therapeutic response. We have then a possibility to easily and more rapidly discriminate the 
patients who benefit switching to different mechanism of action from those who will benefit 
from less immunogenic therapies.  
We propose to assess ADAb only in case of undetectable serum drug trough levels. Due to drug 
interference, the most commonly used assays cannot detect ADAb in the presence of circulating 
drug. By forming immune complexes with the drug, ADAb also promote the drug’s fast 
clearance from the circulation. Hence, detection of ADAb is predictably associated with very 
low/undetectable drug levels. When ADAb are produced at low titers, reduction in drug levels 
is not significant and virtually all ADAb remain in complex with the drug, preventing their 
detection [462]. Assays such as PIA-RIA-ABT, which promote the dissociation of immune 
complexes, allow the detection of such low levels of ADAb, otherwise hidden by high drug 
concentrations. However, in those cases the exceeding drug concentration remains free to 
neutralize TNF, as demonstrated in bioassays, and no significant clinical impact has been 
observed [193, 462]. Therefore, the clinical impact of ADAb, beyond their association with 
adverse events, occurs when ADAb concentration is enough to fully neutralize the drug. High 
sensitive assays are important to monitor ADAb responses and better understand the dynamic 
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of immune responses to biologics, but its added value in clinical practice remains to be 
established. Hence, we found Bridging ELISA a convenient method to monitor ADAb in clinical 
practice, in case of undetectable drug levels. Some authors have argued that ADAb is of little 
relevance, as their most important consequence is mediated through their impact on drug levels. 
However, non-adherence to the therapy may also lead to undetectable drug levels, which should 
not be interpreted as a consequence of drug immunogenicity. Reports of 50% non-adherence to 
chronic therapies have been revealed [540]. Treatment interruptions may have deleterious 
consequences. Poor therapeutic responses have been described after temporary therapeutic 
withdrawal, being more difficult to rescue response as good as previously. Episodic treatment 
regimens have been associated with higher immunogenicity as well. Hence, the assessment of 
ADAb in case of undetectable drug levels may provide added value in the identification of these 
patients, to whom an educational reinforcement regarding their disease and treatment might be 
advisable.  
Other factors may possibly interfere with drug pharmacokinetics/pharmacodynamics, such as 
weight or fat distribution. However, none of those seem to be able to mediate a so huge and fast 
clearance of the drug from circulation, particularly after injecting so high amount of therapeutic 
protein, as it is normally injected during these treatments.  
In case of clinical non-response and ADAb positivity, a switch to a less immunogenic drug, 
irrespectively of mechanism of action, is recommended.  There is no cross-reactivity of ADAb 
with different biologics, as they are highly specific antibodies. However, patients who produce 
ADAb to one biologic have 2-fold higher probability to produce ADAb against a new biologic, 
when compared to biologic-naïve patients [455, 578]. 
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There is a paucity of comparative studies evaluating immunogenicity of different biologics by 
using the same type of assays. The lack of standardization and huge heterogeneity among assays 
prevent direct comparisons between different studies. However, important information already 
exists regarding this topic. By using the same type of assays, it has been verified that: infliximab 
is able to induce more ADAb than adalimumab and, etanercept is free of significant 
immunogenicity. This is highly consistent with drug survival rates observed in clinical practice, 
which are higher for etanercept followed by adalimumab and lastly by infliximab [422].  
These differences in immunogenicity among different biologics, may also explain conflicting 
literature evaluating the clinical outcomes after switching to drugs with the same versus different 
mechanism of action. In a swiss cohort study involving 116 RA patients, evolution of the DAS28 
was more favorable in the group that received rituximab compared with the group that received 
an alternative TNFi. At 6 months, the mean decrease in the DAS28 was -1.61 (95% CI = -1.97, 
-1.25) among patients receiving rituximab and -0.98 (95% CI = -1.33, -0.62) among those 
receiving subsequent TNFi therapy [451]. Different results were obtained from a British cohort 
study involving 1328 RA patients, where no significant changes in DAS28 score or in the 
remission rate were verified among patients who switched to rituximab when compared to an 
alternative TNFi [372]. Any of these studies had taken into consideration which was/were the 
previous TNFi (mAb versus fusion protein), the reason of failure (presence versus absence of 
adequate drug levels) and which was the alternative TNFi (mAb versus fusion protein). By 
scrutinizing patient’s baseline characteristics in the previous studies, we verify that in contrast 
to the first one, in the later the majority of the included patients had failed one mAb (infliximab 
or adalimumab) and switched to etanercept (fusion protein). Thus, it is likely that in the second 
study the majority (although possibly not all) of patients had failed the previous TNFi due to 
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immunogenicity and, thus, a switch to a less immunogenic drug, TNFi or not, represent an 
effective strategy. In agreement to this, is a more recent study published by Gomez-Reino et al, 
evaluating the EULAR responses in 1124 RA switcher patients at 6 and 12 months after 
switching to an alternative TNFi (TNFi-group) versus rituximab (RTX group) [579]. By 
analysing these two groups, a significant higher proportion of EULAR good responses were 
verified in the RTX group. However, by subdividing the TNFi-group in 1) those who had 
previously failed a mAb (infliximab or adalimumab) and switched to etanercept and, 2) those 
who had previously failed etanercept and switched to mAb (infliximab or adalimumab), no 
significant differences in clinical outcomes were verified between RTX-group and those who 
switched to etanercept. In contrast, significant better outcomes were verified in the RTX-group 
when compared to those who had previously failed etanercept. As etanercept is free of 
significant immunogenicity, resistance to the mechanism of action is likely the cause of 
etanercept failures. In this case, the switch to a different mechanism of action represents a more 
effective strategy. 
Overall speaking, fusion proteins are less immunogenic than mAb, in part explained by the 
absence of the highly immunogenic CDR regions, though many other aspects may be 
implicated, as previously discussed. No neutralizing antibodies have been also detected against 
abatacept (CTLA4-Fcγ construct), which lead us to define etanercept and abatacept as less 
immunogenic drugs. Overall speaking, as less as foreign sequences are present in a mAb, the 
lower is its immunogenicity, though this might be not entirely true. Immunogenicity does not 
simply rely on amino acid sequence and other factors contribute to drug immunogenicity. As 
stressed before, further studies comparing the immunogenicity of different biologics by using 
the same type assays are very important to better evaluate the immunogenicity of each biologic 
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induced by its long-term in clinical practice. In the absence of such information we treated all 
the other biologics as a homogeneous group but possibly they may have important differences 
regarding immunogenicity that need to be further explored. Consistent with this has been the 
lower secondary failures and higher remission rates reported under tocilizumab therapy, an 
humanized mAb against the alpha-chain of the IL6-receptor [379, 381, 580]. Moreover, in 
contrast to TNFi, the combination therapy of tocilizumab plus methotrexate has not 
demonstrated better clinical outcomes than tocilizumab monotherapy [581]. All together, this 
evidence suggests a possible lower immunogenic profile of tocilizumab. This lead us to 
hypothesize that drug mechanism of action may also influence drug immunogenicity and it may 
well be that TNF blockade influences differently ADAb production than IL6 inhibition.  
4.7 DRUG MECHANISM OF ACTION AND ADAB PRODUCTION 
TNFa is known to have also immune-regulatory effects, which are believed to be mediated 
through p75-TNFR.  In contrast to p55-TNFR, which have been associated with induction and 
maintenance of chronic inflammation and antibody responses to T cell-dependent antigens [309, 
582-589], p75-TNFR signalling offers protective role in several disorders, including 
autoimmune diseases, heart diseases, and demyelinating/neurodegenerative conditions [590-
596]. Consistently, several defects at the p75-TNFR signalling have been reported in both 
human and mouse models of autoimmune disorders, including Crohn’s disease, Systemic Lupus 
Erythematous (SLE), Multiple Sclerosis (MS), Ankylosing Spondylitis (AS) and Type 1 
Diabetes [597-601]. Interestingly, there is a predominant expression of p75-TNFR on human 
and mice CD4+FoxP3+ T cells. Approximately 70% of human CD4+FoxP3+ cells express p75-
TNFR, compared with approximately 20% of CD4+FoxP3- cells [602-604]. P75-TNFR is 
constitutively expressed on human thymic T regulatory cells, but not on thymic T effector cells 
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[605]. Tregs expressing P75-TNFR generally exhibit a memory/effector phenotype and express 
higher levels of cytotoxic T-lymphocyte Antigen-4 (CTLA4), exhibiting a more potent 
immunosuppressive activity [603, 606, 607]. Even CD4+CD25- cells that express P75-TNFR 
have demonstrated considerable immunosuppressive activity [606]. It has been proposed that 
TNFa produced by activated T effector cells during inflammation activates Tregs through p75-
TNFR [608-610]. Consistently, Treg cells deficient in p75-TNFR have shown lower 
immunosuppressive capacity and poor control of inflammatory responses in vivo [602]. Taken 
together, this evidence highlight the regulatory properties of TNF, known as a potent pro-
inflammatory cytokine. It might be possible that TNFa assumes different properties (pro-
inflammatory versus regulatory) according to its concentration and cytokine milieu. The impact 
of TNF blockade in immune-regulatory effects mediated by TNFa is more evident in chronic 
phases of the disease than during acute inflammatory phases. TNFi have shown higher anti-
inflammatory efficacy and better clinical outcomes when administered at early acute 
inflammatory phases of RA. Similarly, TNF blockade in mice models of antigen-induced 
experimental autoimmune encephalomyelitis (EAE), which mimic acute inflammatory phases 
of Multiple Sclerosis (MS), was associated with significant disease improvement [309-313]. 
However, when administered to chronic MS patients, it was associated with deleterious effects 
[314, 315].  
Prolonged treatment of RA or IBD patients with TNFi has been associated with autoimmune 
phenomena, such as high antinuclear antibodies (ANAs) titres, double-strand (ds)-antiDNA 
antibodies, lupus-like syndrome or neuroinflammatory conditions. TNFi in established SLE was 
also associated with increased titres of lupus-associated antibodies (ANAs, ds-aDNA) and 
severe nephritis, which may suggest a participation of TNFa in the control of those 
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autoantibodies. So far, no association have been found between ADAb and autoantibodies 
production (ANAS or ds-antiDNA antibodies) [611]. However, if we hypothesise that excessive 
TNFa neutralization will lead to increase titres of autoantibodies, we will then expect an inverse 
correlation between autoantibodies and ADAb, as the later prevents TNF neutralization. Further 
longitudional studies assessing both ADAb titres, ANAs and ds-DNA and ideally serum TNFa 
concentration are warranted to better understand a possible correlation between these 
biomarkers.  
In contrast to TNFi, the use of tocilizumab in murine models of lupus and SLE patients has been 
associated with significant decrease of anti-dsDNA and disease activity [612-614]. Prolonged 
treatment with tocilizumab has not been associated with increased titres of ANAs, ds-DNA or 
lupus-like syndromes [615]. IL6 has been shown to play a pivotal role in driving the 
differentiation of naive T cells into pro-inflammatory T cell populations, such as TH17 cells, 
inhibiting the generation of T regulatory cells [616, 617].  IL6 has also been shown ability to 
inhibit the suppressive function of Tregs [618, 619]. The blockade of IL6 signaling has been 
associated with expansion of Tregs, in mice models and in humans [620-623]. It is possible that 
IL6 blockade will potentiate immune-regulatory mechanisms with impact on antibody responses 
and thus, on drug immunogenicity. Alternatively, we may also hypothesize that tocilizumab has 
higher and/or faster efficacy, inducing remission more rapidly. Once in remission, the 
development of immunogenicity would not have significant clinical impact. Further studies are 
warranted to better evaluate the immunogenicity of tocilizumab with its long-term use in clinical 
practice. 
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4.8 BIOLOGIC DOSE REDUCTION PROGRAMS BASED ON SERUM DRUG 
LEVELS 
The EULAR recommendations consider the possibility of dose reduction in patients with stable 
remission [364]. In the last update of EULAR recommendations are not completely clear how 
long should remission be maintained before start the biologic dose reduction, but in the previous 
recommendations one year was the advised period [404]. However, such reduction has been 
proposed on an empirical basis, i.e. simply considering DAS28 remission and not taking into 
account circulating drug levels. Clinical remission may occur in the presence of low serum drug 
trough levels (low or high) or in the absence of detectable circulating drug levels. While in the 
former we can always imagine that remission is maintained by the treatment, in the later case it 
is conceivable to postulate that is not. Hence, we propose that biologic withdrawal might be 
considered earlier among these later subgroup of patients, saving costs and possible adverse 
events. Increasingly evidence about discontinuation and dose titration of biologics in RA 
patients has emerged over the last years. The results have shown that dose titration or even 
discontinuation of TNFi is feasible and leads to overall dose reduction without compromising 
the clinical outcomes, although no circulating drug levels have been taken into account [571-
575]. In our cohort we verified the existence of patients with DAS28<2.6 with undetectable drug 
trough levels and detectable ADAb. Similarly, in another RA cohort, very low or undetectable 
drug levels were found in 33% of remission patients [624]. Those patients represent a subgroup 
of patients in which drug reduction can be proposed safely without waiting too long. 
Nevertheless, we recommend the use of ultrasonography or magnetic resonance imaging (MRI) 
before therapeutic withdrall, to exclude subclinical synovitis.  Those imaging methods have 
revealed higher sensitivity and reproducibility than clinical evaluation and it is well known that 
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subclinical synovitis might lead to bone damage in patients who clinically seem to have 
controlled RA [552-554]. 
However, we have also found patients in remission or low disease activity in the presence of 
very high drug trough levels. Going back to previous studies we can verify that above 1ug/mL 
of serum infliximab levels, no significant differences in clinical outcomes (ACR responses) 
occur between those who had infliximab levels between 1-10ug/mL and those who had 
>10ug/mL [625]. Similarly, it was recently published that above 5ug/mL of serum adalimumab, 
the correlation between DAS28 and adalimumab levels is no longer present [626]. Further larger 
longitudinal studies are warranted to validate those cut-offs, but it is already possible to 
comfortably reduce biologic doses to values close to the previously mentioned, as often much 
higher drug concentrations are found among patients [153, 195, 519].  
One of the main concerns of this strategy has been the possibility of flares and its management. 
However, considerable flare rates have been reported even despite standard dose regimens of 
biologic therapies [627, 628]. Those flares tend to be managed through the optimization of non-
biologic DMARD therapies, chemical synovectomies or even biologic dose intensification [575, 
629, 630]. Studies evaluating tapering strategies, even not considering circulating drug levels, 
have shown no significant differences in the number or severity of flares, when compared to 
standard treatment regimens [571-575]. The integration of serum drug levels assessment will 
offer even more safety, as it will prevent possible over-tapering. The dose reduction will be 
proposed comfortably just up to certain limit, below which some precaution is advised.  
In conclusion, our algorithm, by having a first branching according to drug level that offers the 
possibility to readily identify responder patients who are overtreated or uselessly treated. The 
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assessment of drug levels in first place also prevents unnecessary ADAb assessments, as in 
presence of optimal drug levels, ADAb are unlikely to be revealed by the most common assays, 
such as Bridging ELISA or RIA [195, 209, 210, 484]. Progressive drug reductions or even 
therapy withdrawal can be done safer and more cost-effectively if based on serum drug levels. 
Further studies are now warranted to better discriminate the minimum effective drug level for 
each patient/subgroup of patients. 
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5 CONCLUSIONS 
5.1 RELEVANCE (AND PERSPECTIVE) OF THIS WORK FOR CLINICAL 
PRACTICE 
The clinical heterogeneity among patients is to be considered. Drug immunogenicity is one of 
the main reasons behind therapeutic failure, also increasing the risk of adverse events. 
Monitoring drug levels and anti-drug antibodies represent a very promising tool for an optimized 
and personalized usage of biological therapies. 
The algorithm we proposed and tested operates along a qualitative classification of patients 
according to ADAb and drug level detection. It is expected that extension of this work to 
quantitative large-scale longitudinal studies, will provide the material for its improvement, 
notably for optimization of the effective drug level for each patient. 
Our analysis of 105 patients, each followed for duration of 12 months after therapeutic decision, 
reveals that those who coincidently followed strategies concordant with our algorithm had about 
10-fold higher probability to achieve low disease activity, when compared to those who 
followed different therapeutic strategies. Moreover, had our algorithm been fully applied, about 
8 months would have been gained to achieve those beneficial outcomes.  
Our proposal represents a personalized and scientific-based approach to patients receiving 
biologic therapies, providing more safe and cost-effective strategies. 
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5.2 RELEVANCE FOR ECONOMIC AND SOCIETAL VALUES 
Biological therapies have revolutionized the prognosis of many chronic inflammatory diseases, 
which tend to affect young people at productive age. Despite the overall benefit of these novel 
therapies, some patients never achieve therapeutic response or, more often, do not sustain a good 
response to continuous therapy. The clinical identification of these subgroups is affected by 
several biases, which prevent fast and assertive therapeutic decisions. Moreover, accumulating 
evidence has now suggested that a considerable number of responder patients are indeed over-
treated.  
By using reliable bio-markers, such as levels of drug and of ADAb, these subgroups would be 
easily and rapidly identified. Fast and assertive therapeutic decisions could then be 
implemented, leading to a better control of disease activity and possibly clinical remission, 
which is today the main therapeutic goal, as defined by the European League Against 
Rheumatism (EULAR). 
Our scientific-based strategy for clinical decisions would improve significantly the cost-
effectiveness of biological therapies, a concern of modern societies. Comparing and improving 
immunogenicity tests, we demonstrated that monitoring immunogenicity and drug level can 
easily be implemented in routine clinical practice, for an estimate annual cost of 400€ per 
patient. Considering the modest cost of such a monitoring together with i) the very high cost of 
biological therapies (approximately 12 000€ per patient per year), ii) our evaluation that several 
months of inefficient therapies could be prevented by monitoring immunogenicity and iii) the 
amount of administrated drug could be reduced in a subgroup of patients, there is no doubts that 
implementing this in routine practice would be cost-effective. In addition to direct and 
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immediate costs reductions, this strategy would also provide indirect gains on a longer scale, by 
reducing disability and promoting patients’ functionality and productivity.   
In conclusion, our findings could guide decisions at a National regulatory level as it allows 
revision of the costs engaged in biological therapies while keeping as a priority the welfare of 
patients. 
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